{ "version": "2.2", "instance": { "iva-20231231x20f.htm": { "nsprefix": "iva", "nsuri": "http://www.inventivapharma.com/20231231", "dts": { "schema": { "local": [ "iva-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "iva-20231231_cal.xml" ] }, "definitionLink": { "local": [ "iva-20231231_def.xml" ] }, "labelLink": { "local": [ "iva-20231231_lab.xml" ] }, "presentationLink": { "local": [ "iva-20231231_pre.xml" ] }, "inline": { "local": [ "iva-20231231x20f.htm" ] } }, "keyStandard": 308, "keyCustom": 322, "axisStandard": 35, "axisCustom": 5, "memberStandard": 57, "memberCustom": 163, "hidden": { "total": 16, "http://www.inventivapharma.com/20231231": 7, "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 2, "http://xbrl.sec.gov/dei/2023": 7 }, "contextCount": 865, "entityCount": 1, "segmentCount": 226, "elementCount": 1040, "unitCount": 22, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 1740, "http://xbrl.sec.gov/dei/2023": 46 }, "report": { "R1": { "role": "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition", "longName": "00100 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION", "shortName": "CONSOLIDATED STATEMENTS OF FINANCIAL POSITION", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:NoncurrentAssets", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R3": { "role": "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss", "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF INCOME (LOSS)", "shortName": "CONSOLIDATED STATEMENTS OF INCOME (LOSS)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:SalesAndMarketingExpense", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R4": { "role": "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss", "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R5": { "role": "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity", "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember__9zk3rO24Eem-_4ScC4cdA", "name": "ifrs-full:Equity", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2020_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_EUx2CrsNxUunQgFJ-sIecA", "name": "ifrs-full:Equity", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R6": { "role": "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows", "longName": "00500 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:AdjustmentsForDepreciationAmortisationAndProvisions", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R7": { "role": "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical", "longName": "00505 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "link:footnote", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "link:footnote", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformation", "longName": "10101 - Disclosure - Company information", "shortName": "Company information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:CompanyInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:CompanyInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfCompliance", "longName": "10201 - Disclosure - Basis of preparation and statement of compliance", "shortName": "Basis of preparation and statement of compliance", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:StatementOfIFRSCompliance", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:StatementOfIFRSCompliance", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciples", "longName": "10301 - Disclosure - Accounting Principles", "shortName": "Accounting Principles", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.inventivapharma.com/role/DisclosureIntangibleAssets", "longName": "10401 - Disclosure - Intangible assets", "shortName": "Intangible assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipment", "longName": "10501 - Disclosure - Property, plant, and equipment", "shortName": "Property, plant, and equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethod", "longName": "10601 - Disclosure - Investments accounted for using the equity method", "shortName": "Investments accounted for using the equity method", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssets", "longName": "10701 - Disclosure - Other non-current assets", "shortName": "Other non-current assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssets", "longName": "10801 - Disclosure - Deferred tax assets", "shortName": "Deferred tax assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.inventivapharma.com/role/DisclosureInventories", "longName": "10901 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssets", "longName": "11001 - Disclosure - Trade receivables, tax receivables and other current assets", "shortName": "Trade receivables, tax receivables and other current assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalents", "longName": "11101 - Disclosure - Cash and cash equivalents", "shortName": "Cash and cash equivalents", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquity", "longName": "11201 - Disclosure - Shareholders' equity", "shortName": "Shareholders' equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialDebt", "longName": "11301 - Disclosure - Financial debt", "shortName": "Financial debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.inventivapharma.com/role/DisclosureProvisions", "longName": "11401 - Disclosure - Provisions", "shortName": "Provisions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfProvisionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfProvisionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligations", "longName": "11501 - Disclosure - Provisions for retirement benefit obligations", "shortName": "Provisions for retirement benefit obligations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilities", "longName": "11601 - Disclosure - Other current and non-current liabilities", "shortName": "Other current and non-current liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.inventivapharma.com/role/DisclosureTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilities", "longName": "11701 - Disclosure - Trade payables, short-term contract liabilities and other current liabilities", "shortName": "Trade payables, short-term contract liabilities and other current liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilities", "longName": "11801 - Disclosure - Financial assets and liabilities", "shortName": "Financial assets and liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncome", "longName": "11901 - Disclosure - Revenues and other income", "shortName": "Revenues and other income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.inventivapharma.com/role/DisclosureOperatingExpenses", "longName": "12001 - Disclosure - Operating expenses", "shortName": "Operating expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpenses", "longName": "12101 - Disclosure - Other operating income and expenses", "shortName": "Other operating income and expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpenses", "longName": "12201 - Disclosure - Financial income and expenses", "shortName": "Financial income and expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethod", "longName": "12301 - Disclosure - Share of net profit - Equity method", "shortName": "Share of net profit - Equity method", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.inventivapharma.com/role/DisclosureIncomeTax", "longName": "12401 - Disclosure - Income tax", "shortName": "Income tax", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShare", "longName": "12501 - Disclosure - Basic and diluted loss per share", "shortName": "Basic and diluted loss per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivities", "longName": "12601 - Disclosure - Commitments related to operational activities", "shortName": "Commitments related to operational activities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactions", "longName": "12701 - Disclosure - Related-party transactions", "shortName": "Related-party transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "34", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagement", "longName": "12801 - Disclosure - Financial risk management", "shortName": "Financial risk management", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "35", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDate", "longName": "12901 - Disclosure - Events after the reporting date", "shortName": "Events after the reporting date", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "36", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies", "longName": "20302 - Disclosure - Accounting Principles (Policies)", "shortName": "Accounting Principles (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "37", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables", "longName": "30203 - Disclosure - Basis of preparation and statement of compliance (Tables)", "shortName": "Basis of preparation and statement of compliance (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesTables", "longName": "30303 - Disclosure - Accounting Principles (Tables)", "shortName": "Accounting Principles (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsTables", "longName": "30403 - Disclosure - Intangible Assets (Tables)", "shortName": "Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentTables", "longName": "30503 - Disclosure - Property, plant, and equipment (Tables)", "shortName": "Property, plant, and equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodTables", "longName": "30603 - Disclosure - Investments accounted for using the equity method (Tables)", "shortName": "Investments accounted for using the equity method (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsTables", "longName": "30703 - Disclosure - Other non-current assets (Tables)", "shortName": "Other non-current assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetsTables", "longName": "30803 - Disclosure - Deferred tax assets (Tables)", "shortName": "Deferred tax assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:DisclosureOfDeferredTaxAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:DisclosureOfDeferredTaxAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfDeferredTaxesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.inventivapharma.com/role/DisclosureInventoriesTables", "longName": "30903 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:IfrsScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:IfrsScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTables", "longName": "31003 - Disclosure - Trade receivables, tax receivables and other current assets (Tables)", "shortName": "Trade receivables, tax receivables and other current assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:DisclosureOfTradeReceivablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:DisclosureOfTradeReceivablesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsTables", "longName": "31103 - Disclosure - Cash and cash equivalents (Tables)", "shortName": "Cash and cash equivalents (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:DisclosureOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:DisclosureOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables", "longName": "31203 - Disclosure - Shareholders' equity (Tables)", "shortName": "Shareholders' equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialDebtTables", "longName": "31303 - Disclosure - Financial debt (Tables)", "shortName": "Financial debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "49", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.inventivapharma.com/role/DisclosureProvisionsTables", "longName": "31403 - Disclosure - Provisions (Tables)", "shortName": "Provisions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "50", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfProvisionsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfProvisionsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsTables", "longName": "31503 - Disclosure - Provisions for retirement benefit obligations (Tables)", "shortName": "Provisions for retirement benefit obligations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "51", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:DisclosureOfAssumptionsUsedToMeasureRetirementBenefitObligationsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:DisclosureOfAssumptionsUsedToMeasureRetirementBenefitObligationsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesTables", "longName": "31603 - Disclosure - Other current and non-current liabilities (Tables)", "shortName": "Other current and non-current liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "52", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.inventivapharma.com/role/DisclosureTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesTables", "longName": "31703 - Disclosure - Trade payables, short-term contract liabilities and other current liabilities (Tables)", "shortName": "Trade payables, short-term contract liabilities and other current liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "53", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesTables", "longName": "31803 - Disclosure - Financial assets and liabilities (Tables)", "shortName": "Financial assets and liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "54", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeTables", "longName": "31903 - Disclosure - Revenues and other income (Tables)", "shortName": "Revenues and other income (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "55", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:RevenueAndOtherIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfRevenueExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:RevenueAndOtherIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfRevenueExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.inventivapharma.com/role/DisclosureOperatingExpensesTables", "longName": "32003 - Disclosure - Operating expenses (Tables)", "shortName": "Operating expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "56", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:OperatingExpensesOnResearchAndDevelopmentMarketingAndGeneralAdministrativeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:OperatingExpensesOnResearchAndDevelopmentMarketingAndGeneralAdministrativeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesTables", "longName": "32103 - Disclosure - Other operating income and expenses - (Tables)", "shortName": "Other operating income and expenses - (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "57", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesTables", "longName": "32203 - Disclosure - Financial income and expenses (Tables)", "shortName": "Financial income and expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "58", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:FinancialIncomeAndExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:FinancialIncomeAndExpensesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodTables", "longName": "32303 - Disclosure - Share of net profit - Equity method (Tables)", "shortName": "Share of net profit - Equity method (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "59", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.inventivapharma.com/role/DisclosureIncomeTaxTables", "longName": "32403 - Disclosure - Income Tax (Tables)", "shortName": "Income Tax (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "60", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShareTables", "longName": "32503 - Disclosure - Basic and diluted loss per share (Tables)", "shortName": "Basic and diluted loss per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "61", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:EarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesTables", "longName": "32603 - Disclosure - Commitments related to operational activities (Tables)", "shortName": "Commitments related to operational activities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "62", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:DisclosureOfCommitmentsRelatedOperationalActivitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:DisclosureOfCommitmentsRelatedOperationalActivitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsTables", "longName": "32703 - Disclosure - Related-party transactions (Tables)", "shortName": "Related-party transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "63", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementTables", "longName": "32803 - Disclosure - Financial Risk Management (Tables)", "shortName": "Financial Risk Management (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "64", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:SensitivityAnalysisForEachTypeOfMarketRisk", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "longName": "40101 - Disclosure - Company information - (Details)", "shortName": "Company information - (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_9_29_2023_To_9_29_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_9NijRHvb6Eij7EOPtiLokQ", "name": "ifrs-full:ChangesInEquity", "unitRef": "Unit_Standard_USD_KpL5oHjdjEOIM5rkKphzLA", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R66": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "longName": "40102 - Disclosure - Company information - CTTQ and Share-based payments (Details)", "shortName": "Company information - CTTQ and Share-based payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "Duration_12_29_2023_To_12_29_2023_Hnau1PG--UKkKa-ByVliwQ", "name": "iva:AmountInvoicedToCounterparty", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_12_29_2023_To_12_29_2023_Hnau1PG--UKkKa-ByVliwQ", "name": "iva:ProceedsFromLicensingArrangementsAfterDeductionOfWithholdingTaxes", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R67": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicenseAndCollaborationAgreementWithCttqDetails", "longName": "40103 - Disclosure - Company information - License and collaboration agreement with CTTQ (Details)", "shortName": "Company information - License and collaboration agreement with CTTQ (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "Duration_12_29_2023_To_12_29_2023_Hnau1PG--UKkKa-ByVliwQ", "name": "iva:AmountInvoicedToCounterparty", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": null }, "R68": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "longName": "40104 - Disclosure - Company Information - Tax audit on payroll tax (Details)", "shortName": "Company Information - Tax audit on payroll tax (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "As_Of_12_31_2021_tn-SWu7KqE2bUzR9E0BubQ", "name": "ifrs-full:FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_6_9_2021_To_6_9_2021_HzTiZ2Eh9keoqvURU9drQg", "name": "iva:AmountOfOffsettingVatCreditReceivables", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R69": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails", "longName": "40105 - Disclosure - Company Information - Tax audit on research tax credit (Details)", "shortName": "Company Information - Tax audit on research tax credit (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "Duration_4_21_2022_To_4_21_2022_Ft5apSkm4USLotdjlUGwqg", "name": "iva:ProceedsFromFrenchResearchTaxCredit", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2021_To_12_31_2021_k5b1w8_-zEqkClCATCRpSA", "name": "iva:AmountOfSubcontractingTaxRebateGrantedByTaxAuthorities", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R70": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxDisputeSettlementDetails", "longName": "40106 - Disclosure - Company information - Tax dispute settlement (Details)", "shortName": "Company information - Tax dispute settlement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_ifrs-full_ClassesOfProvisionsAxis_iva_ProvisionForPayrollTaxAudit20162017Member_J8CCfQBgy0yad7FqEyQ7bg", "name": "iva:AccrualsSettledDuringPeriod", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_ifrs-full_ClassesOfProvisionsAxis_iva_ProvisionForPayrollTaxAudit20162017Member_J8CCfQBgy0yad7FqEyQ7bg", "name": "iva:AccrualsSettledDuringPeriod", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationInvestmentInSubsidiaryDetails", "longName": "40107 - Disclosure - Company information - Investment in subsidiary (Details)", "shortName": "Company information - Investment in subsidiary (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "Duration_1_5_2021_To_1_5_2021_ifrs-full_SignificantInvestmentsInSubsidiariesAxis_iva_InventivaIncMember_cRBJtWKiE02awcZxtYYA7g", "name": "ifrs-full:ProportionOfOwnershipInterestInSubsidiary", "unitRef": "Unit_Standard_pure_bVd0MtE5GE6BXL5p4ofGQg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": null }, "R72": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "longName": "40108 - Disclosure - Company information - Equity financing (Details)", "shortName": "Company information - Equity financing (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "Duration_7_15_2020_To_7_15_2020_7-gMmkgvJ0W3aD2psMnvcg", "name": "iva:GrossProceedsFromIssuingShares", "unitRef": "Unit_Standard_USD_KpL5oHjdjEOIM5rkKphzLA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_8_2_2021_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_JefferiesAtmProgramMember_HxJQN8vmQEeXtFhStnIYvw", "name": "ifrs-full:NumberOfSharesRepresentedByOneDepositaryReceipt", "unitRef": "Unit_Standard_pure_bVd0MtE5GE6BXL5p4ofGQg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R73": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationPaymentsReceivedFromResearchTaxCreditDetails", "longName": "40109 - Disclosure - Company Information - Payments received from the Research Tax Credit (Details)", "shortName": "Company Information - Payments received from the Research Tax Credit (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "Duration_1_1_2021_To_6_30_2021_m3vA6gTg10KhFQev3HlLTg", "name": "iva:PaymentsReceivedFromResearchTaxCredit", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2021_To_6_30_2021_m3vA6gTg10KhFQev3HlLTg", "name": "iva:PaymentsReceivedFromResearchTaxCredit", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "longName": "40110 - Disclosure - Company Information - Capital increases and other significant events (Details)", "shortName": "Company Information - Capital increases and other significant events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "As_Of_1_18_2024_l8ElHls0okewfG6T4pwcZw", "name": "ifrs-full:NotionalAmount", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2020_To_12_31_2020_ifrs-full_ClassesOfFinancialInstrumentsAxis_iva_IfrsForeignExchangeForwardMember_MgA4DQ1oA0y9ao6RAVYwUw", "name": "iva:NumberOfForwardContractsExpired", "unitRef": "Unit_Standard_contract_6eeceD4v5EudM6bj9IhQNA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R75": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "longName": "40111 - Disclosure - Company Information - Warrant agreement with the European Investment Bank (Details)", "shortName": "Company Information - Warrant agreement with the European Investment Bank (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "As_Of_1_18_2024_l8ElHls0okewfG6T4pwcZw", "name": "ifrs-full:NotionalAmount", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2022_To_7_1_2022_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_WarrantAgreementWithEuropeanInvestmentBankMember_IS8cem7TDUqbAcYYx52WTg", "name": "iva:ClassOfWarrantOrRightSubscriptionPrice", "unitRef": "Unit_Divide_EUR_shares_M0ettPP0b0G1jtl2RL9smQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R76": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsDetails", "longName": "40112 - Disclosure - Company Information - Share-based payments (Details)", "shortName": "Company Information - Share-based payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_6_28_2021_To_6_28_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_NewBonusShareAwardPlan20191Member_qFMnFzfQVk2llHJz9KpVTg", "name": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R77": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "longName": "40113 - Disclosure - Company information - French state-guaranteed loan (\"PGE\") and equity recovery loans (\"PPR\") (Details)", "shortName": "Company information - French state-guaranteed loan (\"PGE\") and equity recovery loans (\"PPR\") (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_WfJWanks8U-OuMAm-leZ8A", "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_6_1_2020_To_6_30_2020_ifrs-full_BorrowingsByNameAxis_iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember_PqV3HbDPb0a3mfr4Sm-Pyg", "name": "iva:IfrsDebtInstrumentTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R78": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "longName": "40201 - Disclosure - Basis of preparation and statement of compliance - Significant Investments In Subsidiaries (Details)", "shortName": "Basis of preparation and statement of compliance - Significant Investments In Subsidiaries (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "iva:NumberOfEntitiesBeingConsolidated", "unitRef": "Unit_Standard_entity_b7aWPp0O6E-FmxapaotVUQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": null }, "R79": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceConsolidatedFinancialStatementsDetails", "longName": "40202 - Disclosure - Basis of preparation and statement of compliance - Consolidated financial statements (Details)", "shortName": "Basis of preparation and statement of compliance - Consolidated financial statements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_dei_LegalEntityAxis_iva_AdjustmentsToReconcileSeparateFinancialStatementsToConsolidatedFinancialStatementsMember_2c_2fYurtkuOfo6gj0t5YA", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R80": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails", "longName": "40203 - Disclosure - Basis of preparation and statement of compliance - Foreign Exchange Rates (Details)", "shortName": "Basis of preparation and statement of compliance - Foreign Exchange Rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:AverageForeignExchangeRate", "unitRef": "Unit_Divide_USD_EUR_yn7TMNhZrkaIfQCV4n0wEg", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": null }, "R81": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "longName": "40301 - Disclosure - Accounting Principles - Property, plant and equipment (Details)", "shortName": "Accounting Principles - Property, plant and equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_kUcrpTJ7sEaZeeoGVDTorQ", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_BuildingsMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_kUcrpTJ7sEaZeeoGVDTorQ", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R82": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesRoyaltyCertificatesLiabilitiesDetails", "longName": "40302 - Disclosure - Accounting Principles - Royalty certificates liabilities (Details)", "shortName": "Accounting Principles - Royalty certificates liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_RoyaltyCertificateLiabilitiesMember_ifrs-full_ProductsAndServicesAxis_iva_LanifibranorMember_m9F_TyPaU0KcoLv0uTGk1w", "name": "iva:PercentageOfAnnualRoyaltiesOnFutureSalesForRoyaltyCertificateHolders", "unitRef": "Unit_Standard_pure_bVd0MtE5GE6BXL5p4ofGQg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "iva:RoyaltyCertificatesLiabilitiesPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_RoyaltyCertificateLiabilitiesMember_ifrs-full_ProductsAndServicesAxis_iva_LanifibranorMember_m9F_TyPaU0KcoLv0uTGk1w", "name": "iva:PercentageOfAnnualRoyaltiesOnFutureSalesForRoyaltyCertificateHolders", "unitRef": "Unit_Standard_pure_bVd0MtE5GE6BXL5p4ofGQg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "iva:RoyaltyCertificatesLiabilitiesPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R83": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "longName": "40303 - Disclosure - Accounting Principles - Fair value measurement (Details)", "shortName": "Accounting Principles - Fair value measurement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:FinancialLiabilities", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2021_ifrs-full_CategoriesOfFinancialAssetsAxis_ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level1OfFairValueHierarchyMember_gW91m2OF-0-7iXnT87tM6g", "name": "ifrs-full:FinancialAssets", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R84": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesForeignCurrencyTransactionsAndSegmentInformationDetails", "longName": "40304 - Disclosure - Accounting Principles - Foreign currency transactions and Segment information (Details)", "shortName": "Accounting Principles - Foreign currency transactions and Segment information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:AmountOfExpensesDenominatedInForeignCurrency", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:AmountOfExpensesDenominatedInForeignCurrency", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R85": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesSegmentInformationDetails", "longName": "40305 - Disclosure - Accounting Principles - Segment information (Details)", "shortName": "Accounting Principles - Segment information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:IfrsNumberOfOperatingSegments", "unitRef": "Unit_Standard_pure_bVd0MtE5GE6BXL5p4ofGQg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:IfrsNumberOfOperatingSegments", "unitRef": "Unit_Standard_pure_bVd0MtE5GE6BXL5p4ofGQg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R86": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails", "longName": "40306 - Disclosure - Accounting Principles - geographical split (Details)", "shortName": "Accounting Principles - geographical split (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R87": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "longName": "40307 - Disclosure - Accounting principles - Going concern (Details)", "shortName": "Accounting principles - Going concern (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:ShorttermDepositsNotClassifiedAsCashEquivalents", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfGoingConcernExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R88": { "role": "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails", "longName": "40401 - Disclosure - Intangible assets (Details)", "shortName": "Intangible assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "As_Of_12_31_2022_yr-sbBLri02cA-LbcoaIhg", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:IncreasesInIntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R89": { "role": "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails", "longName": "40501 - Disclosure - Property, plant, and equipment (Details)", "shortName": "Property, plant, and equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "As_Of_12_31_2021_tn-SWu7KqE2bUzR9E0BubQ", "name": "ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2020_ZS1sCOo7l0mWQ7t0Hts3cw", "name": "ifrs-full:PropertyPlantAndEquipmentIncludingRightofuseAssets", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R90": { "role": "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "longName": "40502 - Disclosure - Property, plant, and equipment - Additional Information (Details)", "shortName": "Property, plant, and equipment - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:ChangesInPropertyPlantAndEquipment", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:ChangesInPropertyPlantAndEquipment", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R91": { "role": "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails", "longName": "40601 - Disclosure - Investments accounted for using the equity method - Additional Information (Details)", "shortName": "Investments accounted for using the equity method - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "Duration_8_31_2023_To_8_31_2023_fJGqQui34ES67z_32iisJg", "name": "ifrs-full:ProceedsFromIssuingShares", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_9_29_2023_To_9_29_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_Ffbs-kscp0ygCSsNUEq4kQ", "name": "ifrs-full:ProceedsFromIssuingShares", "unitRef": "Unit_Standard_USD_KpL5oHjdjEOIM5rkKphzLA", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ifrs-full:DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R92": { "role": "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "longName": "40602 - Disclosure - Investments accounted for using the equity method - investment in Hepalys accounted for using equity method of accounting (Details)", "shortName": "Investments accounted for using the equity method - investment in Hepalys accounted for using equity method of accounting (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_10_11_2023_dei_LegalEntityAxis_iva_HepalysPharmaIncMember_VipCwLL49UiUJMsjuCzxLg", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R93": { "role": "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails", "longName": "40701 - Disclosure - Other non-current assets (Details)", "shortName": "Other non-current assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "iva:NonCurrentLongTermDepositsFromCustomers", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "iva:NonCurrentLongTermDepositsFromCustomers", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R94": { "role": "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails", "longName": "40702 - Disclosure - Other non-current assets - Long-term deposit accounts (Details)", "shortName": "Other non-current assets - Long-term deposit accounts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:IncreaseDecreaseInLongTermDepositAccounts", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:IncreaseDecreaseInLongTermDepositAccounts", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R95": { "role": "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsAdvancesPaymentsNonCurrentDetails", "longName": "40703 - Disclosure - Other non-current assets - Advances payments - non-current (Details)", "shortName": "Other non-current assets - Advances payments - non-current (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "iva:NonCurrentAdvancesToSuppliers", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "ifrs-full:DisclosureOfOtherNoncurrentAssetsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember_wyHRmHxZc0O7M8Rx37o1ZA", "name": "iva:NonCurrentAdvancesToSuppliers", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R96": { "role": "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetsDetails", "longName": "40801 - Disclosure - Deferred tax assets (Details)", "shortName": "Deferred tax assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:DeferredTaxAssets", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": null }, "R97": { "role": "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetsAdditionalInformationDetails", "longName": "40802 - Disclosure - Deferred tax assets - Additional Information (Details)", "shortName": "Deferred tax assets - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:DeferredTaxAssets", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_dei_LegalEntityAxis_iva_InventivaS.aMember_qEXrmt1QRE2eIrJw6X36pQ", "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R98": { "role": "http://www.inventivapharma.com/role/DisclosureInventoriesDetails", "longName": "40901 - Disclosure - Inventories (Details)", "shortName": "Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:Inventories", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_Q_7aeMdAm0a0ClC__7Gk2A", "name": "ifrs-full:Inventories", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:IfrsScheduleOfInventoryCurrentTableTextBlock", "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R99": { "role": "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails", "longName": "41001 - Disclosure - Trade receivables, tax receivables and other current assets - Trade Receivables (Details)", "shortName": "Trade receivables, tax receivables and other current assets - Trade Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:TradeAndOtherCurrentReceivables", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:CurrentTradeReceivablesAveragePaymentPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R100": { "role": "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails", "longName": "41002 - Disclosure - Trade receivables, tax receivables and other current assets- Other Current Assets and Receivables (Details)", "shortName": "Trade receivables, tax receivables and other current assets- Other Current Assets and Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "iva:CirAndOtherResearchTaxCreditsReceivable", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "iva:OtherCurrentTaxReceivables", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R101": { "role": "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails", "longName": "41003 - Disclosure - Trade receivables, tax receivables and other current assets - Additional Information (Details)", "shortName": "Trade receivables, tax receivables and other current assets - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:CurrentTaxAssetsCurrent", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "iva:CirReceivable", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R102": { "role": "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsDetails", "longName": "41101 - Disclosure - Cash and cash equivalents (Details)", "shortName": "Cash and cash equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfCashAndCashEquivalentsTableTextBlock", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfCashAndCashEquivalentsTableTextBlock", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R103": { "role": "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "longName": "41102 - Disclosure - Cash and cash equivalents - Additional Information (Details)", "shortName": "Cash and cash equivalents - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:IncreaseDecreaseInCashAndCashEquivalents", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R104": { "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "longName": "41201 - Disclosure - Shareholders' equity - Share capital (Details)", "shortName": "Shareholders' equity - Share capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:IssueOfEquity", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Aga2022Member_caKbsnXmmkGnWE6MV3ZN4g", "name": "ifrs-full:IssueOfEquity", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R105": { "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "longName": "41202 - Disclosure - Shareholders' equity - Changes in share capital (Details)", "shortName": "Shareholders' equity - Changes in share capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:Equity", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_12_8_2023_To_12_8_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_grMorDHzXkuPnXIpWnjKkQ", "name": "ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding", "unitRef": "Unit_Standard_shares_QN3-o3_MfEya7w9yidQ2qQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R106": { "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails", "longName": "41203 - Disclosure - Shareholders' equity - Additional Information (Details)", "shortName": "Shareholders' equity - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "As_Of_8_31_2023_7i70l23Dn0O2fR9Vr3kz7Q", "name": "iva:WarrantsSubscriptionPrice", "unitRef": "Unit_Divide_EUR_shares_M0ettPP0b0G1jtl2RL9smQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaShareWarrantsMember_0clS7IaSNUmIOAh6AL6h9g", "name": "iva:NumberOfPlansOutstanding", "unitRef": "Unit_Standard_plan_k5X-GIpoAEOJF8uFnKrvZw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R107": { "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityLiquidityAgreementDetails", "longName": "41204 - Disclosure - Shareholders' equity - Liquidity agreement (Details)", "shortName": "Shareholders' equity - Liquidity agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:LiquidityAgreementTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:LiquidityAgreementTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R108": { "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "longName": "41205 - Disclosure - Shareholders' Equity - Characteristics of BSPCE share warrants plans (Details)", "shortName": "Shareholders' Equity - Characteristics of BSPCE share warrants plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108", "firstAnchor": { "contextRef": "As_Of_8_31_2023_7i70l23Dn0O2fR9Vr3kz7Q", "name": "iva:WarrantsSubscriptionPrice", "unitRef": "Unit_Divide_EUR_shares_M0ettPP0b0G1jtl2RL9smQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_4_16_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bspce2021PlanMember_fBjLeEFee0qAzwY3XxJNVw", "name": "iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "unitRef": "Unit_Standard_shares_QN3-o3_MfEya7w9yidQ2qQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R109": { "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "longName": "41206 - Disclosure - Shareholders equity - BSA and AGA plans (Details)", "shortName": "Shareholders equity - BSA and AGA plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BsaPlansMember_aTdiFTS3lU-Kknf56s-9cg", "name": "ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted", "unitRef": "Unit_Standard_pure_bVd0MtE5GE6BXL5p4ofGQg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_14_2018_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2018PlanMember_Q1At_NhMR0mlljWfNe87eA", "name": "iva:SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted", "unitRef": "Unit_Divide_EUR_shares_M0ettPP0b0G1jtl2RL9smQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R110": { "role": "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails", "longName": "41207 - Disclosure - Shareholders equity - Share warrants (Details)", "shortName": "Shareholders equity - Share warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "110", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R111": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialDebtFinancialDebtDetails", "longName": "41301 - Disclosure - Financial debt - Financial debt (Details)", "shortName": "Financial debt - Financial debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "111", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:LoansReceived", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": null }, "R112": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialDebtMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails", "longName": "41302 - Disclosure - Financial debt - Maturity of long term debt and of short term borrowings and debt (Details)", "shortName": "Financial debt - Maturity of long term debt and of short term borrowings and debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "112", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:LoansReceived", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_ifrs-full_MaturityAxis_ifrs-full_NotLaterThanOneYearMember_T4Ip30Ee_EmPHvcmB05GZA", "name": "ifrs-full:LoansReceived", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R113": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsInPeriodBreakDownDetails", "longName": "41303 - Disclosure - Financial debt - Movements in the period break down (Details)", "shortName": "Financial debt - Movements in the period break down (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "113", "firstAnchor": { "contextRef": "As_Of_12_31_2022_yr-sbBLri02cA-LbcoaIhg", "name": "ifrs-full:Borrowings", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:IncreaseInBorrowingsThroughNewLeases", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfChangesInBorrowingsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R114": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsDetails", "longName": "41304 - Disclosure - Financial debt - Movements (Details)", "shortName": "Financial debt - Movements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "114", "firstAnchor": { "contextRef": "As_Of_12_31_2022_yr-sbBLri02cA-LbcoaIhg", "name": "ifrs-full:Borrowings", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:AdditionsToBorrowings", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfChangesInBorrowingsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R115": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "longName": "41305 - Disclosure - Financial debt - French state-guaranteed loan (\"PGE\") and equity recovery loans (\"PPR\") (Details)", "shortName": "Financial debt - French state-guaranteed loan (\"PGE\") and equity recovery loans (\"PPR\") (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "115", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_WfJWanks8U-OuMAm-leZ8A", "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": null }, "R116": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "longName": "41306 - Disclosure - Financial debt - Credit facility agreement with the European Investment Bank (Details)", "shortName": "Financial debt - Credit facility agreement with the European Investment Bank (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "116", "firstAnchor": { "contextRef": "As_Of_1_18_2024_l8ElHls0okewfG6T4pwcZw", "name": "ifrs-full:NotionalAmount", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember_hPd0EyNfJEmYiyWy7a9y0A", "name": "iva:BorrowingsEffectiveInterestRate", "unitRef": "Unit_Standard_pure_bVd0MtE5GE6BXL5p4ofGQg", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R117": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "longName": "41307 - Disclosure - Financial debt - Derivatives (Details)", "shortName": "Financial debt - Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "117", "firstAnchor": { "contextRef": "As_Of_8_31_2023_7i70l23Dn0O2fR9Vr3kz7Q", "name": "iva:WarrantsSubscriptionPrice", "unitRef": "Unit_Divide_EUR_shares_M0ettPP0b0G1jtl2RL9smQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_11_28_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_Bsa2022Member_gzlzFkH4YEiyU4XNEXXxVg", "name": "iva:IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "unitRef": "Unit_Standard_shares_QN3-o3_MfEya7w9yidQ2qQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R118": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialDebtLeaseLiabilitiesDetails", "longName": "41308 - Disclosure - Financial debt - Lease liabilities (Details)", "shortName": "Financial debt - Lease liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "118", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:LeaseLiabilities", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ifrs-full:DisclosureOfBorrowingsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:IncreaseDecreaseInLeaseLiabilities", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R119": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialDebtRoyaltyCertificatesLiabilitiesDetails", "longName": "41309 - Disclosure - Financial debt - Royalty Certificates liabilities (Details)", "shortName": "Financial debt - Royalty Certificates liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "119", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:FinancialLiabilities", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_BorrowingsByNameAxis_iva_RoyaltyCertificatesLiabilitiesMember_ViifQOEczU-7drZBToDDnQ", "name": "iva:RoyaltyCertificatesEffectiveInterestRate", "unitRef": "Unit_Standard_pure_bVd0MtE5GE6BXL5p4ofGQg", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R120": { "role": "http://www.inventivapharma.com/role/DisclosureProvisionsDetails", "longName": "41401 - Disclosure - Provisions (Details)", "shortName": "Provisions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "120", "firstAnchor": { "contextRef": "As_Of_12_31_2020_ZS1sCOo7l0mWQ7t0Hts3cw", "name": "ifrs-full:OtherLongtermProvisions", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "ifrs-full:DisclosureOfProvisionsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2021_To_12_31_2021_k5b1w8_-zEqkClCATCRpSA", "name": "iva:UnusedProvisionReversedOtherLongTermProvisions", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "ifrs-full:DisclosureOfProvisionsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R121": { "role": "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsPrincipalActuarialAssumptionsDetails", "longName": "41501 - Disclosure - Provisions for retirement benefit obligations - Principal actuarial assumptions (Details)", "shortName": "Provisions for retirement benefit obligations - Principal actuarial assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "121", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:ActuarialAssumptionOfRetirementAge2019", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfAssumptionsUsedToMeasureRetirementBenefitObligationsExplanatory", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:ActuarialAssumptionOfRetirementAge2019", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfAssumptionsUsedToMeasureRetirementBenefitObligationsExplanatory", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R122": { "role": "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsNetProvisionDetails", "longName": "41502 - Disclosure - Provisions for retirement benefit obligations - Net provision (Details)", "shortName": "Provisions for retirement benefit obligations - Net provision (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "122", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:DefinedBenefitObligationAtPresentValue", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": null }, "R123": { "role": "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsChangesInNetProvisionDetails", "longName": "41503 - Disclosure - Provisions for retirement benefit obligations - Changes in the net provision (Details)", "shortName": "Provisions for retirement benefit obligations - Changes in the net provision (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "123", "firstAnchor": { "contextRef": "As_Of_12_31_2022_yr-sbBLri02cA-LbcoaIhg", "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2021_To_12_31_2021_k5b1w8_-zEqkClCATCRpSA", "name": "ifrs-full:IncreaseDecreaseThroughOtherChangesNetDefinedBenefitLiabilityAsset", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R124": { "role": "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails", "longName": "41504 - Disclosure - Provisions for retirement benefit obligations - Breakdown of expense recognized for the year (Details)", "shortName": "Provisions for retirement benefit obligations - Breakdown of expense recognized for the year (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "124", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:CurrentServiceCostDefinedBenefitPlans", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:CurrentServiceCostDefinedBenefitPlans", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R125": { "role": "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails", "longName": "41505 - Disclosure - Provisions for retirement benefit obligations - Breakdown of actuarial gains and losses recognized in comprehensive income (Details)", "shortName": "Provisions for retirement benefit obligations - Breakdown of actuarial gains and losses recognized in comprehensive income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "125", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeLossForRetirementBenefitObligationsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeLossForRetirementBenefitObligationsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R126": { "role": "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails", "longName": "41506 - Disclosure - Provisions for retirement benefit obligations - Sensitivity analysis (Details)", "shortName": "Provisions for retirement benefit obligations - Sensitivity analysis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "126", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:DefinedBenefitObligationAtPresentValue", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_ifrs-full_ActuarialAssumptionsAxis_ifrs-full_ActuarialAssumptionOfDiscountRatesMember_G99bvKjyGUaL3inlSgLt4w", "name": "iva:PercentageOfReasonablyPossibleIncreaseOrDecreaseInActuarialAssumption", "unitRef": "Unit_Standard_pure_bVd0MtE5GE6BXL5p4ofGQg", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R127": { "role": "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails", "longName": "41601 - Disclosure - Other current and non-current liabilities (Details)", "shortName": "Other current and non-current liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "127", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "iva:EmployeeRelatedPayables", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "iva:EmployeeRelatedPayables", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R128": { "role": "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "longName": "41602 - Disclosure - Other current and non-current liabilities - Additional information (Details)", "shortName": "Other current and non-current liabilities - Additional information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "128", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:OtherNoncurrentLiabilities", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "iva:IfrsIncreaseDecreaseInOtherCurrentLiabilities", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R129": { "role": "http://www.inventivapharma.com/role/DisclosureTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails", "longName": "41701 - Disclosure - Trade payables, short-term contract liabilities and other current liabilities (Details)", "shortName": "Trade payables, short-term contract liabilities and other current liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "129", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "iva:TradePayablesAndOtherCurrentLiabilities", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock", "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R130": { "role": "http://www.inventivapharma.com/role/DisclosureTradePayablesBreakDownDetails", "longName": "41702 - Disclosure - Trade payables break down (Details)", "shortName": "Trade payables break down (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "130", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:TradeAndOtherCurrentPayables", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:TradeAndOtherCurrentPayables", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R131": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "longName": "41801 - Disclosure - Financial assets and liabilities (Details)", "shortName": "Financial assets and liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "131", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:FinancialAssets", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember_7PZWDgM020SejkYO00X6Cw", "name": "ifrs-full:FinancialLiabilities", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R132": { "role": "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails", "longName": "41901 - Disclosure - Revenues and other income (Details)", "shortName": "Revenues and other income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "132", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:CurrentTaxCreditResearchIncome", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:RevenueAndOtherIncomeTableTextBlock", "ifrs-full:DisclosureOfRevenueExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R133": { "role": "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails", "longName": "41902 - Disclosure - Revenues and Other Income - Additional information (Details)", "shortName": "Revenues and Other Income - Additional information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "133", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:ResearchTaxCredits", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R134": { "role": "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails", "longName": "42001 - Disclosure - Operating expenses (Details)", "shortName": "Operating expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "134", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:Disposables", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "iva:Disposables", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R135": { "role": "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails", "longName": "42002 - Disclosure - Operating expenses - Personnel costs and headcount (Details)", "shortName": "Operating expenses - Personnel costs and headcount (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "135", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:NumberOfEmployees", "unitRef": "Unit_Standard_employee_mY7CZki_iEmADdBjADDRrg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:NumberOfEmployees", "unitRef": "Unit_Standard_employee_mY7CZki_iEmADdBjADDRrg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R136": { "role": "http://www.inventivapharma.com/role/DisclosureOperatingExpensesAdditionalInformationDetails", "longName": "42003 - Disclosure - Operating expenses - Additional Information (Details)", "shortName": "Operating expenses - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "136", "firstAnchor": { "contextRef": "Duration_11_1_2022_To_11_30_2022_Hb4_tbW4NUCAuQ86c-GSGQ", "name": "iva:WithHoldingTaxRate", "unitRef": "Unit_Standard_pure_bVd0MtE5GE6BXL5p4ofGQg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "iva:OperatingExpensesOnResearchAndDevelopmentMarketingAndGeneralAdministrativeTableTextBlock", "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_11_1_2022_To_11_30_2022_Hb4_tbW4NUCAuQ86c-GSGQ", "name": "iva:WithHoldingTaxRate", "unitRef": "Unit_Standard_pure_bVd0MtE5GE6BXL5p4ofGQg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "iva:OperatingExpensesOnResearchAndDevelopmentMarketingAndGeneralAdministrativeTableTextBlock", "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R137": { "role": "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails", "longName": "42101 - Disclosure - Other operating income and expenses - (Details)", "shortName": "Other operating income and expenses - (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "137", "firstAnchor": { "contextRef": "Duration_1_1_2021_To_12_31_2021_k5b1w8_-zEqkClCATCRpSA", "name": "ifrs-full:GainsOnDisposalsOfNoncurrentAssets", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2021_To_12_31_2021_k5b1w8_-zEqkClCATCRpSA", "name": "ifrs-full:GainsOnDisposalsOfNoncurrentAssets", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R138": { "role": "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails", "longName": "42102 - Disclosure - Other operating income and expenses - Additional Information (Details)", "shortName": "Other operating income and expenses - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "138", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_WfJWanks8U-OuMAm-leZ8A", "name": "iva:IncreaseDecreaseInOtherOperatingExpense", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2022_To_12_31_2022_WfJWanks8U-OuMAm-leZ8A", "name": "iva:IncreaseDecreaseInOtherOperatingExpense", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DisclosureOfOtherOperatingIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R139": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails", "longName": "42201 - Disclosure - Financial income and expenses (Details)", "shortName": "Financial income and expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "139", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:FinancialIncomeAndExpensesTableTextBlock", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:FinancialIncomeAndExpensesTableTextBlock", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R140": { "role": "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails", "longName": "42301 - Disclosure - Share of net profit - Equity method (Details)", "shortName": "Share of net profit - Equity method (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "140", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:GeneralAndAdministrativeExpense", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_10_11_2023_To_12_31_2023_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_bKuX6ZdevkW3Rz76A8PVuA", "name": "iva:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock", "iva:ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R141": { "role": "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails", "longName": "42401 - Disclosure - Income tax (Details)", "shortName": "Income tax (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "141", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:AccountingProfit", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:AccountingProfit", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R142": { "role": "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShareDetails", "longName": "42501 - Disclosure - Basic and diluted loss per share (Details)", "shortName": "Basic and diluted loss per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "142", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_rRHA5CAUL0-a9MCpYXsUHg", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": null }, "R143": { "role": "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails", "longName": "42601 - Disclosure - Commitments related to operational activities (Details)", "shortName": "Commitments related to operational activities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "143", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:ContractualCapitalCommitments", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfCommitmentsRelatedOperationalActivitiesTableTextBlock", "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis_iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember_wyHRmHxZc0O7M8Rx37o1ZA", "name": "iva:CommitmentsAmountPayableForServicesReceivedUnderContract", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R144": { "role": "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesCommitmentsGivenAndReceivedDetails", "longName": "42602 - Disclosure - Commitments related to operational activities - Commitments given and received (Details)", "shortName": "Commitments related to operational activities - Commitments given and received (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "144", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:ContractualCapitalCommitments", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfCommitmentsRelatedOperationalActivitiesTableTextBlock", "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "iva:AgreementsConcerningProvisionOfFacilities", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfCommitmentsRelatedOperationalActivitiesTableTextBlock", "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R145": { "role": "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails", "longName": "42701 - Disclosure - Related party transactions - Summary of transactions with key management personnel (Details)", "shortName": "Related party transactions - Summary of transactions with key management personnel (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "145", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_pBhT7Zr00UCatGAzwqXrLQ", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_12_31_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_ifrs-full_KeyManagementPersonnelOfEntityOrParentMember_pBhT7Zr00UCatGAzwqXrLQ", "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R146": { "role": "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "longName": "42702 - Disclosure - Related-party transactions (Details)", "shortName": "Related-party transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "146", "firstAnchor": { "contextRef": "Duration_5_25_2023_To_5_25_2023_Hvt9rdQC4kOwhMjz4XJajQ", "name": "iva:PercentageOfSeverancePaymentCappedOnSalary", "unitRef": "Unit_Standard_pure_bVd0MtE5GE6BXL5p4ofGQg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_5_25_2023_To_5_25_2023_Hvt9rdQC4kOwhMjz4XJajQ", "name": "iva:PercentageOfSeverancePaymentCappedOnSalary", "unitRef": "Unit_Standard_pure_bVd0MtE5GE6BXL5p4ofGQg", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true, "unique": true } }, "R147": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskDetails", "longName": "42801 - Disclosure - Financial risk management - Exposure to foreign exchange risk (Details)", "shortName": "Financial risk management - Exposure to foreign exchange risk (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "147", "firstAnchor": { "contextRef": "Duration_7_15_2020_To_7_15_2020_7-gMmkgvJ0W3aD2psMnvcg", "name": "iva:GrossProceedsFromIssuingShares", "unitRef": "Unit_Standard_USD_KpL5oHjdjEOIM5rkKphzLA", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_15_2020_To_5_14_2021_ifrs-full_ClassesOfFinancialInstrumentsAxis_iva_IfrsForeignExchangeForwardMember_ytArDaUO1UujmnE9eL_s2g", "name": "iva:NumberOfDerivativeContractsCompleted", "unitRef": "Unit_Standard_contract_6eeceD4v5EudM6bj9IhQNA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R148": { "role": "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails", "longName": "42802 - Disclosure - Financial risk management - Exposure to foreign exchange risk - Sensitivity Analysis (Details)", "shortName": "Financial risk management - Exposure to foreign exchange risk - Sensitivity Analysis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "148", "firstAnchor": { "contextRef": "As_Of_12_31_2023_LKSJiS4A90i-xdUO-VcuBQ", "name": "ifrs-full:FinancialAssetsAtFairValue", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_ifrs-full_TypesOfRisksAxis_iva_DerivativesRiskMember_ihQPjQsToES0f1ENUDx5AQ", "name": "iva:IncreaseOrDecreaseInFairValueOfWarrantsDueToReasonablyPossibleIncreaseOrDecreaseInVolatility", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } }, "R149": { "role": "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "longName": "42901 - Disclosure - Events after the reporting date (Details)", "shortName": "Events after the reporting date (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "149", "firstAnchor": { "contextRef": "As_Of_1_18_2024_l8ElHls0okewfG6T4pwcZw", "name": "ifrs-full:NotionalAmount", "unitRef": "Unit_Standard_EUR_Y7WQMavxGUyUMCsEXmcvcA", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_1_4_2024_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfWarrantsMember_QcoZXripo0Sxz1-GOlnDZg", "name": "iva:PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised", "unitRef": "Unit_Standard_pure_bVd0MtE5GE6BXL5p4ofGQg", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20231231x20f.htm", "unique": true } } }, "tag": { "iva_AccountingPrinciplesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AccountingPrinciplesAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Accounting Principles" } } }, "auth_ref": [] }, "ifrs-full_AccountingProfit": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccountingProfit", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Accounting profit", "terseLabel": "Loss before tax" } }, "en": { "role": { "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r47", "r48" ] }, "iva_AccrualInterestsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AccrualInterestsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The information pertaining to accrual interest.", "label": "Accrual Interests [Member]" } } }, "auth_ref": [] }, "ifrs-full_AccrualsClassifiedAsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccrualsClassifiedAsCurrent", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accruals classified as current", "terseLabel": "Accrued expenses" } }, "en": { "role": { "documentation": "The amount of accruals classified as current. [Refer: Accruals]" } } }, "auth_ref": [ "r290" ] }, "iva_AccrualsClassifiedAsCurrentRelatingToScientificProjects": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AccrualsClassifiedAsCurrentRelatingToScientificProjects", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of accruals classified as current relating to scientific projects", "label": "Accruals classified as current relating to scientific projects", "terseLabel": "Accrued liabilities relating to scientific projects" } } }, "auth_ref": [] }, "iva_AccrualsSettledDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AccrualsSettledDuringPeriod", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxDisputeSettlementDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents the accruals settled during the period.", "label": "Accruals Settled During Period", "terseLabel": "Accruals settlement" } } }, "auth_ref": [] }, "iva_AccrualsSettledOffSetAgainstValueAddedTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AccrualsSettledOffSetAgainstValueAddedTaxReceivables", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxDisputeSettlementDetails" ], "lang": { "en-us": { "role": { "documentation": "it represents the accruals offset against value added tax receivables.", "label": "Accruals Settled Off Set Against Value Added Tax Receivables", "terseLabel": "Accruals settled through offset against VAT credits" } } }, "auth_ref": [] }, "iva_AccrualsSettledThroughPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AccrualsSettledThroughPayments", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxDisputeSettlementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of accruals settled through payments.", "label": "Accruals Settled Through Payments", "terseLabel": "Settlement payments" } } }, "auth_ref": [] }, "iva_AccruedExpensesToBePaidToTaxAuthorities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AccruedExpensesToBePaidToTaxAuthorities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued expenses to be paid to the tax authorities.", "label": "Accrued Expenses To Be Paid to Tax Authorities", "terseLabel": "Accrued expenses to be paid to the tax authorities - CIR 2013 to 2015" } } }, "auth_ref": [] }, "iva_AccruedIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AccruedIncomeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for accrued income.", "label": "Current accrued income", "terseLabel": "Current accrued income" } } }, "auth_ref": [] }, "iva_AccruedPayrollAndOtherEmployeeRelatedTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AccruedPayrollAndOtherEmployeeRelatedTaxes", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount pertaining to accrued payroll and other employee related taxes.", "label": "Accrued payroll and other employeerelated taxes", "terseLabel": "Accrued payroll and other employeerelated taxes" } } }, "auth_ref": [] }, "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated depreciation, amortisation and impairment [member]", "terseLabel": "Amortization", "verboseLabel": "Depreciation and impairment" } }, "en": { "role": { "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]" } } }, "auth_ref": [ "r55", "r60", "r96", "r105", "r108" ] }, "ifrs-full_AccumulatedImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AccumulatedImpairmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInventoriesDetails" ], "lang": { "en-us": { "role": { "label": "Inventories write-down" } }, "en": { "role": { "documentation": "This member stands for accumulated impairment. [Refer: Impairment loss]" } } }, "auth_ref": [ "r173", "r183", "r258", "r295", "r304", "r305", "r306" ] }, "ifrs-full_ActuarialAssumptionOfDiscountRates": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ActuarialAssumptionOfDiscountRates", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsPrincipalActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial assumption of discount rates", "terseLabel": "Discount rate" } }, "en": { "role": { "documentation": "The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]" } } }, "auth_ref": [ "r298" ] }, "iva_ActuarialAssumptionOfDiscountRatesAt0.75PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ActuarialAssumptionOfDiscountRatesAt0.75PercentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 0.75% used as actuarial assumptions.", "label": "Discount rate at 0.75%" } } }, "auth_ref": [] }, "iva_ActuarialAssumptionOfDiscountRatesAt1.00PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ActuarialAssumptionOfDiscountRatesAt1.00PercentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 1.00% used as actuarial assumptions.", "label": "Discount rate at 1.00%" } } }, "auth_ref": [] }, "iva_ActuarialAssumptionOfDiscountRatesAt1.25PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ActuarialAssumptionOfDiscountRatesAt1.25PercentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 1.25% used as actuarial assumptions", "label": "Discount rate at 1.25%" } } }, "auth_ref": [] }, "iva_ActuarialAssumptionOfDiscountRatesAt2.95PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ActuarialAssumptionOfDiscountRatesAt2.95PercentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 2.95% used as actuarial assumptions.", "label": "Actuarial Assumption Of Discount Rates At 2.95 Percent [Member]", "terseLabel": "Discount rate at 2.95%" } } }, "auth_ref": [] }, "iva_ActuarialAssumptionOfDiscountRatesAt3.20PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ActuarialAssumptionOfDiscountRatesAt3.20PercentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 3.20% used as actuarial assumptions.", "label": "Actuarial Assumption Of Discount Rates At 3.20 Percent [Member]", "terseLabel": "Discount rate at 3.20%" } } }, "auth_ref": [] }, "iva_ActuarialAssumptionOfDiscountRatesAt3.45PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ActuarialAssumptionOfDiscountRatesAt3.45PercentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 3.45% used as actuarial assumptions.", "label": "Discount rate at 3.45%" } } }, "auth_ref": [] }, "iva_ActuarialAssumptionOfDiscountRatesAt3.45PercentOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ActuarialAssumptionOfDiscountRatesAt3.45PercentOneMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 3.45% used as actuarial assumptions.", "label": "Actuarial Assumption Of Discount Rates At 3.45 Percent one [Member]", "terseLabel": "Discount rate at 3.45%" } } }, "auth_ref": [] }, "iva_ActuarialAssumptionOfDiscountRatesAt3.70PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ActuarialAssumptionOfDiscountRatesAt3.70PercentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 3.70% used as actuarial assumptions.", "label": "Discount rate at 3.70%" } } }, "auth_ref": [] }, "iva_ActuarialAssumptionOfDiscountRatesAt3.95PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ActuarialAssumptionOfDiscountRatesAt3.95PercentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the discount rates of 3.95% used as actuarial assumptions.", "label": "Discount rate at 3.95%" } } }, "auth_ref": [] }, "ifrs-full_ActuarialAssumptionOfDiscountRatesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ActuarialAssumptionOfDiscountRatesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Discount rate" } }, "en": { "role": { "documentation": "This member stands for the discount rates used as actuarial assumptions. [Refer: Actuarial assumptions [member]]" } } }, "auth_ref": [ "r299" ] }, "ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ActuarialAssumptionOfExpectedRatesOfSalaryIncreases", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsPrincipalActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial assumption of expected rates of salary increases", "terseLabel": "Salary growth rate" } }, "en": { "role": { "documentation": "The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]" } } }, "auth_ref": [ "r298" ] }, "iva_ActuarialAssumptionOfRatesOfPayrollTaxes": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ActuarialAssumptionOfRatesOfPayrollTaxes", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsPrincipalActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The expected rate of payroll taxes used as a significant actuarial assumption to determine the present value of a defined benefit obligation.", "label": "Actuarial Assumption Of Rates Of Payroll Taxes", "terseLabel": "Payroll taxes" } } }, "auth_ref": [] }, "ifrs-full_ActuarialAssumptionOfRetirementAge2019": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ActuarialAssumptionOfRetirementAge2019", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsPrincipalActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial assumption of retirement age", "terseLabel": "Retirement age" } }, "en": { "role": { "documentation": "The retirement age used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]" } } }, "auth_ref": [ "r298" ] }, "ifrs-full_ActuarialAssumptionsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ActuarialAssumptionsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial assumptions [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r65" ] }, "ifrs-full_ActuarialAssumptionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ActuarialAssumptionsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial assumptions [member]" } }, "en": { "role": { "documentation": "This member stands for all actuarial assumptions. Actuarial assumptions are the entity\u2019s unbiased and mutually compatible best estimates of the demographic and financial variables that will determine the ultimate cost of providing post-employment benefits. It also represents the standard value for the 'Actuarial assumptions' axis if no other member is used." } } }, "auth_ref": [ "r65" ] }, "ifrs-full_ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ActuarialGainsLossesArisingFromChangesInDemographicAssumptionsNetOfTaxDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails": { "parentTag": "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial gains (losses) arising from changes in demographic assumptions, net of tax, defined benefit plans", "terseLabel": "Demographic changes" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, resulting from actuarial gains (losses) arising from changes in demographic assumptions that result in remeasurements of the net defined benefit liability (asset). Demographic assumptions deal with matters such as: (a) mortality; (b) rates of employee turnover, disability and early retirement; (c) the proportion of plan members with dependants who will be eligible for benefits; (d) the proportion of plan members who will select each form of payment option available under the plan terms; and (e) claim rates under medical plans. [Refer: Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in demographic assumptions]" } } }, "auth_ref": [ "r296" ] }, "ifrs-full_ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ActuarialGainsLossesArisingFromChangesInFinancialAssumptionsNetOfTaxDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails": { "parentTag": "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Actuarial gains (losses) arising from changes in financial assumptions, net of tax, defined benefit plans", "terseLabel": "Changes in actuarial assumptions" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, resulting from actuarial gains (losses) arising from changes in financial assumptions that result in remeasurements of the net defined benefit liability (asset). Financial assumptions deal with items such as: (a) the discount rate; (b) benefit levels, excluding any cost of the benefits to be met by employees, and future salary; (c) in the case of medical benefits, future medical costs, including claim handling costs (ie the costs that will be incurred in processing and resolving claims, including legal and adjuster's fees); and (d) taxes payable by the plan on contributions relating to service before the reporting date or on benefits resulting from that service. [Refer: Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from actuarial gains (losses) arising from changes in financial assumptions]" } } }, "auth_ref": [ "r296" ] }, "ifrs-full_AdditionalProvisionsOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionalProvisionsOtherProvisions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Additional provisions, other provisions", "terseLabel": "Additions" } }, "en": { "role": { "documentation": "The amount of additional other provisions made. [Refer: Other provisions]" } } }, "auth_ref": [ "r93" ] }, "iva_AdditionalProvisionsOtherShortTermProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AdditionalProvisionsOtherShortTermProvisions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of additional other provisions made, classified as short-term.", "label": "Additional Provisions, Other Short-Term Provisions", "terseLabel": "Additions" } } }, "auth_ref": [] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Additions other than through business combinations, intangible assets other than goodwill", "terseLabel": "Increases", "verboseLabel": "Intangible assets acquired" } }, "en": { "role": { "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r97" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Additions other than through business combinations, property, plant and equipment", "terseLabel": "Acquisitions" } }, "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]" } } }, "auth_ref": [ "r56" ] }, "iva_AdditionsToBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AdditionsToBorrowings", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of additions to borrowings.", "label": "Additions to Borrowings", "terseLabel": "Additions" } } }, "auth_ref": [] }, "ifrs-full_AdditionsToRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdditionsToRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Additions To Right of use Assets", "terseLabel": "Additions to right-of-use assets" } }, "en": { "role": { "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r153" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Adjusted weighted average number of ordinary shares outstanding", "terseLabel": "Weighted average number of shares outstanding used to calculate diluted loss per share" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r88" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInInventories", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in inventories", "terseLabel": "Decrease / (increase) in inventories" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]" } } }, "auth_ref": [ "r309" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in prepaid expenses", "terseLabel": "Decrease / (increase) of prepaid expenses" } }, "en": { "role": { "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]" } } }, "auth_ref": [ "r311" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in trade and other receivables", "terseLabel": "Decrease / (increase) in operating and other receivables" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } } }, "auth_ref": [ "r311" ] }, "iva_AdjustmentsForDepreciationAmortisationAndProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AdjustmentsForDepreciationAmortisationAndProvisions", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for depreciation, amortisation expense and provisions to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments for Depreciation, Amortisation and Provisions", "terseLabel": "Depreciation, amortization and provisions" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForFairValueGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForFairValueGainsLosses", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for fair value losses (gains)", "terseLabel": "Fair value variation through profit and loss" } }, "en": { "role": { "documentation": "Adjustments for fair value losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r310" ] }, "ifrs-full_AdjustmentsForFinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForFinanceIncomeCost", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for finance income (cost)", "negatedLabel": "Cost of debt" } }, "en": { "role": { "documentation": "Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]" } } }, "auth_ref": [ "r311" ] }, "ifrs-full_AdjustmentsForIncomeTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForIncomeTaxExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for income tax expense", "terseLabel": "Deferred and current taxes" } }, "en": { "role": { "documentation": "Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r115" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade and other payables", "verboseLabel": "Increase / (decrease) in operating and other payables" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } } }, "auth_ref": [ "r311" ] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile profit (loss) [abstract]", "terseLabel": "Elimination of non-cash or non-operating income and expenses" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for share-based payments", "terseLabel": "Sharebased compensation expense" } }, "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r310" ] }, "iva_AdjustmentsForTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AdjustmentsForTaxCredits", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for tax credit to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Tax Credits", "terseLabel": "Tax credits" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForUndistributedProfitsOfAssociates": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForUndistributedProfitsOfAssociates", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for undistributed profits of associates", "negatedLabel": "Share of net profit of associates and joint ventures accounted for using the equity method" } }, "en": { "role": { "documentation": "Adjustments for undistributed profits of associates to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Associates [member]; Profit (loss)]" } } }, "auth_ref": [ "r310" ] }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for unrealised foreign exchange losses (gains)", "terseLabel": "Exchange (gains) / losses" } }, "en": { "role": { "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r246", "r310" ] }, "iva_AdjustmentsToReconcileSeparateFinancialStatementsToConsolidatedFinancialStatementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AdjustmentsToReconcileSeparateFinancialStatementsToConsolidatedFinancialStatementsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceConsolidatedFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands Adjustments to reconcile separate financial statements to consolidated financial statements", "label": "Adjustments to reconcile separate financial statements to consolidated financial statements [member]", "terseLabel": "Adjustments to reconcile separate financial statements to consolidated financial statements" } } }, "auth_ref": [] }, "iva_AdvancePaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AdvancePaymentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for advance payment.", "label": "Advance payment", "terseLabel": "Advance payment" } } }, "auth_ref": [] }, "iva_Aga2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "Aga2022Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2022 Plan).", "label": "AGA 2022 [Member]", "terseLabel": "AGA 2022" } } }, "auth_ref": [] }, "iva_AgaBonusPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AgaBonusPlansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA Bonus plan", "label": "AGA Bonus Plans", "terseLabel": "AGA Bonus Plans" } } }, "auth_ref": [] }, "iva_AgaBonusShareAwardPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AgaBonusShareAwardPlansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA bonus share award plans.", "label": "AGA Bonus Share Award Plans Member" } } }, "auth_ref": [] }, "iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AggregateAmountToBeReceivedEitherInExchangeForNewSharesOfCompanyOrThroughReceiptOfUpfrontOrMilestonePayments", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Aggregate amount to be received by the company, either in exchange for new shares of the Company or through the receipt of upfront or milestone payments, pursuant to the debt arrangement.", "label": "Aggregate Amount To Be Received Either In Exchange For New Shares Of The Company Or Through The Receipt Of Upfront Or Milestone Payments", "verboseLabel": "Aggregate amount to be received under the conditions precedent to the EIB Financing" } } }, "auth_ref": [] }, "ifrs-full_AggregatedTimeBandsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AggregatedTimeBandsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails", "http://www.inventivapharma.com/role/DisclosureTradePayablesBreakDownDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Aggregated time bands [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r24", "r150", "r154", "r155", "r156", "r157", "r158", "r164", "r177", "r234", "r260", "r265" ] }, "iva_AgreementWithContractManufacturingOrganizationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AgreementWithContractManufacturingOrganizationsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for agreement with clinical and commercial supply manufacturing, commercial and pre-commercial activities, research and development activities and other services and products.", "label": "Agreement With Contract Manufacturing Organizations [Member]", "terseLabel": "CMO" } } }, "auth_ref": [] }, "iva_AgreementsConcerningProvisionOfFacilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AgreementsConcerningProvisionOfFacilities", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of agreements concerning provision of facilities.", "label": "Agreements concerning the provision of facilities", "terseLabel": "Agreements concerning the provision of facilities" } } }, "auth_ref": [] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "AllCurrenciesDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ifrs-full_AllLevelsOfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AllLevelsOfFairValueHierarchyMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "All levels of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r64", "r143" ] }, "iva_AllWarrantsAreExercisedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AllWarrantsAreExercisedMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents the scenario that all warrants are exercised", "label": "All warrants are exercised [Member]", "terseLabel": "All warrants are exercised" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "iva_AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AmericanDepositarySharesEachRepresentingOneOrdinaryShareMember", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "This member stands for American Depositary Shares, each representing one ordinary share.", "label": "American Depositary Shares, each representing one ordinary share" } } }, "auth_ref": [] }, "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AmortisationIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Amortisation, intangible assets other than goodwill", "terseLabel": "Depreciation expenses" } }, "en": { "role": { "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r99" ] }, "iva_AmountInvoicedToCounterparty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AmountInvoicedToCounterparty", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicenseAndCollaborationAgreementWithCttqDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This amount represents the information of invoiced to counterparty.", "label": "Amount Invoiced To Counterparty", "terseLabel": "Milestone payment received", "verboseLabel": "Amount invoiced to counterparty" } } }, "auth_ref": [] }, "iva_AmountInvoicedToCounterpartyForAdditionalPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AmountInvoicedToCounterpartyForAdditionalPayment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicenseAndCollaborationAgreementWithCttqDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This amount represents the information of invoiced to counterparty for additional payment.", "label": "Amount Invoiced To Counterparty For Additional Payment", "terseLabel": "Amount invoiced to counterparty for additional payment" } } }, "auth_ref": [] }, "iva_AmountInvoicedToCounterpartyForInitialPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AmountInvoicedToCounterpartyForInitialPayment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicenseAndCollaborationAgreementWithCttqDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This amount represents the information of invoiced to counterparty for initial payment.", "label": "Amount Invoiced To Counterparty For Initial Payment", "terseLabel": "Amount invoiced to counterparty for milestone payment" } } }, "auth_ref": [] }, "iva_AmountOfAdditionalClaim": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AmountOfAdditionalClaim", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of additional claim.", "label": "Amount of additional claim", "terseLabel": "Amount of additional claim" } } }, "auth_ref": [] }, "iva_AmountOfBankGuaranteeRelatedToPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AmountOfBankGuaranteeRelatedToPrincipal", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of bank guarantee related to principal", "label": "Amount Of Bank Guarantee Related To Principal", "verboseLabel": "Amount of bank guarantee related to principal" } } }, "auth_ref": [] }, "iva_AmountOfDepositsClosed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AmountOfDepositsClosed", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of deposits of the entity closed during the period.", "label": "Amount Of Deposits Closed", "terseLabel": "Amount of deposits closed" } } }, "auth_ref": [] }, "iva_AmountOfExpensesDenominatedInForeignCurrency": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AmountOfExpensesDenominatedInForeignCurrency", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesForeignCurrencyTransactionsAndSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of expenses denominated in foreign currency", "label": "Amount of expenses denominated in foreign currency" } } }, "auth_ref": [] }, "iva_AmountOfOffsettingVatCreditReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AmountOfOffsettingVatCreditReceivables", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the settlement of duties in respective with VAT credit receivables.", "label": "Amount of Offsetting VAT Credit Receivables", "terseLabel": "Amount of offsetting against VAT credit receivables" } } }, "auth_ref": [] }, "iva_AmountOfReinvoicingOfSpecificCostsRelatedToCroExpensesForClinicalTrailsInChina": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AmountOfReinvoicingOfSpecificCostsRelatedToCroExpensesForClinicalTrailsInChina", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of reinvoicing of specific costs related to CRO expenses for clinical trials in China.", "label": "Amount of Reinvoicing of Specific Costs Related to CRO Expenses for Clinical Trails in China", "terseLabel": "Specific costs related to CRO expenses for clinical trials" } } }, "auth_ref": [] }, "iva_AmountOfReleaseOfTermAccountPledge": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AmountOfReleaseOfTermAccountPledge", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of release of term account pledge.", "label": "Amount of Release of Term Account Pledge", "terseLabel": "Amount of Release of Term Account Pledge" } } }, "auth_ref": [] }, "iva_AmountOfSubcontractingProvisionReversed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AmountOfSubcontractingProvisionReversed", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of subcontracting expenses reversed.", "label": "Amount of Subcontracting Provision Reversed", "terseLabel": "Amount of expenses reversed" } } }, "auth_ref": [] }, "iva_AmountOfSubcontractingTaxCreditReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AmountOfSubcontractingTaxCreditReceivable", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of subcontracting tax credit receivable.", "label": "Amount of Subcontracting Tax Credit Receivable", "terseLabel": "Amount of receivable" } } }, "auth_ref": [] }, "iva_AmountOfSubcontractingTaxRebateGrantedByTaxAuthorities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AmountOfSubcontractingTaxRebateGrantedByTaxAuthorities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of subcontracting tax rebate received from French tax authorities.", "label": "Amount of Subcontracting Tax Rebate Granted by Tax Authorities", "terseLabel": "Amount of expenses reversed" } } }, "auth_ref": [] }, "iva_AmountOfVestingOfBonusSharesAwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AmountOfVestingOfBonusSharesAwards", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the shares awarded vested amount.", "label": "Vesting of bonus shares awards", "terseLabel": "Vesting of bonus shares" } } }, "auth_ref": [] }, "iva_AmountPaidInCashForDuties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AmountPaidInCashForDuties", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the net amount paid in cash to French tax authorities.", "label": "Amount Paid in Cash For Duties", "terseLabel": "Net amount paid by bank transfer" } } }, "auth_ref": [] }, "iva_AmountPayableToRelatedPartiesForTransferOfPatentIntellectualPropertyRights": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AmountPayableToRelatedPartiesForTransferOfPatentIntellectualPropertyRights", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount payable to related parties for transfer of patent intellectual property rights", "label": "Amount payable to related parties for transfer of patent intellectual property rights" } } }, "auth_ref": [] }, "iva_AmountPayableToRelatedPartiesForTransferOfPatentIntellectualPropertyRightsConditionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AmountPayableToRelatedPartiesForTransferOfPatentIntellectualPropertyRightsConditionalAmount", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount payable to related parties for transfer of patent intellectual property rights, conditional amount", "label": "Amount payable to related parties for transfer of patent intellectual property rights, conditional amount" } } }, "auth_ref": [] }, "iva_AmountPayableToRelatedPartiesForTransferOfPatentIntellectualPropertyRightsUnconditionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AmountPayableToRelatedPartiesForTransferOfPatentIntellectualPropertyRightsUnconditionalAmount", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount payable to related parties for transfer of patent intellectual property rights, unconditional amount", "label": "Amount payable to related parties for transfer of patent intellectual property rights, unconditional amount" } } }, "auth_ref": [] }, "ifrs-full_ApplicableTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ApplicableTaxRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Applicable tax rate", "verboseLabel": "Theoretical tax rate" } }, "en": { "role": { "documentation": "The applicable income tax rate." } } }, "auth_ref": [ "r48" ] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceConsolidatedFinancialStatementsDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r21", "r142", "r143", "r145", "r207", "r211" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets [abstract]", "terseLabel": "ASSETS" } } }, "auth_ref": [] }, "iva_AtMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AtMarketOfferingMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for at-the market offering (ATM).", "label": "At Market Offering [Member]", "terseLabel": "ATM" } } }, "auth_ref": [] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Attribution of expenses by nature to their function [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r281", "r284" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r272", "r273", "r274" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r272", "r273", "r274" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r272", "r273", "r274" ] }, "iva_August2023FinancingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "August2023FinancingMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for August 2023 financing.", "label": "August 2023 financing [Member]", "terseLabel": "August 2023 financing" } } }, "auth_ref": [] }, "iva_August2023ShareIssuanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "August2023ShareIssuanceMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents august 2023.", "label": "August 2023 Share Issuance [Member]", "terseLabel": "August 2023" } } }, "auth_ref": [] }, "ifrs-full_AverageEffectiveTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AverageEffectiveTaxRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Average effective tax rate", "terseLabel": "Effective tax rate" } }, "en": { "role": { "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]" } } }, "auth_ref": [ "r48" ] }, "ifrs-full_AverageForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "AverageForeignExchangeRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Average foreign exchange rate", "terseLabel": "Average exchange rate for the period" } }, "en": { "role": { "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies." } } }, "auth_ref": [ "r284" ] }, "iva_AverageLifeOtherEquityInstrumentsGranted": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "AverageLifeOtherEquityInstrumentsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "The average life of other equity instruments granted.", "label": "Average Life, Other Equity Instruments Granted", "terseLabel": "Average life (years)" } } }, "auth_ref": [] }, "iva_BasedOnMarketConditionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "BasedOnMarketConditionMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to based on market condition.", "label": "Based On Market Condition [Member]", "terseLabel": "Based On Market Condition" } } }, "auth_ref": [] }, "iva_BasedOnNonMarketConditionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "BasedOnNonMarketConditionMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to based on non-market condition.", "label": "Based On Non-Market Condition [Member]", "terseLabel": "Based On Non-Market Condition" } } }, "auth_ref": [] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Basic earnings (loss) per share", "terseLabel": "Basic loss per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r86", "r87" ] }, "iva_BeiEmpruntPart12022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "BeiEmpruntPart12022Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The information pertaining to BEI EMPRUNT PART 1 2022.", "label": "BEI EMPRUNT PART 1 2022 [Member]", "terseLabel": "BEI EMPRUNT PART 1 2022" } } }, "auth_ref": [] }, "iva_BenefitObligationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "BenefitObligationPercentage", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of benefit obligation percentage.", "label": "Benefit Obligation Percentage" } } }, "auth_ref": [] }, "iva_BonusShareAwardPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "BonusShareAwardPlansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "documentation": "This member stands for bonus share award plans.", "label": "Bonus Share Award Plans [Member]", "terseLabel": "Bonus share award plans" } } }, "auth_ref": [] }, "ifrs-full_BorrowingCostsIncurred": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingCostsIncurred", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Borrowing costs incurred", "terseLabel": "Borrowing costs" } }, "en": { "role": { "documentation": "The amount of interest and other costs that an entity incurs in connection with the borrowing of funds." } } }, "auth_ref": [ "r284" ] }, "ifrs-full_Borrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Borrowings", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialDebtFinancialDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsInPeriodBreakDownDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Borrowings", "totalLabel": "Total debt" } }, "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } } }, "auth_ref": [ "r287" ] }, "iva_BorrowingsActualizationRate": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "BorrowingsActualizationRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "The actualization interest rate on borrowings.", "label": "Borrowings, Actualization Rate", "terseLabel": "Actualization rate" } } }, "auth_ref": [] }, "ifrs-full_BorrowingsByNameAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsByNameAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r316" ] }, "ifrs-full_BorrowingsByNameMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsByNameMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [member]" } }, "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } } }, "auth_ref": [ "r316" ] }, "iva_BorrowingsEffectiveInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "BorrowingsEffectiveInterestRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "The effective interest rate on borrowings.", "label": "Borrowings, effective interest rate" } } }, "auth_ref": [] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings, interest rate", "terseLabel": "Interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r316" ] }, "iva_BorrowingsMaximumExtensionTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "BorrowingsMaximumExtensionTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "Period up to which the maturity term of the borrowings can be extended.", "label": "Borrowings, Maximum Extension Term", "verboseLabel": "Extension of term of debt" } } }, "auth_ref": [] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Minimum", "terseLabel": "Minimum" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r146", "r158", "r168", "r249", "r250", "r316" ] }, "iva_Bsa2017PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "Bsa2017PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA - 2017 plan.", "label": "BSA - 2017 plan" } } }, "auth_ref": [] }, "iva_Bsa2018PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "Bsa2018PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA - 2018 plan.", "label": "BSA - 2018 plan" } } }, "auth_ref": [] }, "iva_Bsa2019PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "Bsa2019PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA - 2019 plan.", "label": "BSA - 2019 plan", "terseLabel": "BSA 2019" } } }, "auth_ref": [] }, "iva_Bsa2021ShareWarrantPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "Bsa2021ShareWarrantPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA 2021 share warrants plan.", "label": "BSA 2021 Share Warrant Plan [Member]", "terseLabel": "BSA 2021" } } }, "auth_ref": [] }, "iva_Bsa2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "Bsa2022Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the BSA 2022 share-based payment plan", "label": "BSA 2022 [Member]", "terseLabel": "BSA 2022" } } }, "auth_ref": [] }, "iva_Bsa20231ShareWarrantPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "Bsa20231ShareWarrantPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA 2023-1 share warrants plan.", "label": "BSA 2023-1 Share Warrant Plan [Member]", "terseLabel": "BSA 2023 plan" } } }, "auth_ref": [] }, "iva_Bsa20232PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "Bsa20232PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the BSA 2023-2 plan share-based payment plan", "label": "BSA 2023-2 plan [Member]", "terseLabel": "BSA 2023-2 plan" } } }, "auth_ref": [] }, "iva_Bsa20232ShareWarrantPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "Bsa20232ShareWarrantPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA 2023-2 share warrants plan.", "label": "BSA 2023-2 Share Warrant Plan [Member]", "terseLabel": "BSA- 2 2023 plan", "verboseLabel": "BSA 2023-2" } } }, "auth_ref": [] }, "iva_BsaPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "BsaPlansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA plans.", "label": "BSA plans" } } }, "auth_ref": [] }, "iva_BsaShareWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "BsaShareWarrantMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA share warrant.", "label": "BSA Share warrant [Member]" } } }, "auth_ref": [] }, "iva_BsaShareWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "BsaShareWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA share warrants.", "label": "BSA share warrants" } } }, "auth_ref": [] }, "iva_Bspce20131PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "Bspce20131PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE 2013-1 plan.", "label": "BSPCE 2013-1" } } }, "auth_ref": [] }, "iva_Bspce2013PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "Bspce2013PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE - 2013 plan.", "label": "BSPCE - 2013 Plan" } } }, "auth_ref": [] }, "iva_Bspce2021PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "Bspce2021PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE 2021 plan.", "label": "BSPCE 2021", "terseLabel": "BSPCE 2021" } } }, "auth_ref": [] }, "iva_Bspce2021ShareWarrantPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "Bspce2021ShareWarrantPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the BSPCE 2021 plan share-based payment plan.", "label": "Bspce 2021 Share Warrant Plan [Member]", "terseLabel": "BSPCE 2021" } } }, "auth_ref": [] }, "iva_BspceAndBsaShareWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "BspceAndBsaShareWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE and BSA share warrants.", "label": "BSPCE and BSA Share Warrants" } } }, "auth_ref": [] }, "iva_BspcePlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "BspcePlansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE plans.", "label": "BSPCE plans" } } }, "auth_ref": [] }, "iva_BspceShareWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "BspceShareWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE share warrants.", "label": "BSPCE Share Warrants [Member]" } } }, "auth_ref": [] }, "ifrs-full_BuildingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "BuildingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Buildings" } }, "en": { "role": { "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r293" ] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "BusinessContactMember", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r273", "r274" ] }, "country_CN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "CN", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "label": "China" } } }, "auth_ref": [] }, "ifrs-full_CapitalCommitmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CapitalCommitmentsAbstract", "lang": { "en-us": { "role": { "label": "Commitments related to operational activities" } } }, "auth_ref": [] }, "ifrs-full_CapitalReserve": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CapitalReserve", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "label": "Capital reserve", "terseLabel": "Capital reserve" } }, "en": { "role": { "documentation": "A component of equity representing the capital reserves." } } }, "auth_ref": [ "r287" ] }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureInventoriesDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r55", "r58", "r96", "r100", "r104", "r105", "r106", "r107", "r108", "r173", "r183", "r184" ] }, "ifrs-full_CarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CarryingAmountMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureInventoriesDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Carrying amount [member]" } }, "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r58", "r100", "r104", "r106", "r107", "r173", "r183", "r184" ] }, "ifrs-full_Cash": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Cash", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Cash", "terseLabel": "Cash at bank and at hand" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } } }, "auth_ref": [ "r312" ] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails": { "parentTag": "iva_CurrentAssetsExcludingDeferredAssets", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 4.0 }, "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalent", "periodEndLabel": "Net cash and cash equivalents at the end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r15", "r116", "r135" ] }, "ifrs-full_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and cash equivalents" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) decrease (increase) in short-term deposits and investments", "terseLabel": "Decrease / (Increase) in short-term deposit accounts" } }, "en": { "role": { "documentation": "The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments." } } }, "auth_ref": [ "r307" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash flows provided by financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } } }, "auth_ref": [ "r109", "r118" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities [abstract]", "terseLabel": "Cash flows provided by (used in) financing activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash flows provided by (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } } }, "auth_ref": [ "r109", "r118" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities [abstract]", "terseLabel": "Cash flows provided by (used in) investing activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash used in operating activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } } }, "auth_ref": [ "r109", "r118" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities [abstract]", "terseLabel": "Cash flows used in operating activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows used in operations before tax, interest and changes in working capital", "totalLabel": "Cash flows used in operations before tax, interest and changes in working capital" } }, "en": { "role": { "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital." } } }, "auth_ref": [ "r246", "r311" ] }, "iva_CashUnderLiquidityAgreementCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "CashUnderLiquidityAgreementCurrent", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash under liquidity agreement, classified as current.", "label": "Cash Under Liquidity Agreement, Current", "terseLabel": "Liquidity agreement - Cash" } } }, "auth_ref": [] }, "iva_CatalysOptionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "CatalysOptionAgreementMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Catalys Option Agreement.", "label": "Catalys Option Agreement [Member]", "terseLabel": "Catalys Option Agreement" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CategoriesOfFinancialAssetsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Categories of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r199" ] }, "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Categories of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r199" ] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r77" ] }, "ifrs-full_ChangesInEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ChangesInEquity", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in equity", "terseLabel": "Capital increase" } }, "en": { "role": { "documentation": "The increase (decrease) in equity. [Refer: Equity]" } } }, "auth_ref": [ "r5" ] }, "ifrs-full_ChangesInPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ChangesInPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in property, plant and equipment", "terseLabel": "Increase in net value of property, plant and equipment" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r58" ] }, "iva_ChiefExecutiveOfficerAndChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ChiefExecutiveOfficerAndChairmanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for chief executive officer and chairman.", "label": "Chief Executive Officer And Chairman [Member]", "terseLabel": "Frdric Cren, Chief executive officer and chairman" } } }, "auth_ref": [] }, "iva_CirAndOtherResearchTaxCreditsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "CirAndOtherResearchTaxCreditsReceivable", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_CurrentTaxAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of CIR and other research tax credits receivable.", "label": "CIR and Other Research Tax Credits Receivable", "terseLabel": "CIR and other research tax credits receivable" } } }, "auth_ref": [] }, "iva_CirReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "CirReceivable", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "CIR receivable", "label": "CIR receivable" } } }, "auth_ref": [] }, "iva_CirRelatingToSubcontractingOperations2017Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "CirRelatingToSubcontractingOperations2017Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for cir relating to subcontracting operations 2017.", "label": "2017 CIR Relating To Subcontracting Operations [Member]", "verboseLabel": "2017 CIR relating to subcontracting operations" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "iva_ClaimIncludingSurchargeAndInterestRejectedByTaxAuthorities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ClaimIncludingSurchargeAndInterestRejectedByTaxAuthorities", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of claim (including surcharge and interest) rejected by tax authorities.", "label": "Claim Including Surcharge And Interest Rejected By Tax Authorities", "terseLabel": "Claim for total amount" } } }, "auth_ref": [] }, "iva_ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsAsPercentageOfVolumeWeightedAveragePriceOfCompanySShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise price of warrants issued, represented as a percentage of volume-weighted average price of the Company's shares.", "label": "Class Of Warrant Or Right, Exercise Price Of Warrants As A Percentage Of Volume-Weighted Average Price Of The Company's Shares", "terseLabel": "Exercise price of warrants as a percentage of volume-weighted average price of the Company's shares" } } }, "auth_ref": [] }, "iva_ClassOfWarrantOrRightGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ClassOfWarrantOrRightGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights granted.", "label": "Class of Warrant or Right, Granted", "terseLabel": "Number of warrants granted", "verboseLabel": "Number of warrants issued" } } }, "auth_ref": [] }, "iva_ClassOfWarrantOrRightMaturityTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ClassOfWarrantOrRightMaturityTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Maturity term of the warrants issued by the entity.", "label": "Class Of Warrant Or Right, Maturity Term", "terseLabel": "Maturity term of warrants" } } }, "auth_ref": [] }, "iva_ClassOfWarrantOrRightSubscriptionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ClassOfWarrantOrRightSubscriptionPrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Subscription price per share or per unit of warrants or rights outstanding.", "label": "Class Of Warrant Or Right, Subscription Price", "terseLabel": "Subscription price per warrant" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfFinancialAssetsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r165", "r192", "r193", "r218", "r219" ] }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfFinancialInstrumentsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r183", "r185", "r187", "r188" ] }, "ifrs-full_ClassesOfFinancialInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfFinancialInstrumentsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskDetails" ], "lang": { "en-us": { "role": { "label": "Financial instruments, class [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r183", "r185", "r187", "r188" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r192", "r193", "r218", "r219" ] }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r101" ] }, "ifrs-full_ClassesOfInventoriesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfInventoriesAbstract", "lang": { "en-us": { "role": { "label": "Inventories" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r59" ] }, "ifrs-full_ClassesOfProvisionsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfProvisionsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxDisputeSettlementDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of other provisions [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r95" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r33" ] }, "ifrs-full_ClassesOfShareCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClassesOfShareCapitalMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Share capital [member]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r33" ] }, "ifrs-full_ClosingForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ClosingForeignExchangeRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicenseAndCollaborationAgreementWithCttqDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Closing foreign exchange rate", "terseLabel": "Exchange rate at period end", "verboseLabel": "Exchange rate" } }, "en": { "role": { "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery." } } }, "auth_ref": [ "r284" ] }, "iva_CollaborationAgreementWithAbbvieMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "CollaborationAgreementWithAbbvieMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the collaboration agreement with AbbVie", "label": "Collaboration agreement with AbbVie [Member]", "terseLabel": "Collaboration agreement with AbbVie" } } }, "auth_ref": [] }, "iva_CollaborativeArrangementMilestonePaymentsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "CollaborativeArrangementMilestonePaymentsReceived", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the cash inflows from milestone payments in collaborative arrangements.", "label": "Collaborative Arrangement, Milestone Payments Received", "terseLabel": "Milestone payments received", "verboseLabel": "Milestone payment" } } }, "auth_ref": [] }, "iva_CollaborativeArrangementRevenueFromMilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "CollaborativeArrangementRevenueFromMilestonePayments", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Revenue from milestone payments", "label": "Collaborative Arrangement, Revenue from milestone payments", "terseLabel": "Revenue from milestone payments" } } }, "auth_ref": [] }, "iva_CommitmentsAmountPayableForServicesReceivedUnderContract": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "CommitmentsAmountPayableForServicesReceivedUnderContract", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Commitment amount payable for services received under contract.", "label": "Commitments Amount Payable For Services Received Under Contract", "verboseLabel": "Amount committed to pay" } } }, "auth_ref": [] }, "iva_CommitmentsAmountPayableForServicesReceivedUnderContractMaximumBonusOrMalusAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "CommitmentsAmountPayableForServicesReceivedUnderContractMaximumBonusOrMalusAmount", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum amount of bonus or malus payable on amount committed by the company to pay for services received under contract.", "label": "Commitments, Amount Payable For Services Received Under Contract, Maximum Bonus Or Malus Amount", "terseLabel": "Bonus or malus maximum amount" } } }, "auth_ref": [] }, "iva_CommitmentsAmountPayableForServicesReceivedUnderContracts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "CommitmentsAmountPayableForServicesReceivedUnderContracts", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum amount of bonus or malus payable on amount committed by the company to pay for services received under contract.", "label": "Commitments amount payable for services received under contracts" } } }, "auth_ref": [] }, "iva_CommitmentsIncrementalAmountPayableForServicesReceivedUnderContract": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "CommitmentsIncrementalAmountPayableForServicesReceivedUnderContract", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents the incremental amount committed to pay by the company for extension of services under the contract.", "label": "Commitments, Incremental Amount Payable For Services Received Under Contract", "terseLabel": "Incremental amount committed to pay" } } }, "auth_ref": [] }, "iva_CommitmentsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "CommitmentsReceived", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of commitments received.", "label": "Commitments Received", "terseLabel": "Total commitments received" } } }, "auth_ref": [] }, "ifrs-full_CommunicationAndNetworkEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CommunicationAndNetworkEquipmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Technical facilities, equipment and tooling" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing communications and network equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r293" ] }, "iva_CompanyInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "CompanyInformationAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Company information" } } }, "auth_ref": [] }, "iva_CompanyInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "CompanyInformationLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxDisputeSettlementDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.", "label": "Company Information [Line Items]", "terseLabel": "Company Information" } } }, "auth_ref": [] }, "iva_CompanyInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "CompanyInformationTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxDisputeSettlementDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information pertaining to company information.", "label": "Company Information [Table]" } } }, "auth_ref": [] }, "iva_CompanyInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "CompanyInformationTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformation" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure on company information.", "label": "Company Information [Text Block]", "terseLabel": "Company information" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r6" ] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive income", "totalLabel": "Total comprehensive loss" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r1", "r37", "r120", "r122", "r132", "r248" ] }, "ifrs-full_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "IT equipment" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r293" ] }, "ifrs-full_ComputerSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ComputerSoftwareMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Software licenses" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r239" ] }, "ifrs-full_ConsolidatedAndSeparateFinancialStatementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ConsolidatedAndSeparateFinancialStatementsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceConsolidatedFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "label": "Consolidated and separate financial statements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r84" ] }, "ifrs-full_ConsolidatedMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ConsolidatedMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceConsolidatedFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "label": "Consolidated [member]" } }, "en": { "role": { "documentation": "This member stands for the financial statements of a group in which the assets, liabilities, equity, income, expenses and cash flows of the parent and its subsidiaries are presented as those of a single economic entity. It also represents the standard value for the 'Consolidated and separate financial statements' axis if no other member is used." } } }, "auth_ref": [ "r84" ] }, "ifrs-full_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment in progress" } }, "en": { "role": { "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r293" ] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContactPersonnelName", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ContractCroWithPharmaceuticalResearchAssociatesB.vMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesCommitmentsGivenAndReceivedDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsAdvancesPaymentsNonCurrentDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Contract CRO with PRA.", "label": "Contract CRO With Pharmaceutical Research Associates B.V [Member]", "terseLabel": "Contract CRO with Pharmaceutical Research Associates B.V.", "verboseLabel": "Contract CRO with Pharmaceutical Research Associates B.V." } } }, "auth_ref": [] }, "ifrs-full_ContractualCapitalCommitments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ContractualCapitalCommitments", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesCommitmentsGivenAndReceivedDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Contractual capital commitments", "terseLabel": "Total commitments given", "verboseLabel": "Commitment amount" } }, "en": { "role": { "documentation": "The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]" } } }, "auth_ref": [ "r284" ] }, "ifrs-full_CounterpartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CounterpartiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Counterparties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r201" ] }, "ifrs-full_CounterpartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CounterpartiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Counterparties" } }, "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } } }, "auth_ref": [ "r201" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "iva_CowenAtmProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "CowenAtmProgramMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Cowen ATM Program.", "label": "Cowen ATM Program [Member]", "verboseLabel": "Cowen ATM program" } } }, "auth_ref": [] }, "iva_CreditAgricoleBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "CreditAgricoleBankMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Credit Agricole Bank.", "label": "Crdit Agricole bank", "terseLabel": "Crdit Agricole bank" } } }, "auth_ref": [] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CurrencyAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Currency [Axis]" } } }, "auth_ref": [] }, "ifrs-full_CurrencyRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrencyRiskMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Currency Risk [Member]", "terseLabel": "Exposure to foreign exchange risk" } }, "en": { "role": { "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r159", "r160", "r161", "r162", "r202" ] }, "ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentAccruedIncomeIncludingCurrentContractAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Current accrued income including current contract assets", "terseLabel": "Current accrued income" } }, "en": { "role": { "documentation": "The amount of current accrued income including current contract assets. [Refer: Accrued income including contract assets]" } } }, "auth_ref": [ "r287", "r290" ] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r25", "r128", "r248" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets [abstract]", "terseLabel": "Current assets" } } }, "auth_ref": [] }, "iva_CurrentAssetsExcludingDeferredAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "CurrentAssetsExcludingDeferredAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "documentation": "Current assets excluding deferred assets", "label": "Current assets excluding deferred assets", "totalLabel": "Total current assets" } } }, "auth_ref": [] }, "iva_CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "Current borrowings and current portion of non-current borrowings and current lease liabilities", "label": "Current borrowings and current portion of non-current borrowings and current lease liabilities", "terseLabel": "Shortterm debt" } } }, "auth_ref": [] }, "ifrs-full_CurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentContractLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails": { "parentTag": "iva_TradePayablesAndOtherCurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current contract liabilities", "terseLabel": "Short-term contract liabilities" } }, "en": { "role": { "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r147" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current liabilities", "totalLabel": "Total current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r26", "r130", "r248" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current liabilities [abstract]", "terseLabel": "Current liabilities" } } }, "auth_ref": [] }, "ifrs-full_CurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Current prepaid expenses", "terseLabel": "Prepaid expenses" } }, "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } } }, "auth_ref": [ "r284" ] }, "ifrs-full_CurrentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentProvisions", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current provisions", "terseLabel": "Short-term provisions" } }, "en": { "role": { "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r17" ] }, "ifrs-full_CurrentServiceCostDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentServiceCostDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails" ], "lang": { "en-us": { "role": { "label": "Current service cost, defined benefit plans", "negatedLabel": "Service cost for the period" } }, "en": { "role": { "documentation": "The expense of employee service in the current period arising from defined benefit plans. [Refer: Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase in net defined benefit liability (asset) resulting from current service cost]" } } }, "auth_ref": [ "r296" ] }, "ifrs-full_CurrentTaxAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentTaxAssetsCurrent", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "iva_OtherCurrentAssetsAndReceivables", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current tax assets, current", "terseLabel": "Tax receivables", "totalLabel": "Tax receivables" } }, "en": { "role": { "documentation": "The current amount of current tax assets. [Refer: Current tax assets]" } } }, "auth_ref": [ "r18" ] }, "iva_CurrentTaxCreditResearchIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "CurrentTaxCreditResearchIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails": { "parentTag": "iva_OtherIncomeFromOrdinaryActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of income from tax credit research.", "label": "Current Tax Credit Research Income", "terseLabel": "Tax Credits" } } }, "auth_ref": [] }, "ifrs-full_CurrentTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentTaxExpenseIncome", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Current tax expense (income)", "negatedLabel": "Current taxes" } }, "en": { "role": { "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period." } } }, "auth_ref": [ "r229" ] }, "iva_CurrentTradeReceivablesAveragePaymentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "CurrentTradeReceivablesAveragePaymentPeriod", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the average payment period for trade receivables.", "label": "Current Trade Receivables, Average Payment Period", "terseLabel": "Average payment period for trade receivables" } } }, "auth_ref": [] }, "ifrs-full_CurrentValueAddedTaxPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentValueAddedTaxPayables", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Current value added tax payables", "terseLabel": "VAT payables" } }, "en": { "role": { "documentation": "The amount of current value added tax payables. [Refer: Value added tax payables]" } } }, "auth_ref": [ "r290" ] }, "ifrs-full_CurrentValueAddedTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "CurrentValueAddedTaxReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Current value added tax receivables", "terseLabel": "VAT receivables" } }, "en": { "role": { "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]" } } }, "auth_ref": [ "r288" ] }, "iva_DailyDoseOfLanifibranorInTrial": { "xbrltype": "massItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DailyDoseOfLanifibranorInTrial", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Daily dose of lanifibranor in trial", "label": "Daily dose of lanifibranor in trial" } } }, "auth_ref": [] }, "iva_DavidNikodemAndJeremyGoldbergMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DavidNikodemAndJeremyGoldbergMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for David Nikodem and Jeremy Goldberg", "label": "David Nikodem and Jeremy Goldberg [Member]", "terseLabel": "David Nikodem and Jeremy Goldberg" } } }, "auth_ref": [] }, "iva_DavidNikodemMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DavidNikodemMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for David Nikodem, a member of Sapidus Consulting Group LLC, a service provider to the Company.", "label": "David Nikodem", "terseLabel": "David Nikodem" } } }, "auth_ref": [] }, "iva_DecreaseInBorrowingsThroughAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DecreaseInBorrowingsThroughAccruedInterest", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Decrease in borrowings through accrued interest.", "label": "Decrease In Borrowings Through Accrued Interest", "negatedLabel": "Accrued interests" } } }, "auth_ref": [] }, "iva_DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DecreaseInBorrowingsThroughRepaymentOfLeaseLiabilities", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of decrease in borrowings through repayment of lease liabilities.", "label": "Decrease in borrowings through repayment of lease liabilities", "negatedLabel": "Repayment of lease liabilities" } } }, "auth_ref": [] }, "iva_DecreaseInBorrowingsThroughRepayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DecreaseInBorrowingsThroughRepayments", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of decrease in borrowings through repayments.", "label": "Decrease in borrowings through repayments", "negatedLabel": "Repayments" } } }, "auth_ref": [] }, "iva_DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DecreaseInBorrowingsThroughRepaymentsOfBankBorrowings", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of decrease in borrowings through repayments of bank borrowings", "label": "Decrease in borrowings through repayments of bank borrowings", "negatedLabel": "Repayment of bank borrowings" } } }, "auth_ref": [] }, "iva_DecreaseInCirAndOtherResearchTaxCreditsThroughCorrectiveClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DecreaseInCirAndOtherResearchTaxCreditsThroughCorrectiveClaims", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Decrease in CIR and other research tax credits through corrective claims", "label": "Decrease in CIR and other research tax credits through corrective claims" } } }, "auth_ref": [] }, "iva_DecreaseInCirAndOtherResearchTaxCreditsThroughPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DecreaseInCirAndOtherResearchTaxCreditsThroughPayments", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Decrease in CIR and other research tax credits through payments", "label": "Decrease in CIR and other research tax credits through payments" } } }, "auth_ref": [] }, "iva_DecreaseInFinancialAssetsPledgedAsCollateralThroughRelease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DecreaseInFinancialAssetsPledgedAsCollateralThroughRelease", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "Decrease in financial assets pledged as collateral through release", "label": "Decrease in financial assets pledged as collateral through release" } } }, "auth_ref": [] }, "iva_DecreasesInIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DecreasesInIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of decreases to intangible assets other than goodwill.", "label": "Decreases in intangible assets other than goodwill", "negatedLabel": "Decreases" } } }, "auth_ref": [] }, "iva_DecreasesInPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DecreasesInPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of decreases in property, plant and equipment", "label": "Decreases in property, plant and equipment", "negatedLabel": "Decreases" } } }, "auth_ref": [] }, "iva_DeferredAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DeferredAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "documentation": "Deferred assets", "label": "Deferred assets" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetsDetails", "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets", "terseLabel": "Deferred tax asset", "verboseLabel": "Deferred tax assets" } }, "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r19", "r22", "r50" ] }, "iva_DeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferencesUnrecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DeferredTaxAssetsRelatedToTaxLossesAndTemporaryDifferencesUnrecognized", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount due to unrecognized deferred tax assets related to tax losses and temporary differences for reconciliation between accounting profit and tax expense income.", "label": "Deferred Tax Assets Related To Tax Losses And Temporary Differences Unrecognized", "negatedLabel": "Non recognition of deferred tax assets related to tax losses and temporary differences" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DeferredTaxExpenseIncomeRecognisedInProfitOrLoss", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax expense (income) recognised in profit or loss", "terseLabel": "Deferred taxes" } }, "en": { "role": { "documentation": "The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]" } } }, "auth_ref": [ "r51" ] }, "ifrs-full_DefinedBenefitObligationAtPresentValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DefinedBenefitObligationAtPresentValue", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsNetProvisionDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Defined benefit obligation, at present value", "terseLabel": "Benefit obligation at December 31", "verboseLabel": "Retirement benefit obligations" } }, "en": { "role": { "documentation": "The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]" } } }, "auth_ref": [ "r301" ] }, "iva_DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DemonstratedReductionOfHepaticFatMeasuredByProtonMagneticResonanceSpectroscopy", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Demonstrated reduction of hepatic fat measured by proton magnetic resonance spectroscopy", "label": "Demonstrated reduction of hepatic fat measured by proton magnetic resonance spectroscopy" } } }, "auth_ref": [] }, "iva_DepositsRepaidDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DepositsRepaidDuringPeriod", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "Deposits repaid during the period", "label": "Deposits repaid during the period" } } }, "auth_ref": [] }, "iva_DepreciationAmortizationAndProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DepreciationAmortizationAndProvisions", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to depreciation, amortization and provisions.", "label": "Depreciation, amortization and provisions", "negatedLabel": "Depreciation, amortization and provisions" } } }, "auth_ref": [] }, "iva_DerivativeInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DerivativeInstrumentsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for derivative instruments.", "label": "Derivative instruments", "terseLabel": "Derivative instruments" } } }, "auth_ref": [] }, "iva_DerivativesRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DerivativesRiskMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for derivatives risk.", "label": "Derivatives Risk [Member]", "terseLabel": "Derivatives Risk" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForBorrowingsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for borrowings [text block]", "terseLabel": "Loans and borrowings" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r285" ] }, "ifrs-full_DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForDerivativeFinancialInstrumentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for derivative financial instruments [text block]", "terseLabel": "Derivatives" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for derivative financial instruments. [Refer: Financial instruments, class [member]; Derivatives [member]]" } } }, "auth_ref": [ "r285" ] }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for employee benefits [text block]", "terseLabel": "Provisions for retirement benefit obligations" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } } }, "auth_ref": [ "r285" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for fair value measurement [text block]", "terseLabel": "Fair value measurement" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r285" ] }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for foreign currency translation [text block]", "terseLabel": "Foreign currency transactions" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for foreign currency translation." } } }, "auth_ref": [ "r285" ] }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for impairment of non-financial assets [text block]", "terseLabel": "Impairment of non-financial assets" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r285" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for income tax [text block]", "terseLabel": "Current and deferred tax" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for income tax." } } }, "auth_ref": [ "r285" ] }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for leases [text block]", "terseLabel": "Lease contracts" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } } }, "auth_ref": [ "r285" ] }, "iva_DescriptionOfAccountingPolicyForOtherIncomePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DescriptionOfAccountingPolicyForOtherIncomePolicyTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for other income.", "label": "Description Of Accounting Policy For Other Income [Policy Text Block]", "terseLabel": "Other income" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for property, plant and equipment [text block]", "verboseLabel": "Property, plant, and equipment" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r285" ] }, "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for provisions [text block]", "terseLabel": "Other provisions" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]" } } }, "auth_ref": [ "r285" ] }, "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for recognition of revenue [text block]", "terseLabel": "Revenue" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]" } } }, "auth_ref": [ "r285" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for segment reporting [text block]", "terseLabel": "Segment information" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for segment reporting." } } }, "auth_ref": [ "r285" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for share-based payment transactions [text block]", "terseLabel": "Share-based payments plans" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]" } } }, "auth_ref": [ "r285" ] }, "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]", "terseLabel": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r117" ] }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility, share options granted", "terseLabel": "Expected volatility" } }, "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } } }, "auth_ref": [ "r170" ] }, "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfOptionLifeShareOptionsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails" ], "lang": { "en-us": { "role": { "label": "Option life, share options granted", "terseLabel": "Average life (years)" } }, "en": { "role": { "documentation": "The option life of share options granted." } } }, "auth_ref": [ "r170" ] }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails" ], "lang": { "en-us": { "role": { "label": "Risk free interest rate, share options granted", "terseLabel": "Risk free rate" } }, "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } } }, "auth_ref": [ "r170" ] }, "iva_DetteBsaBei2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DetteBsaBei2022Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The information pertaining to DETTE BSA BEI 2022.", "label": "DETTE BSA BEI 2022 [Member]", "terseLabel": "DETTE BSA BEI 2022" } } }, "auth_ref": [] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Diluted earnings (loss) per share", "terseLabel": "Diluted loss per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r86", "r87" ] }, "iva_DirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DirectorsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Directors.", "label": "Directors", "terseLabel": "Directors" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Disclosure of accounting judgements and estimates [text block]", "terseLabel": "Use of estimates and judgment" } }, "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r280" ] }, "iva_DisclosureOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeLossForRetirementBenefitObligationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DisclosureOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeLossForRetirementBenefitObligationsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about actuarial gains (losses) recognized in comprehensive income (loss) for Retirement Benefit Obligations.", "label": "Disclosure Of Actuarial Gains And Losses Recognized In Comprehensive Income (Loss) For Retirement Benefit Obligations, Explanatory", "terseLabel": "Schedule of actuarial gains and losses recognized in comprehensive income" } } }, "auth_ref": [] }, "iva_DisclosureOfAssumptionsUsedToMeasureRetirementBenefitObligationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DisclosureOfAssumptionsUsedToMeasureRetirementBenefitObligationsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about assumptions used to measure Retirement Benefit Obligations.", "label": "Disclosure Of Assumptions Used To Measure Retirement Benefit Obligations, Explanatory", "terseLabel": "Schedule of assumptions used to measure retirement benefit obligations" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [line items]", "terseLabel": "Operating expenses" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to attribution of expenses by nature to analysis of expenses by function in the statement of profit or loss." } } }, "auth_ref": [ "r281", "r284" ] }, "ifrs-full_DisclosureOfBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfBorrowingsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebt" ], "lang": { "en-us": { "role": { "label": "Disclosure of borrowings [text block]", "terseLabel": "Financial debt" } }, "en": { "role": { "documentation": "The disclosure of borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r280" ] }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalents" ], "lang": { "en-us": { "role": { "label": "Disclosure of cash and cash equivalents [text block]", "terseLabel": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r280" ] }, "iva_DisclosureOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DisclosureOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of cash and cash equivalents.", "label": "Disclosure Of Cash And Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of cash and cash equivalents" } } }, "auth_ref": [] }, "iva_DisclosureOfChangesInBorrowingsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DisclosureOfChangesInBorrowingsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of changes in borrowings.", "label": "Disclosure Of Changes In Borrowings [Table Text Block]", "terseLabel": "Schedule of changes in borrowings" } } }, "auth_ref": [] }, "iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about change in the provision recorded in respect of defined benefit schemes.", "label": "Disclosure Of Changes In Provision Recorded In Respect Of Defined Benefit Schemes, Explanatory", "terseLabel": "Schedule of change in the provision recorded in respect of defined benefit schemes" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalAbstract", "lang": { "en-us": { "role": { "label": "Shareholders' equity" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [text block]", "terseLabel": "Schedule of changes in share capital" } }, "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]" } } }, "auth_ref": [ "r33" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [line items]", "terseLabel": "Shareholders' equity" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } } }, "auth_ref": [ "r33" ] }, "ifrs-full_DisclosureOfCommitmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfCommitmentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivities" ], "lang": { "en-us": { "role": { "label": "Disclosure of commitments [text block]", "terseLabel": "Commitments related to operational activities" } }, "en": { "role": { "documentation": "The disclosure of commitments." } } }, "auth_ref": [ "r280" ] }, "iva_DisclosureOfCommitmentsRelatedOperationalActivitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DisclosureOfCommitmentsRelatedOperationalActivitiesTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of commitments related to operational activities.", "label": "Disclosure of Commitments Related Operational Activities [Table Text Block]", "terseLabel": "Schedule of contractual obligations and commitments" } } }, "auth_ref": [] }, "iva_DisclosureOfDeferredTaxAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DisclosureOfDeferredTaxAssetsAbstract", "lang": { "en-us": { "role": { "documentation": "Disclosure of deferred tax assets.", "label": "Deferred tax assets." } } }, "auth_ref": [] }, "iva_DisclosureOfDeferredTaxAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DisclosureOfDeferredTaxAssetsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetsTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of deferred tax assets.", "label": "Disclosure Of Deferred Tax Assets [Table Text Block]", "terseLabel": "Schedule of deferred tax assets" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDeferredTaxesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDeferredTaxesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssets" ], "lang": { "en-us": { "role": { "label": "Disclosure of deferred taxes [text block]", "terseLabel": "Deferred tax assets" } }, "en": { "role": { "documentation": "The disclosure of deferred taxes. [Refer: Deferred tax liabilities; Deferred tax assets]" } } }, "auth_ref": [ "r280" ] }, "ifrs-full_DisclosureOfDefinedBenefitPlansAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDefinedBenefitPlansAbstract", "lang": { "en-us": { "role": { "label": "Provisions for retirement benefit obligations" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsAbstract", "lang": { "en-us": { "role": { "label": "Financial debt" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [text block]", "terseLabel": "Schedule of debt" } }, "en": { "role": { "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r316" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [line items]", "terseLabel": "Guarantee Details", "verboseLabel": "Financial debt" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } } }, "auth_ref": [ "r316" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [text block]", "terseLabel": "Schedule of financial assets and liabilities" } }, "en": { "role": { "documentation": "The disclosure of detailed information about financial instruments. [Refer: Financial instruments, class [member]]" } } }, "auth_ref": [ "r179", "r185", "r194" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [text block]", "terseLabel": "Schedule of intangible assets" } }, "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r101" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [text block]", "terseLabel": "Schedule of property, plant and equipment" } }, "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r59" ] }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfEarningsPerShareExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShare" ], "lang": { "en-us": { "role": { "label": "Disclosure of earnings per share [text block]", "terseLabel": "Basic and diluted loss per share" } }, "en": { "role": { "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r89" ] }, "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of effect of changes in foreign exchange rates [text block]", "terseLabel": "Schedule of exchange rates" } }, "en": { "role": { "documentation": "The entire disclosure for the effect of changes in foreign exchange rates." } } }, "auth_ref": [ "r71" ] }, "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfEmployeeBenefitsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligations" ], "lang": { "en-us": { "role": { "label": "Disclosure of employee benefits [text block]", "terseLabel": "Provisions for retirement benefit obligations" } }, "en": { "role": { "documentation": "The entire disclosure for employee benefits." } } }, "auth_ref": [ "r66" ] }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDate" ], "lang": { "en-us": { "role": { "label": "Disclosure of events after reporting period [text block]", "terseLabel": "Events after the reporting date" } }, "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } } }, "auth_ref": [ "r45" ] }, "iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about expense recognized in the statement of income (loss) for Retirement Benefit Obligations.", "label": "Disclosure Of Expenses Recognized In Statement Of Income (Loss) For Retirement Benefit Obligations, Explanatory", "terseLabel": "Schedule of expense recognized in the statement of income (loss)" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value of financial instruments [text block]", "terseLabel": "Schedule of financial assets and liabilities measured at fair value" } }, "en": { "role": { "documentation": "The disclosure of the fair value of financial instruments. [Refer: Financial instruments, class [member]; At fair value [member]]" } } }, "auth_ref": [ "r280" ] }, "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinanceIncomeExpenseExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpenses" ], "lang": { "en-us": { "role": { "label": "Disclosure of finance income (cost) [text block]", "verboseLabel": "Financial income and expenses" } }, "en": { "role": { "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]" } } }, "auth_ref": [ "r280" ] }, "ifrs-full_DisclosureOfFinancialAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialAssetsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial assets [line items]", "terseLabel": "Cash and Cash Equivalents" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialAssetsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to financial assets." } } }, "auth_ref": [ "r194" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Financial assets and liabilities" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilities" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial instruments [text block]", "terseLabel": "Financial assets and liabilities" } }, "en": { "role": { "documentation": "The entire disclosure for financial instruments." } } }, "auth_ref": [ "r203" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesCommitmentsGivenAndReceivedDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [line items]", "terseLabel": "Foreign currency forwards contract", "verboseLabel": "Financial assets and liabilities" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesCommitmentsGivenAndReceivedDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } } }, "auth_ref": [ "r179", "r185", "r194" ] }, "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfFinancialRiskManagementExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagement" ], "lang": { "en-us": { "role": { "label": "Disclosure of financial risk management [text block]", "terseLabel": "Financial risk management" } }, "en": { "role": { "documentation": "The disclosure of the entity's financial risk management practices and policies." } } }, "auth_ref": [ "r280" ] }, "ifrs-full_DisclosureOfGeographicalAreasExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfGeographicalAreasExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of geographical areas [text block]", "terseLabel": "Summary of entity's geographical split" } }, "en": { "role": { "documentation": "The disclosure of geographical information." } } }, "auth_ref": [ "r216" ] }, "ifrs-full_DisclosureOfGeographicalAreasLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfGeographicalAreasLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of geographical areas [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfGeographicalAreasTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfGeographicalAreasTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of geographical areas [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to geographical areas." } } }, "auth_ref": [ "r216" ] }, "ifrs-full_DisclosureOfGoingConcernExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfGoingConcernExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Disclosure of going concern [text block]", "terseLabel": "Going concern" } }, "en": { "role": { "documentation": "The disclosure of the entity's ability to continue as a going concern." } } }, "auth_ref": [ "r280" ] }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIncomeTaxExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTax" ], "lang": { "en-us": { "role": { "label": "Disclosure of income tax [text block]", "terseLabel": "Income tax" } }, "en": { "role": { "documentation": "The entire disclosure for income taxes." } } }, "auth_ref": [ "r53" ] }, "ifrs-full_DisclosureOfIntangibleAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsAbstract", "lang": { "en-us": { "role": { "label": "Intangible Assets" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Disclosure of intangible assets [text block]", "terseLabel": "Intangible Assets" } }, "en": { "role": { "documentation": "The entire disclosure for intangible assets." } } }, "auth_ref": [ "r103" ] }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [line items]", "verboseLabel": "Intangible Assets" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfIntangibleAssetsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } } }, "auth_ref": [ "r101" ] }, "ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfInterestsInSubsidiariesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of interests in subsidiaries [text block]", "terseLabel": "Schedule of subsidiaries" } }, "en": { "role": { "documentation": "The disclosure of interests in subsidiaries. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r126" ] }, "ifrs-full_DisclosureOfInventoriesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfInventoriesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInventories" ], "lang": { "en-us": { "role": { "label": "Disclosure of inventories [text block]", "terseLabel": "Inventories" } }, "en": { "role": { "documentation": "The entire disclosure for inventories." } } }, "auth_ref": [ "r68" ] }, "ifrs-full_DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfInvestmentsAccountedForUsingEquityMethodExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethod" ], "lang": { "en-us": { "role": { "label": "Disclosure of investments accounted for using equity method [text block]", "terseLabel": "Investments accounted for using the equity method" } }, "en": { "role": { "documentation": "The disclosure of investments accounted for using the equity method. [Refer: Investments accounted for using equity method]" } } }, "auth_ref": [ "r280" ] }, "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciples" ], "lang": { "en-us": { "role": { "label": "Disclosure of material accounting policy information [text block]", "terseLabel": "Accounting principles" } }, "en": { "role": { "documentation": "The entire disclosure of material accounting policy information applied by the entity." } } }, "auth_ref": [ "r7" ] }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsAbstract", "lang": { "en-us": { "role": { "label": "Financial risk management" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of nature and extent of risks arising from financial instruments [line items]", "terseLabel": "Financial risk management" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of nature and extent of risks arising from financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the nature and extent of risks arising from financial instruments." } } }, "auth_ref": [ "r180", "r181" ] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "lang": { "en-us": { "role": { "label": "Events after the reporting date" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [line items]", "verboseLabel": "Events after the reporting date" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period." } } }, "auth_ref": [ "r44" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]", "terseLabel": "Schedule of movements in BSPCE and BSA share warrants and Bonus shares" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r315" ] }, "ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherCurrentAssetsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of other current assets [text block]", "terseLabel": "Schedule of other current assets and receivables" } }, "en": { "role": { "documentation": "The disclosure of other current assets. [Refer: Other current assets]" } } }, "auth_ref": [ "r280" ] }, "ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherCurrentLiabilitiesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of other current liabilities [text block]", "terseLabel": "Schedule of other current liabilities" } }, "en": { "role": { "documentation": "The disclosure of other current liabilities. [Refer: Other current liabilities]" } } }, "auth_ref": [ "r280" ] }, "ifrs-full_DisclosureOfOtherLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherLiabilitiesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilities" ], "lang": { "en-us": { "role": { "label": "Disclosure of other liabilities [text block]", "terseLabel": "Other current and non-current liabilities" } }, "en": { "role": { "documentation": "The disclosure of other liabilities. [Refer: Other liabilities]" } } }, "auth_ref": [ "r280" ] }, "ifrs-full_DisclosureOfOtherNoncurrentAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherNoncurrentAssetsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssets" ], "lang": { "en-us": { "role": { "label": "Disclosure of other non-current assets [text block]", "terseLabel": "Other non-current assets" } }, "en": { "role": { "documentation": "The disclosure of other non-current assets. [Refer: Other non-current assets]" } } }, "auth_ref": [ "r280" ] }, "iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DisclosureOfOtherNoncurrentAssetsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of other non current assets.", "label": "Disclosure Of Other Noncurrent Assets [Table Text Block]", "terseLabel": "Schedule of other non current assets" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherOperatingIncomeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherOperatingIncomeExpenseExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpenses" ], "lang": { "en-us": { "role": { "label": "Disclosure of other operating income (expense) [text block]", "terseLabel": "Other operating income and expenses" } }, "en": { "role": { "documentation": "The disclosure of other operating income or expense. [Refer: Other operating income (expense)]" } } }, "auth_ref": [ "r280" ] }, "iva_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of other operating income (expense).", "label": "Disclosure Of Other Operating Income Expense [Table Text Block]", "terseLabel": "Schedule of other operating income and expenses" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherProvisionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherProvisionsAbstract", "lang": { "en-us": { "role": { "label": "Provisions" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherProvisionsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of other provisions [text block]", "terseLabel": "Schedule of provisions" } }, "en": { "role": { "documentation": "The disclosure of other provisions. [Refer: Other provisions]" } } }, "auth_ref": [ "r95" ] }, "ifrs-full_DisclosureOfOtherProvisionsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherProvisionsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of other provisions [line items]", "terseLabel": "Other operating income and expenses", "verboseLabel": "Tax dispute settlement" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherProvisionsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfOtherProvisionsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of other provisions [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to other provisions." } } }, "auth_ref": [ "r95" ] }, "ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpenses" ], "lang": { "en-us": { "role": { "label": "Disclosure of profit (loss) from operating activities [text block]", "terseLabel": "Operating expenses" } }, "en": { "role": { "documentation": "The disclosure of profit (loss) from operating activities. [Refer: Profit (loss) from operating activities]" } } }, "auth_ref": [ "r280" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, plant, and equipment" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipment" ], "lang": { "en-us": { "role": { "label": "Disclosure of property, plant and equipment [text block]", "terseLabel": "Property, plant, and equipment" } }, "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } } }, "auth_ref": [ "r61" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [line items]", "terseLabel": "Accounting Principles", "verboseLabel": "Property, Plant and Equipment" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } } }, "auth_ref": [ "r59" ] }, "iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about provision recorded in respect of defined benefit schemes at the end of each reporting period.", "label": "Disclosure Of Provision Recorded In Respect Of Defined Benefit Schemes At End Of Each Reporting Period, Explanatory", "terseLabel": "Schedule of provision recorded in respect of defined benefit schemes at the end of each reporting period" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfProvisionsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisions" ], "lang": { "en-us": { "role": { "label": "Disclosure of provisions [text block]", "terseLabel": "Provisions" } }, "en": { "role": { "documentation": "The disclosure of provisions. [Refer: Provisions]" } } }, "auth_ref": [ "r280" ] }, "ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of summarised financial information of associate accounted for using equity method to carrying amount of interest in associate [text block]", "terseLabel": "Schedule of investment in Hepalys is accounted for using the equity method of accounting" } }, "en": { "role": { "documentation": "The disclosure of the reconciliation of the summarised financial information of an associate accounted for using the equity method to the carrying amount of the reporting entity's interest in the associate. [Refer: Carrying amount [member]; Associates [member]]" } } }, "auth_ref": [ "r138" ] }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfRelatedPartyExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Disclosure of related party [text block]", "terseLabel": "Related-party transactions" } }, "en": { "role": { "documentation": "The entire disclosure for related parties." } } }, "auth_ref": [ "r78" ] }, "ifrs-full_DisclosureOfRevenueExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfRevenueExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncome" ], "lang": { "en-us": { "role": { "label": "Disclosure of revenue [text block]", "terseLabel": "Revenues and other income" } }, "en": { "role": { "documentation": "The entire disclosure for revenue." } } }, "auth_ref": [ "r280" ] }, "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of sensitivity analysis for actuarial assumptions [text block]", "terseLabel": "Schedule of sensitivity analysis" } }, "en": { "role": { "documentation": "The disclosure of a sensitivity analysis for significant actuarial assumptions used to determine the present value of a defined benefit obligation. [Refer: Actuarial assumptions [member]; Defined benefit obligation, at present value]" } } }, "auth_ref": [ "r65" ] }, "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of sensitivity analysis for actuarial assumptions [line items]" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of sensitivity analysis for actuarial assumptions [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the sensitivity analysis for actuarial assumptions." } } }, "auth_ref": [ "r65" ] }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Disclosure of share capital, reserves and other equity interest [text block]", "terseLabel": "Shareholders' equity" } }, "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } } }, "auth_ref": [ "r34" ] }, "iva_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of share of profit loss of associates and joint ventures accounted for using equity method investments.", "label": "Disclosure Of Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method Investments [Table Text Block]", "terseLabel": "Schedule of share of net profit - Equity method" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInAssociatesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails" ], "lang": { "en-us": { "role": { "label": "Other financial information [line items]", "terseLabel": "Investments accounted for using the equity method" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInAssociatesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of associates [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to associates." } } }, "auth_ref": [ "r81", "r83", "r141" ] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceConsolidatedFinancialStatementsDetails", "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationInvestmentInSubsidiaryDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of subsidiaries [line items]", "terseLabel": "General principles and statement of compliance", "verboseLabel": "Company Information" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceConsolidatedFinancialStatementsDetails", "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationInvestmentInSubsidiaryDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of subsidiaries [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to subsidiaries." } } }, "auth_ref": [ "r81", "r83", "r140" ] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetsDetails", "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [Line Items]", "terseLabel": "Deferred tax assets" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetsDetails", "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits." } } }, "auth_ref": [ "r52" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]", "verboseLabel": "Notes to the consolidated balance sheet" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } } }, "auth_ref": [ "r169" ] }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of trade and other payables [text block]", "terseLabel": "Schedule of trade payables break down by payment" } }, "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r280" ] }, "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssets" ], "lang": { "en-us": { "role": { "label": "Disclosure of trade and other receivables [text block]", "terseLabel": "Trade receivables, tax receivables and other current assets" } }, "en": { "role": { "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]" } } }, "auth_ref": [ "r280" ] }, "iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure for trade payables and other current liabilities.", "label": "Disclosure Of Trade Payables and Other Current Liabilities [Table Text Block]", "terseLabel": "Schedule of trade payables and other current liabilities" } } }, "auth_ref": [] }, "iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilities" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for trade payables and other current liabilities.", "label": "Disclosure Of Trade Payables and Other Current Liabilities [Text Block]", "terseLabel": "Trade payables and short-term contract liabilities" } } }, "auth_ref": [] }, "iva_DisclosureOfTradeReceivablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DisclosureOfTradeReceivablesTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of trade receivables.", "label": "Disclosure of Trade Receivables [Table Text Block]", "terseLabel": "Schedule of trade receivables and others break down" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract", "lang": { "en-us": { "role": { "label": "Related-party transactions" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [text block]", "terseLabel": "Schedule of transactions with key management personnel" } }, "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]" } } }, "auth_ref": [ "r75" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [line items]", "terseLabel": "Related-party transactions" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } } }, "auth_ref": [ "r77" ] }, "iva_DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DisclosureOfValuationApproachForBsaShareBasedPaymentArrangementTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of valuation approach for BSA share-based payment arrangement", "label": "Disclosure of valuation approach for BSA share-based payment arrangement [table text block]", "terseLabel": "Schedule of valuation approach for BSA arrangement" } } }, "auth_ref": [] }, "ifrs-full_DiscountRateMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "DiscountRateMeasurementInputMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Discount rate, measurement input [member]" } }, "en": { "role": { "documentation": "This member stands for a discount rate used as a measurement input used in valuation techniques based on a present value calculation." } } }, "auth_ref": [ "r313" ] }, "iva_Disposables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "Disposables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to disposables.", "label": "Disposables", "negatedLabel": "Disposables" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r273" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r272", "r273", "r274" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r272", "r273", "r274", "r276" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "terseLabel": "Document and Entity Information", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r268" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r273" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r275" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "iva_DrawdownOfBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DrawdownOfBorrowingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for drawdown of borrowings", "label": "Drawdown of borrowings [Member]", "terseLabel": "Drawdown of borrowings" } } }, "auth_ref": [] }, "iva_DurationOfClinicalTrial": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "DurationOfClinicalTrial", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Duration of clinical trial", "label": "Duration of clinical trial" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Basic and diluted loss per share" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EarningsPerShareExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Earnings per share [text block]", "terseLabel": "Schedule of basic and diluted loss per share" } }, "en": { "role": { "documentation": "The disclosure of earnings per share." } } }, "auth_ref": [ "r86" ] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "Exchange (gains) / losses" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r113", "r114" ] }, "iva_EliminationOfDownstreamSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "EliminationOfDownstreamSales", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails": { "parentTag": "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of elimination of downstream sales.", "label": "Elimination Of Downstream Sales", "negatedLabel": "Elimination of downstream sales" } } }, "auth_ref": [] }, "ifrs-full_EmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EmployeeBenefitsExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 3.0 }, "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Employee benefits expense", "negatedTerseLabel": "Personnel costs", "negatedTotalLabel": "Total personnel costs" } }, "en": { "role": { "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment." } } }, "auth_ref": [ "r0", "r43", "r220" ] }, "iva_EmployeeRelatedPayables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "EmployeeRelatedPayables", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount pertaining to employee related payables.", "label": "Employee related payables", "verboseLabel": "Employeerelated payables" } } }, "auth_ref": [] }, "iva_EmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "EmployeesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for employees.", "label": "Employees" } } }, "auth_ref": [] }, "iva_EnergyAndLiquids": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "EnergyAndLiquids", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to energy and liquids.", "label": "Energy and liquids", "negatedLabel": "Energy and liquids" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r270" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceConsolidatedFinancialStatementsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r270" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r279" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r270" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r277" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r270" ] }, "iva_EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "documentation": "Entity's share of net assets in investments accounted for using the equity method", "label": "Entity's share of net assets in investments accounted for using the equity method", "terseLabel": "Group's share" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r270" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r278" ] }, "ifrs-full_EntitysTotalForAssociatesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForAssociatesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails" ], "lang": { "en-us": { "role": { "label": "Entity's total for associates [member]", "terseLabel": "Entity's total for associates [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used." } } }, "auth_ref": [ "r81", "r83", "r141" ] }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForRelatedPartiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Entity's total for related parties [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r77" ] }, "ifrs-full_EntitysTotalForSubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EntitysTotalForSubsidiariesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationInvestmentInSubsidiaryDetails" ], "lang": { "en-us": { "role": { "label": "Entity's total for subsidiaries [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used." } } }, "auth_ref": [ "r81", "r83", "r140" ] }, "iva_EquipmentAndToolingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "EquipmentAndToolingMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for equipment and tooling.", "label": "Equipment and tooling" } } }, "auth_ref": [] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceConsolidatedFinancialStatementsDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "totalLabel": "Total Shareholders' equity", "verboseLabel": "Shareholders' equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r21", "r30", "r119", "r121", "r142", "r143", "r145" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity [abstract]", "terseLabel": "Shareholders' equity" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity and liabilities", "terseLabel": "Total equity and liabilities", "totalLabel": "Total liabilities and shareholders' equity" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r21" ] }, "ifrs-full_EquityAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityAndLiabilitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity and liabilities [abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "auth_ref": [] }, "ifrs-full_EquityMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "EquityMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity [member]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r6" ] }, "iva_EquityRecoveryLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "EquityRecoveryLoansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for equity recovery loans.", "label": "Equity Recovery Loans [Member]", "terseLabel": "Equity recovery loans" } } }, "auth_ref": [] }, "iva_EstimatedAmountPayableUnderAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "EstimatedAmountPayableUnderAgreement", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the estimated amount payable under the agreement.", "label": "Estimated Amount Payable Under Agreement", "terseLabel": "Estimated amount payable" } } }, "auth_ref": [] }, "iva_ExpectedVolatility": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ExpectedVolatility", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Expected volatility used to calculate fair value of warrants.", "label": "Expected volatility", "terseLabel": "Expected volatility", "verboseLabel": "Volatility" } } }, "auth_ref": [] }, "iva_ExpectedVolatilityOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ExpectedVolatilityOtherEquityInstrumentsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "The expected volatility of other equity instruments granted.", "label": "Expected Volatility, Other Equity Instruments Granted", "terseLabel": "Expected volatility" } } }, "auth_ref": [] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets", "terseLabel": "Share based payment expense" } }, "en": { "role": { "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets." } } }, "auth_ref": [ "r172" ] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Expense from share-based payment transactions with employees", "negatedLabel": "Share-based payments" } }, "en": { "role": { "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]" } } }, "auth_ref": [ "r284" ] }, "iva_ExpirationNoticePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ExpirationNoticePeriod", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "The expiration of the term with a notice period.", "label": "Expiration Notice Period", "terseLabel": "Expiration term of notice period" } } }, "auth_ref": [] }, "country_FR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "FR", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails" ], "lang": { "en-us": { "role": { "label": "France" } } }, "auth_ref": [] }, "iva_FairValueOfOptionToAcquireSharesInAssociate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "FairValueOfOptionToAcquireSharesInAssociate", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of option to acquire shares in associate", "label": "Fair value of option to acquire shares in associate" } } }, "auth_ref": [] }, "iva_FairValueOfWarrantsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "FairValueOfWarrantsOutstanding", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of warrants outstanding", "label": "Fair value of warrants outstanding", "terseLabel": "Fair value" } } }, "auth_ref": [] }, "iva_FairValueVariationLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "FairValueVariationLosses", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of fair value variation losses.", "label": "Fair Value Variation Losses", "negatedLabel": "Losses on fair value variation" } } }, "auth_ref": [] }, "iva_Fees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "Fees", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to fees.", "label": "Fees", "negatedLabel": "Fees" } } }, "auth_ref": [] }, "iva_FibroscanMachinesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "FibroscanMachinesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for fibroscan machines.", "label": "Fibroscan machines" } } }, "auth_ref": [] }, "iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "FinanceContractWithEuropeanInvestmentBankFirstTrancheMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to first tranche of the finance contract with European Investment Bank (\"EIB\").", "label": "Finance Contract With European Investment Bank, First Tranche [Member]", "terseLabel": "Finance contract with EIB, first tranche (Tranche A)", "verboseLabel": "Finance contract with EIB, Tranche A" } } }, "auth_ref": [] }, "iva_FinanceContractWithEuropeanInvestmentBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "FinanceContractWithEuropeanInvestmentBankMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the Finance contract with the European Investment Bank", "label": "Finance contract with European Investment Bank [Member]", "terseLabel": "Finance contract with EIB" } } }, "auth_ref": [] }, "iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "FinanceContractWithEuropeanInvestmentBankSecondTrancheMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to second tranche of the finance contract with European investment bank (\"EIB\").", "label": "Finance Contract With European Investment Bank, Second Tranche [Member]", "terseLabel": "Finance contract with EIB, second tranche (Tranche B)", "verboseLabel": "Finance contract with EIB, Tranche B" } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Finance costs", "negatedTerseLabel": "Financial expenses", "negatedTotalLabel": "Total financial expenses", "terseLabel": "Financial expenses" } }, "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } } }, "auth_ref": [ "r39" ] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Finance income", "terseLabel": "Financial income", "totalLabel": "Total financial income" } }, "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } } }, "auth_ref": [ "r292" ] }, "ifrs-full_FinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinanceIncomeCost", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Finance income (cost)", "terseLabel": "Net financial income", "totalLabel": "Financial income (loss)" } }, "en": { "role": { "documentation": "The amount of income or cost associated with interest and other financing activities of the entity." } } }, "auth_ref": [ "r292" ] }, "ifrs-full_FinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets", "terseLabel": "Financial assets" } }, "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]" } } }, "auth_ref": [ "r178", "r183", "r184", "r187", "r258" ] }, "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsAtAmortisedCostCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets carried at amortized cost", "terseLabel": "Financial assets carried at amortized cost" } }, "en": { "role": { "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]" } } }, "auth_ref": [ "r197" ] }, "ifrs-full_FinancialAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsAtFairValue", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets, at fair value", "terseLabel": "Financial assets, at fair value", "verboseLabel": "Assets, fair value" } }, "en": { "role": { "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]" } } }, "auth_ref": [ "r178" ] }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets carried at fair value through profit or loss", "terseLabel": "Financial assets carried at fair value through profit or loss" } }, "en": { "role": { "documentation": "This member stands for the financial assets at fair value through profit or loss category. [Refer: Financial assets at fair value through profit or loss]" } } }, "auth_ref": [ "r195" ] }, "ifrs-full_FinancialAssetsCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets, category [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r199" ] }, "ifrs-full_FinancialAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets, class [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r165", "r192", "r193", "r218", "r219" ] }, "ifrs-full_FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialAssetsPledgedAsCollateralForLiabilitiesOrContingentLiabilities", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets pledged as collateral for liabilities or contingent liabilities", "verboseLabel": "Cash pledged as security" } }, "en": { "role": { "documentation": "The amount of financial assets that the entity has pledged as collateral for liabilities or contingent liabilities, including amounts that have been reclassified in accordance with paragraph 3.2.23(a) of IFRS 9. [Refer: Contingent liabilities [member]; Financial assets]" } } }, "auth_ref": [ "r175" ] }, "iva_FinancialIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "FinancialIncomeAndExpensesAbstract", "lang": { "en-us": { "role": { "documentation": "The entire disclosure of financial income and expenses.", "label": "Financial income and expenses" } } }, "auth_ref": [] }, "iva_FinancialIncomeAndExpensesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "FinancialIncomeAndExpensesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Financial Income And Expenses [Line Items]", "verboseLabel": "Financial income and expenses" } } }, "auth_ref": [] }, "iva_FinancialIncomeAndExpensesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "FinancialIncomeAndExpensesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information pertaining to disclosure of financial income and expenses.", "label": "Financial Income And Expenses [Table]" } } }, "auth_ref": [] }, "iva_FinancialIncomeAndExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "FinancialIncomeAndExpensesTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of financial income and expense.", "label": "Financial Income and Expenses [Table Text Block]", "terseLabel": "Schedule of financial income and expenses" } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities", "terseLabel": "Financial liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r178" ] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities carried at amortized cost", "verboseLabel": "Liabilities carried at amortized cost" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]" } } }, "auth_ref": [ "r198" ] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCostMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities at amortised cost, class [member]", "terseLabel": "Financial liabilities at amortized cost" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities measured at amortised cost class. [Refer: Financial liabilities at amortised cost]" } } }, "auth_ref": [ "r200" ] }, "ifrs-full_FinancialLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesAtFairValue", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities, at fair value", "verboseLabel": "Financial liabilities, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]" } } }, "auth_ref": [ "r178" ] }, "ifrs-full_FinancialLiabilitiesAtFairValueMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesAtFairValueMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities at fair value, class [member]", "terseLabel": "Financial liabilities at fair value" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities measured at fair value class. [Refer: Financial liabilities; At fair value [member]]" } } }, "auth_ref": [ "r200" ] }, "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities at fair value through profit or loss, category [member]", "terseLabel": "Financial liabilities carried at fair value through profit or loss" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]" } } }, "auth_ref": [ "r196" ] }, "ifrs-full_FinancialLiabilitiesCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities, category [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r199" ] }, "ifrs-full_FinancialLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FinancialLiabilitiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities, class [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r192", "r193", "r218", "r219" ] }, "iva_FinancingFromSyndicateOfFrenchBanksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "FinancingFromSyndicateOfFrenchBanksMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for financing from a syndicate of French banks.", "label": "Financing from a syndicate of French banks" } } }, "auth_ref": [] }, "iva_FinancingPeriodOfLoan": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "FinancingPeriodOfLoan", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the financing period of loan.", "label": "Financing Period of Loan", "terseLabel": "Financing period of loan" } } }, "auth_ref": [] }, "iva_FirstApprovalFromCentralIrbOverseeingClinicalResearchInUnitedStatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "FirstApprovalFromCentralIrbOverseeingClinicalResearchInUnitedStatesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the first approval from the central IRB overseeing clinical research in the United States", "label": "First approval from the central IRB overseeing clinical research in the United States [Member]", "terseLabel": "First approval from the central IRB overseeing clinical research in the United States" } } }, "auth_ref": [] }, "ifrs-full_FixturesAndFittingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "FixturesAndFittingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Fixtures and fittings" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing fixtures and fittings that are not permanently attached to real property. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r231" ] }, "ifrs-full_ForeignExchangeGain": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ForeignExchangeGain", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Foreign exchange gain", "terseLabel": "Foreign exchange gains" } }, "en": { "role": { "documentation": "The gross gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } } }, "auth_ref": [ "r9", "r69" ] }, "iva_ForeignExchangeGainsOnShortTermDepositUnwinding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ForeignExchangeGainsOnShortTermDepositUnwinding", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Foreign exchange gains on short term deposit unwinding", "label": "Foreign exchange gains on short term deposit unwinding" } } }, "auth_ref": [] }, "ifrs-full_ForeignExchangeLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ForeignExchangeLoss", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Foreign exchange loss", "negatedLabel": "Foreign exchange losses" } }, "en": { "role": { "documentation": "The gross loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } } }, "auth_ref": [ "r9", "r69" ] }, "iva_ForeignExchangeRateWithReasonablyPossibleIncreaseInRiskAssumption": { "xbrltype": "decimalItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ForeignExchangeRateWithReasonablyPossibleIncreaseInRiskAssumption", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "Foreign exchange rate with reasonably possible increase in risk assumption", "label": "Foreign exchange rate with reasonably possible increase in risk assumption" } } }, "auth_ref": [] }, "ifrs-full_ForeignExchangeRatesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ForeignExchangeRatesAbstract", "lang": { "en-us": { "role": { "label": "Exchange rate (USD per EUR)" } } }, "auth_ref": [] }, "iva_FredericCrenAndPierreBroquaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "FredericCrenAndPierreBroquaMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Frederic Cren and Pierre Broqua.", "label": "Frederic Cren and Pierre Broqua" } } }, "auth_ref": [] }, "iva_FredericCrenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "FredericCrenMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Frederic Cren", "label": "Frederic Cren [Member]", "terseLabel": "Frederic Cren" } } }, "auth_ref": [] }, "iva_FurnitureMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "FurnitureMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for furniture.", "label": "Furniture" } } }, "auth_ref": [] }, "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsChangesInNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income", "terseLabel": "Actuarial gains or losses recognized in other comprehensive income" } }, "en": { "role": { "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r63" ] }, "ifrs-full_GainsOnDisposalsOfNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GainsOnDisposalsOfNoncurrentAssets", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Gains on disposals of non-current assets", "terseLabel": "Proceeds - Disposals of fixed assets" } }, "en": { "role": { "documentation": "The gain on disposals of non-current assets. [Refer: Non-current assets]" } } }, "auth_ref": [ "r284" ] }, "ifrs-full_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "General and administrative expense", "negatedLabel": "General and administrative expenses" } }, "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } } }, "auth_ref": [ "r284" ] }, "iva_GeneralFacilitiesMiscellaneousFixturesAndFittingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "GeneralFacilitiesMiscellaneousFixturesAndFittingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for general facilities, miscellaneous fixtures and fittings.", "label": "General facilities, miscellaneous fixtures and fittings" } } }, "auth_ref": [] }, "ifrs-full_GeographicalAreasAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GeographicalAreasAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "label": "Geographical areas [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r216", "r233", "r252", "r255" ] }, "ifrs-full_GeographicalAreasMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GeographicalAreasMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "label": "Geographical areas [member]" } }, "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } } }, "auth_ref": [ "r216", "r233", "r252", "r255" ] }, "iva_GoingConcernLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "GoingConcernLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.", "label": "Going Concern [Line Items]", "terseLabel": "Going Concern" } } }, "auth_ref": [] }, "iva_GoingConcernTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "GoingConcernTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to going concern.", "label": "Going Concern [Table]" } } }, "auth_ref": [] }, "ifrs-full_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Goodwill", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill", "terseLabel": "Goodwill" } }, "en": { "role": { "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]" } } }, "auth_ref": [ "r11", "r90", "r91", "r173" ] }, "ifrs-full_GrossCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "GrossCarryingAmountMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureInventoriesDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Gross", "terseLabel": "Laboratory inventories" } }, "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r55", "r96", "r105", "r108", "r173", "r184", "r187", "r258" ] }, "iva_GrossProceedsFromIssuanceOfEquityAndRoyaltyCertificates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "GrossProceedsFromIssuanceOfEquityAndRoyaltyCertificates", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of gross proceeds from the issuance of share capital and royalty certificates.", "label": "Gross Proceeds from Issuance of Equity and Royalty Certificates", "terseLabel": "Gross proceeds from issuance of equity and royalty certificates" } } }, "auth_ref": [] }, "iva_GrossProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "GrossProceedsFromIssuingShares", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of gross proceeds from issuing shares.", "label": "Gross Proceeds From Issuing Shares", "terseLabel": "Gross proceeds", "verboseLabel": "Gross proceeds from initial public offering" } } }, "auth_ref": [] }, "iva_GuaranteeGivenToTaxAuthoritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "GuaranteeGivenToTaxAuthoritiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for guarantee given to the tax authorities.", "label": "Guarantee Given To The Tax Authorities [Member]", "terseLabel": "Guarantee given to the tax authorities" } } }, "auth_ref": [] }, "iva_HepalysPharmaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "HepalysPharmaIncMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Hepalys Pharma, Inc.", "label": "Hepalys Pharma, Inc [Member]", "terseLabel": "Hepalys Pharma, Inc" } } }, "auth_ref": [] }, "iva_HoldingPeriodOfAwardsGrantedInShareBasedPaymentArrangement": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "HoldingPeriodOfAwardsGrantedInShareBasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the holding period of awards granted in share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Holding Period Of Awards Granted In Share-Based Payment Arrangement", "terseLabel": "Holding period (year)" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r272", "r273", "r274" ] }, "iva_IfrsAdrMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsAdrMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Ifrs ADR Member\n.", "label": "Adr [Member]", "terseLabel": "ADS" } } }, "auth_ref": [] }, "iva_IfrsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsCashAndCashEquivalentsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for cash and cash equivalents.", "label": "Cash and Cash equivalents", "terseLabel": "Cash and cash equivalents" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "IFRS Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrant" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Ifrs Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of shares per warrant", "verboseLabel": "Number of shares per instrument" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "IFRS Class of Warrant or Right, Outstanding", "terseLabel": "Number of share warrants outstanding", "verboseLabel": "Number of BSA outstanding" } } }, "auth_ref": [] }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesCommitmentsGivenAndReceivedDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicenseAndCollaborationAgreementWithCttqDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsAdvancesPaymentsNonCurrentDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "auth_ref": [] }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesCommitmentsGivenAndReceivedDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicenseAndCollaborationAgreementWithCttqDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsAdvancesPaymentsNonCurrentDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "auth_ref": [] }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicenseAndCollaborationAgreementWithCttqDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Ifrs Collaborative Arrangement And Arrangement Other Than Collaborative [Line items]", "verboseLabel": "Collaborative Arrangements" } } }, "auth_ref": [] }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicenseAndCollaborationAgreementWithCttqDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "auth_ref": [] }, "iva_IfrsDebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsDebtInstrumentTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Ifrs Debt Instrument, Term", "terseLabel": "Maturity term", "verboseLabel": "Maturity term after the disbursement of the tranche" } } }, "auth_ref": [] }, "iva_IfrsDisclosureOfOperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsDisclosureOfOperatingExpensesAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Operating expenses" } } }, "auth_ref": [] }, "iva_IfrsForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsForeignExchangeForwardMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskDetails" ], "lang": { "en-us": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign currency forwards", "terseLabel": "Foreign currency forwards" } } }, "auth_ref": [] }, "iva_IfrsGeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsGeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for general and administrative expense member.", "label": "General and administrative expenses" } } }, "auth_ref": [] }, "iva_IfrsIncreaseDecreaseInOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsIncreaseDecreaseInOtherCurrentLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in other current liabilities of the entity.", "label": "IFRS Increase (Decrease) In Other Current Liabilities", "terseLabel": "Decrease in other current liabilities" } } }, "auth_ref": [] }, "iva_IfrsIncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsIncreaseDecreaseInPrepaidExpense", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "IFRS Increase (Decrease) in Prepaid Expense", "terseLabel": "Increase (decrease) in prepaid expenses" } } }, "auth_ref": [] }, "iva_IfrsLeaseAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsLeaseAgreementsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for lease agreements.", "label": "ifrs Lease Agreements [Member]", "terseLabel": "Lease" } } }, "auth_ref": [] }, "iva_IfrsNumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsNumberOfOperatingSegments", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of operating segments", "terseLabel": "Number of operating segments" } } }, "auth_ref": [] }, "iva_IfrsOtherOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsOtherOperatingIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails": { "parentTag": "iva_OtherIncomeFromOrdinaryActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.", "label": "Ifrs Other Operating Income", "terseLabel": "Other" } } }, "auth_ref": [] }, "iva_IfrsResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for research and development expense member.", "label": "Ifrs Research And Development Expense [Member]", "terseLabel": "Research and development costs" } } }, "auth_ref": [] }, "iva_IfrsSaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsSaleOfStockAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "IFRS Sale of Stock [Axis]" } } }, "auth_ref": [] }, "iva_IfrsSaleOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsSaleOfStockDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "IFRS Sale of Stock [Domain]" } } }, "auth_ref": [] }, "iva_IfrsSalesAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsSalesAndMarketingExpenseMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for sales and marketing expense member.", "label": "Marketing - Business development expenses", "terseLabel": "Marketing - business development expenses" } } }, "auth_ref": [] }, "iva_IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carry forwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Ifrs Schedule of Components of Income Tax Expense Benefit [Table text block]", "terseLabel": "Schedule of income tax expense" } } }, "auth_ref": [] }, "iva_IfrsScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInventoriesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "IFRS Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventories" } } }, "auth_ref": [] }, "iva_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Period which the right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "IFRS Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "verboseLabel": "Vesting and holding period (year)" } } }, "auth_ref": [] }, "iva_IfrsShareBasedPaymentArrangementTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsShareBasedPaymentArrangementTrancheOneMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Tranche one" } } }, "auth_ref": [] }, "iva_IfrsShareBasedPaymentArrangementTrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsShareBasedPaymentArrangementTrancheThreeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Tranche three" } } }, "auth_ref": [] }, "iva_IfrsShareBasedPaymentArrangementTrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsShareBasedPaymentArrangementTrancheTwoMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Tranche two" } } }, "auth_ref": [] }, "iva_IfrsSharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsSharesIssuedPricePerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Ifrs Shares Issued, Price Per Share", "terseLabel": "Price per share" } } }, "auth_ref": [] }, "iva_IfrsVestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsVestingAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Ifrs Vesting [Axis]" } } }, "auth_ref": [] }, "iva_IfrsVestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IfrsVestingDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Ifrs Vesting [Domain]" } } }, "auth_ref": [] }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Impairment loss recognised in profit or loss, intangible assets other than goodwill", "terseLabel": "Impairment amount on amortizable intangible assets" } }, "en": { "role": { "documentation": "The amount of impairment loss recognised in profit or loss for intangible assets other than goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r98" ] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF INCOME (LOSS)" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 3.0 }, "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Tax expense (income)", "negatedLabel": "Income tax", "negatedTotalLabel": "Actual income tax benefit" } }, "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } } }, "auth_ref": [ "r40", "r46", "r47", "r48", "r79", "r137", "r206" ] }, "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income taxes paid (refund), classified as operating activities", "negatedLabel": "Tax credit received" } }, "en": { "role": { "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]" } } }, "auth_ref": [ "r115", "r240" ] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents", "terseLabel": "Decrease in cash and cash equivalents" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r116" ] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r116" ] }, "iva_IncreaseDecreaseInCurrentDepositAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreaseDecreaseInCurrentDepositAccounts", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in current deposit accounts", "label": "Increase (decrease) in current deposit accounts", "terseLabel": "Decrease in current deposit accounts" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumptionPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumptionPercent", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of increase (decrease) in a defined benefit obligation that would have been caused by an increase in a significant actuarial assumption that was reasonably possible at the end of the reporting period.", "label": "Increase (Decrease) In Defined Benefit Obligation Due To Reasonably Possible Increase In Actuarial Assumption, Percent", "terseLabel": "Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption (as a percent)" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInFinancialInstrumentDueToReasonablyPossibleIncreaseDecreaseInDesignatedRiskComponent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreaseDecreaseInFinancialInstrumentDueToReasonablyPossibleIncreaseDecreaseInDesignatedRiskComponent", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in a financial instrument as a result of an increase (decrease) in a designated risk component that was reasonably possible at the end of the reporting period. Excludes defined benefit plan obligations.", "label": "Increase (Decrease) In Financial Instrument Due To Reasonably Possible Increase (Decrease) In Designated Risk Component", "terseLabel": "Impact of a 5% change in fair value" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreaseDecreaseInLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in lease liabilities during the period.", "label": "Increase (Decrease) in Lease Liabilities", "terseLabel": "Increase (decrease) in lease liabilities" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInLongTermDepositAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreaseDecreaseInLongTermDepositAccounts", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in long-term deposit accounts", "label": "Increase (decrease) in long-term deposit accounts", "terseLabel": "Increase (decrease) in long-term deposit accounts" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsChangesInNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss", "negatedLabel": "Expense for the period" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from expense (income) included in profit or loss. [Refer: Net defined benefit liability (asset); Profit (loss)] [Contrast: Post-employment benefit expense in profit or loss, defined benefit plans]" } } }, "auth_ref": [ "r297" ] }, "ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInNumberOfSharesOutstanding", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in number of shares outstanding" } }, "en": { "role": { "documentation": "The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]" } } }, "auth_ref": [ "r32" ] }, "iva_IncreaseDecreaseInOtherMiscellaneousCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreaseDecreaseInOtherMiscellaneousCurrentLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in other miscellaneous current liabilities of the entity.", "label": "Increase (Decrease) In Other Miscellaneous Current Liabilities", "terseLabel": "Decrease in other miscellaneous liabilities" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInOtherOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreaseDecreaseInOtherOperatingExpense", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in other operating expense", "label": "Increase (decrease) in other operating expense" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInOtherOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreaseDecreaseInOtherOperatingIncome", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in other operating income", "label": "Increase (decrease) in other operating income" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInSalesTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreaseDecreaseInSalesTaxLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in sales tax liabilities of the entity.", "label": "Increase (Decrease) In Sales Tax Liabilities", "terseLabel": "Increase in VAT payable" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInSharesThroughExerciseAndVestingOfEquityInstruments": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreaseDecreaseInSharesThroughExerciseAndVestingOfEquityInstruments", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in shares resulting from the exercise and vesting of equity instruments.", "label": "Increase Decrease In Shares Through Exercise And Vesting Of Equity Instruments", "terseLabel": "Vesting of bonus shares (in shares)" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInTradeAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreaseDecreaseInTradeAccountsPayable", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in trade accounts payable", "label": "Increase (decrease) in trade accounts payable", "terseLabel": "Increase in trade accounts payable" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseInWorkingCapital", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in working capital", "negatedTotalLabel": "Tax, interest and changes in operating working capital" } }, "en": { "role": { "documentation": "The increase (decrease) in working capital." } } }, "auth_ref": [ "r311" ] }, "ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughAppropriationOfRetainedEarnings", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through appropriation of retained earnings, equity", "terseLabel": "Appropriation of net income (loss)" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the appropriation of retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r282" ] }, "iva_IncreaseDecreaseThroughCapitalVariations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreaseDecreaseThroughCapitalVariations", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) through capital variations, equity", "label": "Increase (decrease) through capital variations", "terseLabel": "Capital variations" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through exercise of warrants, equity", "terseLabel": "Vesting of bonus shares" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of warrants." } } }, "auth_ref": [ "r282" ] }, "ifrs-full_IncreaseDecreaseThroughOtherChangesNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughOtherChangesNetDefinedBenefitLiabilityAsset", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsChangesInNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in net defined benefit liability (asset) resulting from other changes", "terseLabel": "Other changes" } }, "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r297" ] }, "ifrs-full_IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughOtherChangesPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through other changes, property, plant and equipment", "terseLabel": "Others" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r57" ] }, "iva_IncreaseDecreaseThroughShareWarrantsSubscriptionPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreaseDecreaseThroughShareWarrantsSubscriptionPremium", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase decrease in reserves resulting from BSA share warrants subscription premium.", "label": "Increase (Decrease) Through Share Warrants Subscription Premium", "terseLabel": "BSA share warrants subscription premium" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through share-based payment transactions, equity", "terseLabel": "Share-based payment compensation expenses", "verboseLabel": "Capital increase arising from the vesting of bonus share awards" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r4" ] }, "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesEquity", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through other changes, equity", "terseLabel": "Other" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]" } } }, "auth_ref": [ "r5" ] }, "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IncreaseDecreaseThroughTreasuryShareTransactions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through treasury share transactions, equity", "terseLabel": "Treasury shares" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]" } } }, "auth_ref": [ "r5" ] }, "iva_IncreaseInBorrowingsThroughAccruedAndCapitalizedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreaseInBorrowingsThroughAccruedAndCapitalizedInterest", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase in borrowings through accrued and capitalized interest", "label": "Increase in borrowings through accrued and capitalized interest", "terseLabel": "Capitalized interest" } } }, "auth_ref": [] }, "iva_IncreaseInBorrowingsThroughCapitalizedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreaseInBorrowingsThroughCapitalizedInterest", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in borrowings through capitalized interest.", "label": "Increase in borrowings through capitalized interest", "terseLabel": "Capitalized interests" } } }, "auth_ref": [] }, "iva_IncreaseInBorrowingsThroughNewLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreaseInBorrowingsThroughNewLeases", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase in borrowings through new leases.", "label": "Increase In Borrowings Through New Leases", "terseLabel": "Subscription of new leases" } } }, "auth_ref": [] }, "iva_IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreaseInBorrowingsThroughSubscriptionOfDerivativesInstruments", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in borrowings through Subscription of derivatives instruments.", "label": "Increase in Borrowings Through Subscription Of Derivatives Instruments", "terseLabel": "Subscription of derivatives instruments" } } }, "auth_ref": [] }, "iva_IncreaseInBorrowingsThroughSubscriptionOfPprLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreaseInBorrowingsThroughSubscriptionOfPprLoan", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in borrowings through Subscription of PPR loan.", "label": "Increase in Borrowings Through Subscription Of PPR Loan", "terseLabel": "Subscription of PPR loan" } } }, "auth_ref": [] }, "iva_IncreaseInBorrowingsThroughSubscriptionOfStateGuaranteedPgeLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreaseInBorrowingsThroughSubscriptionOfStateGuaranteedPgeLoan", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in borrowings through Subscription of state-guaranteed PGE loan.", "label": "Increase in Borrowings Through Subscription Of State-Guaranteed PGE Loan", "terseLabel": "Subscription of state-guaranteed PGE loan" } } }, "auth_ref": [] }, "iva_IncreaseInResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreaseInResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in research and development expense.", "label": "Increase in Research and Development Expense", "terseLabel": "Increase in research and development expense" } } }, "auth_ref": [] }, "iva_IncreaseInSharesThroughIssueOfOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreaseInSharesThroughIssueOfOrdinaryShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase in shares resulting from the issuance of shares.", "label": "Increase In Shares Through Issue of Ordinary Shares", "terseLabel": "Issue of ordinary shares (in shares)", "verboseLabel": "Number of shares issued during the period" } } }, "auth_ref": [] }, "iva_IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreaseOrDecreaseInBorrowingsDueToChangeInFairValueOfDerivativesInstruments", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase or decrease in borrowings due to change in fair value of derivatives instruments.", "label": "Increase Or Decrease In Borrowings Due To Change in Fair Value of Derivatives Instruments", "terseLabel": "Fair Value Variations" } } }, "auth_ref": [] }, "iva_IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreaseOrDecreaseInBorrowingsDueToChangesInExchangeRates", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase or decrease in borrowings due to exchange rate change.", "label": "Increase or Decrease in Borrowings Due to Changes in Exchange Rates", "terseLabel": "Exchange rate change", "verboseLabel": "Effect of movements in exchange rates" } } }, "auth_ref": [] }, "iva_IncreaseOrDecreaseInFairValueOfWarrantsDueToReasonablyPossibleIncreaseOrDecreaseInVolatility": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreaseOrDecreaseInFairValueOfWarrantsDueToReasonablyPossibleIncreaseOrDecreaseInVolatility", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase or decrease in fair value of warrants due to reasonably possible increase or decrease in volatility", "label": "Increase or decrease in fair value of warrants due to reasonably possible increase or decrease in volatility" } } }, "auth_ref": [] }, "iva_Increaseinborrowingsthroughborrowingsreceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "Increaseinborrowingsthroughborrowingsreceived", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in borrowings through borrowings received.", "label": "IncreaseInBorrowingsThroughBorrowingsReceived", "terseLabel": "Subscription of bank borrowings" } } }, "auth_ref": [] }, "iva_IncreasesInIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreasesInIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of increases to intangible assets other than goodwill.", "label": "Increases in intangible assets other than goodwill", "terseLabel": "Increases" } } }, "auth_ref": [] }, "iva_IncreasesInPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncreasesInPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of increases in property, plant and equipment", "label": "Increases in property, plant and equipment", "terseLabel": "Increases" } } }, "auth_ref": [] }, "iva_IncurredExpensesThatAreDueToBeReinvoiced": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IncurredExpensesThatAreDueToBeReinvoiced", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Incurred expenses that are due to be reinvoiced", "label": "Incurred expenses that are due to be reinvoiced" } } }, "auth_ref": [] }, "iva_IndemnificationAmountReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IndemnificationAmountReceived", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Amount of indemnification received under guarantee.", "label": "Indemnification Amount Received", "terseLabel": "Indemnification amount received" } } }, "auth_ref": [] }, "iva_InflationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "InflationRiskMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for inflation risk.", "label": "Inflation Risk [Member]", "terseLabel": "Inflation Risk" } } }, "auth_ref": [] }, "iva_InitialPublicOfferingInsuranceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "InitialPublicOfferingInsuranceCosts", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of insurance cost related to IPO.", "label": "Initial Public Offering Insurance Costs", "terseLabel": "Insurance costs" } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails": { "parentTag": "iva_NonCurrentAssetsExcludingDeferredAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails", "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Intangible assets other than goodwill", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "terseLabel": "Intangible assets" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r11", "r100" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwillMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets other than goodwill [member]" } }, "en": { "role": { "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r101", "r236", "r253" ] }, "iva_IntercompanyEliminationsInAssociates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IntercompanyEliminationsInAssociates", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of intercompany eliminations in associates", "label": "Intercompany Eliminations in Associates", "negatedLabel": "Elimination of unrealised profit on downstream sales" } } }, "auth_ref": [] }, "ifrs-full_InterestCostsCapitalised": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestCostsCapitalised", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Interest costs capitalised", "terseLabel": "Capitalized interest" } }, "en": { "role": { "documentation": "The amount of interest costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset." } } }, "auth_ref": [ "r284" ] }, "ifrs-full_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense", "negatedLabel": "Interest cost" } }, "en": { "role": { "documentation": "The amount of expense arising from interest." } } }, "auth_ref": [ "r136", "r205", "r213" ] }, "ifrs-full_InterestExpenseDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestExpenseDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense, defined benefit plans", "negatedLabel": "Interest cost for the period" } }, "en": { "role": { "documentation": "The amount of interest expense arising from defined benefit plans. [Refer: Interest expense; Post-employment benefit expense in profit or loss, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)]" } } }, "auth_ref": [ "r296" ] }, "ifrs-full_InterestExpenseOnBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestExpenseOnBorrowings", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense on borrowings" } }, "en": { "role": { "documentation": "The amount of interest expense on borrowings. [Refer: Interest expense; Borrowings]" } } }, "auth_ref": [ "r284" ] }, "ifrs-full_InterestIncomeOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestIncomeOnCashAndCashEquivalents", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Interest income on cash and cash equivalents", "terseLabel": "Income from cash equivalents" } }, "en": { "role": { "documentation": "The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]" } } }, "auth_ref": [ "r284" ] }, "iva_InterestOnRoyaltyCertificates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "InterestOnRoyaltyCertificates", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in borrowings through interests on royalty certificates.", "label": "Interest On Royalty Certificates", "verboseLabel": "Interests on royalty certificates" } } }, "auth_ref": [] }, "ifrs-full_InterestPayable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InterestPayable", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialDebtFinancialDebtDetails": { "parentTag": "ifrs-full_Borrowings", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" ], "lang": { "en-us": { "role": { "label": "Interest payable", "terseLabel": "Accrued interest payable on loans" } }, "en": { "role": { "documentation": "The amount of interest recognised as a liability." } } }, "auth_ref": [ "r284" ] }, "iva_InventivaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "InventivaIncMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceConsolidatedFinancialStatementsDetails", "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationInvestmentInSubsidiaryDetails", "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Inventiva Inc, U.S. affiliate.", "label": "Inventiva Inc [Member]", "terseLabel": "Inventiva Inc." } } }, "auth_ref": [] }, "iva_InventivaS.aMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "InventivaS.aMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceConsolidatedFinancialStatementsDetails", "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Inventiva S.A, U.S. affiliate.", "label": "Inventiva S.A [Member]", "terseLabel": "Inventiva S.A" } } }, "auth_ref": [] }, "ifrs-full_Inventories": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Inventories", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureInventoriesDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current inventories", "terseLabel": "Inventories" } }, "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } } }, "auth_ref": [ "r13", "r67", "r223" ] }, "ifrs-full_InvestmentAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InvestmentAccountedForUsingEquityMethod", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Investments accounted for using equity method", "netLabel": "Carrying amount", "terseLabel": "Investments accounted for using the equity method", "verboseLabel": "Carrying value" } }, "en": { "role": { "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]" } } }, "auth_ref": [ "r12", "r139", "r208" ] }, "iva_InvestmentThresholdMinimumMaturityTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "InvestmentThresholdMinimumMaturityTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsPrincipalActuarialAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold minimum maturity term of the investments, considered for determination of discount rate for actuarial assumptions used to determine the present value of a defined benefit obligation.", "label": "Investment, Threshold Minimum Maturity Term", "terseLabel": "Threshold minimum maturity term for Eurozone AA rated corporate bonds" } } }, "auth_ref": [] }, "ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "InvestmentsAccountedForUsingEquityMethodAbstract", "lang": { "en-us": { "role": { "label": "Investments accounted for using the equity method" } } }, "auth_ref": [] }, "iva_IslsConsultingAndDavidNikademMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IslsConsultingAndDavidNikademMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for ISLS Consulting and David nikadem member.", "label": "ISLS Consulting and David Nikadem" } } }, "auth_ref": [] }, "iva_IslsConsultingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IslsConsultingMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for ISLS Consulting, a company owned by Jean Louis Junien, a director of the Company", "label": "ISLS Consulting" } } }, "auth_ref": [] }, "iva_IssuanceOfWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IssuanceOfWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for issuance of warrants", "label": "Issuance of warrants [Member]", "terseLabel": "Issuance of warrants" } } }, "auth_ref": [] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issue of equity", "terseLabel": "Issue of ordinary shares", "verboseLabel": "Share capital" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r4" ] }, "iva_IssueOfRoyaltyCertificates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "IssueOfRoyaltyCertificates", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsInPeriodBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of increase in borrowings through issue of royalty certificates.", "label": "Issue of Royalty Certificates", "terseLabel": "Issue of royalty certificates" } } }, "auth_ref": [] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Issued capital", "terseLabel": "Share capital", "verboseLabel": "Capital stock" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r226" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share capital" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r6" ] }, "iva_ItSystems": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ItSystems", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to it systems.", "label": "IT Systems", "negatedLabel": "IT systems" } } }, "auth_ref": [] }, "country_JP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "JP", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "label": "JAPAN", "terseLabel": "Japan" } } }, "auth_ref": [] }, "iva_JefferiesAtmProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "JefferiesAtmProgramMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Jefferies ATM Program.", "label": "Jefferies ATM Program [Member]", "terseLabel": "Jefferies ATM program" } } }, "auth_ref": [] }, "country_KR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "KR", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "label": "KOREA, REPUBLIC OF" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensation", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "label": "Key management personnel compensation", "totalLabel": "Net total" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r74" ] }, "iva_KeyManagementPersonnelCompensationAdjustmentOfCompensationPostEmploymentBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "KeyManagementPersonnelCompensationAdjustmentOfCompensationPostEmploymentBenefits", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "documentation": "Key management personnel compensation (adjustment of compensation), post-employment benefits", "label": "Key management personnel compensation (adjustment of compensation), post-employment benefits", "terseLabel": "Post-employment benefits" } } }, "auth_ref": [] }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "label": "Key management personnel compensation, share-based payment", "terseLabel": "Share-based payment" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r73" ] }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails": { "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "label": "Key management personnel compensation, short-term employee benefits", "terseLabel": "Short-term benefits" } }, "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r72" ] }, "ifrs-full_KeyManagementPersonnelOfEntityOrParentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "KeyManagementPersonnelOfEntityOrParentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsSummaryOfTransactionsWithKeyManagementPersonnelDetails" ], "lang": { "en-us": { "role": { "label": "Key Management Personnel Of Entity Or Parent [Member]", "terseLabel": "Executive and corporate officers" } }, "en": { "role": { "documentation": "This member stands for those persons having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity." } } }, "auth_ref": [ "r76" ] }, "ifrs-full_LandMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LandMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Land" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing land held by the entity for use in operations. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r230" ] }, "iva_LanifibranorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LanifibranorMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Lanifbranor", "label": "Lanifibranor [Member]", "terseLabel": "Lanifibranor" } } }, "auth_ref": [] }, "iva_LatePaymentOfInterestOnFrenchResearchTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LatePaymentOfInterestOnFrenchResearchTaxCredit", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of late payment of interest to be paid on French Research tax credit.", "label": "Late Payment of Interest on French Research Tax Credit", "terseLabel": "Late payment interest on CIR 2013-2015" } } }, "auth_ref": [] }, "ifrs-full_LaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanFiveYearsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" ], "lang": { "en-us": { "role": { "label": "More than 5 years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than five years." } } }, "auth_ref": [ "r154", "r155", "r164", "r260", "r264", "r267" ] }, "ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanOneMonthAndNotLaterThanTwoMonthsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "label": "Due in 30 60 days", "terseLabel": "Due in 30-60 days" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one month and not later than two months." } } }, "auth_ref": [ "r258", "r266", "r284" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanThreeYearsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" ], "lang": { "en-us": { "role": { "label": "Between 1 and 3 years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than three years." } } }, "auth_ref": [ "r260", "r262", "r267" ] }, "ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LaterThanThreeYearsAndNotLaterThanFiveYearsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" ], "lang": { "en-us": { "role": { "label": "Between 3 and 5 years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than three years and not later than five years." } } }, "auth_ref": [ "r260", "r263", "r267" ] }, "iva_LaterThanTwoMonthsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LaterThanTwoMonthsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for a time band of later than two months.", "label": "Due in more than 60 days", "terseLabel": "Due in more than 60 days" } } }, "auth_ref": [] }, "ifrs-full_LeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LeaseLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialDebtFinancialDebtDetails": { "parentTag": "ifrs-full_Borrowings", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" ], "lang": { "en-us": { "role": { "label": "Lease liabilities", "terseLabel": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } } }, "auth_ref": [ "r152" ] }, "ifrs-full_LeaseLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LeaseLiabilitiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Lease liabilities [member]", "terseLabel": "Lease liabilities" } }, "en": { "role": { "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r245", "r247" ] }, "iva_LeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LeaseTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Lease term.", "label": "Lease Term", "terseLabel": "Lease term" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceConsolidatedFinancialStatementsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "ifrs-full_LegalProceedingsProvisionMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LegalProceedingsProvisionMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "AMR penalties", "terseLabel": "AMR Penalties" } }, "en": { "role": { "documentation": "This member stands for a provision for legal proceedings. [Refer: Other provisions [member]]" } } }, "auth_ref": [ "r237", "r238" ] }, "iva_LegendAndNativ3PhaseIiiTrialPharmaceuticalResearchAssociatesGroupB.v.AgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LegendAndNativ3PhaseIiiTrialPharmaceuticalResearchAssociatesGroupB.v.AgreementMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to LEGEND and NATiV3 PRA Agreements.", "label": "LEGEND And NATiV3 Phase III Trial, Pharmaceutical Research Associates Group B.V. Agreement [Member]", "terseLabel": "LEGEND and NATiV3 Phase III trial, pharmaceutical research associates group B.V. agreement" } } }, "auth_ref": [] }, "iva_LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D", "label": "LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D [Member]" } } }, "auth_ref": [] }, "ifrs-full_Level1OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Level1OfFairValueHierarchyMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Level 1" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date." } } }, "auth_ref": [ "r64", "r143" ] }, "ifrs-full_Level3OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Level3OfFairValueHierarchyMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Level 3" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } } }, "auth_ref": [ "r143" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r64", "r143" ] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r21", "r142", "r143", "r145", "r207", "r212" ] }, "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LiabilityAssetOfDefinedBenefitPlans", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsChangesInNetProvisionDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Net defined benefit liability (asset)", "negatedPeriodEndLabel": "At end of period", "negatedPeriodStartLabel": "At beginning of period", "totalLabel": "Total Obligation" } }, "en": { "role": { "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]" } } }, "auth_ref": [ "r62" ] }, "iva_LibraryOfCompoundsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LibraryOfCompoundsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for library of compounds.", "label": "Library of compounds" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LicenseAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainMilestones", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum additional amount receivable by the entity, upon the achievement of certain milestones, pursuant to licensing and collaborative arrangements.", "label": "License And Collaboration Agreement, Maximum Additional Amount Receivable Upon Achievement Of Certain Milestones", "terseLabel": "Maximum milestone payments receivable" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementMaximumPotentialRegulatoryAndCommercialMilestonePaymentsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LicenseAndCollaborationAgreementMaximumPotentialRegulatoryAndCommercialMilestonePaymentsReceivable", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum potential amount of regulatory and commercial milestone payments receivable, pursuant to licensing and collaborative arrangements.", "label": "License And Collaboration Agreement Maximum Potential Regulatory And Commercial Milestone Payments Receivable", "terseLabel": "Maximum potential Regulatory and Commercial Milestone payments receivable" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementMilestonePaymentReceivableUponAchievementOfCertainMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LicenseAndCollaborationAgreementMilestonePaymentReceivableUponAchievementOfCertainMilestone", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount of milestone payment receivable in license and collaboration agreements.", "label": "License and Collaboration Agreement, Milestone Payment Receivable upon Achievement of Certain Milestone", "terseLabel": "Milestone payment receivable" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementNumberOfDevelopmentAndRegulatoryMilestones": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LicenseAndCollaborationAgreementNumberOfDevelopmentAndRegulatoryMilestones", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of development and regulatory milestones to be achieved under the licensing and collaborative arrangements.", "label": "License And Collaboration Agreement Number Of Development And Regulatory Milestones", "terseLabel": "Number of development and regulatory milestones" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementNumberOfSuccessiveTargets": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LicenseAndCollaborationAgreementNumberOfSuccessiveTargets", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of successive targets to be achieved under the licensing and collaborative arrangements.", "label": "License And Collaboration Agreement Number Of Successive Targets", "terseLabel": "Number of successive targets" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementRevenueFromRecognitionOfFairValueOfSharesAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LicenseAndCollaborationAgreementRevenueFromRecognitionOfFairValueOfSharesAcquired", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "License and Collaboration Agreement, revenue from recognition of fair value of shares acquired", "label": "License and Collaboration Agreement, revenue from recognition of fair value of shares acquired", "terseLabel": "Revenue from recognition of fair value of shares acquired" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementRevenueFromUpfrontPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LicenseAndCollaborationAgreementRevenueFromUpfrontPayments", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "License and Collaboration Agreement, revenue from upfront payments", "label": "License and Collaboration Agreement, revenue from upfront payments", "terseLabel": "Revenue from upfront payments" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementUpfrontFeeReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LicenseAndCollaborationAgreementUpfrontFeeReceivable", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of upfront fee receivable by the entity, pursuant to licensing and collaborative arrangements.", "label": "License And Collaboration Agreement Upfront Fee Receivable", "terseLabel": "Upfront payment receivable" } } }, "auth_ref": [] }, "iva_LicenseAndCollaborationAgreementUpfrontFeeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LicenseAndCollaborationAgreementUpfrontFeeReceived", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of upfront fee received by the entity, pursuant to licensing and collaborative arrangements.", "label": "License and Collaboration Agreement Upfront Fee Received", "terseLabel": "Upfront payment received" } } }, "auth_ref": [] }, "iva_LicensingAgreementWithHepalysMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LicensingAgreementWithHepalysMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Licensing agreement with Hepalys.", "label": "Licensing Agreement With Hepalys [Member]", "terseLabel": "Licensing agreement with Hepalys" } } }, "auth_ref": [] }, "iva_LicensingAndCollaborationAgreementAmountReceivedAttributableToWithholdingTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LicensingAndCollaborationAgreementAmountReceivedAttributableToWithholdingTaxes", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicenseAndCollaborationAgreementWithCttqDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount received by the entity from licensing and collaborative arrangements, attributable to withholding taxes.", "label": "Licensing And Collaboration Agreement, Amount Received Attributable To Withholding Taxes", "terseLabel": "Amount received attributable to withholding taxes" } } }, "auth_ref": [] }, "iva_LicensingAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainCommercialMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LicensingAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainCommercialMilestones", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicenseAndCollaborationAgreementWithCttqDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum additional amount receivable by the entity, upon the achievement of certain commercial milestones, pursuant to licensing and collaborative arrangements.", "label": "Licensing And Collaboration Agreement, Maximum Additional Amount Receivable Upon The Achievement Of Certain Commercial Milestones", "terseLabel": "Maximum additional amount receivable upon the achievement of certain commercial milestones", "verboseLabel": "Maximum additional amount receivable upon the achievement of certain commercial milestones" } } }, "auth_ref": [] }, "iva_LicensingAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LicensingAndCollaborationAgreementMaximumAdditionalAmountReceivableUponAchievementOfCertainDevelopmentAndRegulatoryMilestones", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicenseAndCollaborationAgreementWithCttqDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum additional amount receivable by the entity, upon the achievement of certain development and regulatory milestones, pursuant to licensing and collaborative arrangements.", "label": "Licensing And Collaboration Agreement, Maximum Additional Amount Receivable Upon The Achievement Of Certain Development And Regulatory Milestones", "terseLabel": "Maximum additional amount receivable upon the achievement of certain development and regulatory milestones" } } }, "auth_ref": [] }, "iva_LicensingAndCollaborationAgreementWithCttqMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LicensingAndCollaborationAgreementWithCttqMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicenseAndCollaborationAgreementWithCttqDetails", "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Licensing and collaboration agreement with CTTQ.", "label": "Licensing and collaboration agreement with CTTQ [Member]", "terseLabel": "Licensing and collaboration agreement with CTTQ" } } }, "auth_ref": [] }, "ifrs-full_LineItemsByFunctionMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LineItemsByFunctionMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Line items by function [member]" } }, "en": { "role": { "documentation": "This member stands for the standard value of the \u2018Attribution of expenses by nature to their function' axis if no other member is used." } } }, "auth_ref": [ "r281", "r284" ] }, "iva_LiquidityAgreementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LiquidityAgreementTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityLiquidityAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of days used to determine liquidity agreement term in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Liquidity Agreement Term", "terseLabel": "Liquidity agreement term" } } }, "auth_ref": [] }, "iva_LoanAgreementsWithSyndicateOfFrenchBanksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LoanAgreementsWithSyndicateOfFrenchBanksMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for loan agreements with a syndicate of French banks.", "label": "Loan Agreements With Syndicate of French Banks [Member]", "verboseLabel": "Loan agreements with a syndicate of French banks" } } }, "auth_ref": [] }, "iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat)", "label": "Loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat) [Member]", "terseLabel": "Loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat)" } } }, "auth_ref": [] }, "iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for loan agreements with a syndicate of French banks, under a stimulus economic plan.", "label": "Loan agreements with syndicate of French banks, under stimulus economic plan [Member]", "terseLabel": "Loan agreements with syndicate of French banks, under stimulus economic plan" } } }, "auth_ref": [] }, "ifrs-full_LoansReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LoansReceived", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialDebtFinancialDebtDetails": { "parentTag": "ifrs-full_Borrowings", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" ], "lang": { "en-us": { "role": { "label": "Loans received", "terseLabel": "Bank borrowings" } }, "en": { "role": { "documentation": "The amount of loans received." } } }, "auth_ref": [ "r284" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "iva_LongTermAccruedIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LongTermAccruedIncomeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for long term accrued income.", "label": "Long-term accrued income", "terseLabel": "Long-term accrued income" } } }, "auth_ref": [] }, "iva_LongTermDepositAccountsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LongTermDepositAccountsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for long term deposit accounts.", "label": "Long-term deposit accounts", "terseLabel": "Long-term deposit accounts" } } }, "auth_ref": [] }, "iva_LongTermDepositForwardContractMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LongTermDepositForwardContractMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for long-term deposit forward contract.", "label": "Long-Term Deposit Forward Contract [Member]", "terseLabel": "Long-term deposit forward contract" } } }, "auth_ref": [] }, "iva_LongTermDepositsTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LongTermDepositsTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "Term of the long-term deposits of the entity.", "label": "Long-Term Deposits Term", "terseLabel": "Period of long-term deposit" } } }, "auth_ref": [] }, "iva_LongTermFinancialDebtDerivativesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LongTermFinancialDebtDerivativesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Long-term financial debt, derivatives.", "label": "Derivatives", "terseLabel": "Long-term financial debt - derivatives" } } }, "auth_ref": [] }, "iva_LongTermIncentivePlanInPerformanceUnits2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LongTermIncentivePlanInPerformanceUnits2023Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for 2023 long-term incentive plan in performance units or \"PAGUP 2023\".", "label": "Long-Term Incentive Plan In Performance Units, 2023 [Member]", "terseLabel": "PAGUP 2023" } } }, "auth_ref": [] }, "iva_LongTermIncentivePlanInPerformanceUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LongTermIncentivePlanInPerformanceUnitsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for long-term incentive plan in performance units or \"PAGUP\".", "label": "Long-Term Incentive Plan In Performance Units [Member]", "terseLabel": "PAGUP" } } }, "auth_ref": [] }, "iva_LongTermSecurityDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "LongTermSecurityDepositsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for long-term security deposits.", "label": "Long-term security deposits", "terseLabel": "Long-term security deposits" } } }, "auth_ref": [] }, "ifrs-full_LongtermBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LongtermBorrowingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Long-term debt", "terseLabel": "Long-term debt" } }, "en": { "role": { "documentation": "This member stands for long-term borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r245", "r247" ] }, "ifrs-full_LongtermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LongtermDeposits", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "label": "Long-term deposits", "terseLabel": "Long-term deposit" } }, "en": { "role": { "documentation": "The amount of long-term deposits held by the entity." } } }, "auth_ref": [ "r287" ] }, "ifrs-full_LossesOnDisposalsOfNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "LossesOnDisposalsOfNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Losses on disposals of non-current assets", "terseLabel": "Disposals of assets" } }, "en": { "role": { "documentation": "The losses on disposals of non-current assets. [Refer: Non-current assets]" } } }, "auth_ref": [ "r284" ] }, "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MajorComponentsOfTaxExpenseIncomeAbstract", "lang": { "en-us": { "role": { "label": "Income tax" } } }, "auth_ref": [] }, "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]", "terseLabel": "Schedule of maturity of long-term and short-term debt" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r189" ] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails", "http://www.inventivapharma.com/role/DisclosureTradePayablesBreakDownDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r24", "r150", "r154", "r155", "r156", "r157", "r158", "r164", "r177", "r191", "r234", "r260" ] }, "iva_MaximumAggregateSalesProceedsFromIssuanceOfShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "MaximumAggregateSalesProceedsFromIssuanceOfShares", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the maximum aggregate sales proceeds under issuance of shares.", "label": "Maximum Aggregate Sales Proceeds From Issuance Of Shares", "terseLabel": "Maximum aggregate sales proceeds" } } }, "auth_ref": [] }, "iva_MaximumDurationOfClinicalTrial": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "MaximumDurationOfClinicalTrial", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum duration of the clinical trial of the entity.", "label": "Maximum Duration Of The Clinical Trial", "verboseLabel": "Maximum duration of Phase III trial" } } }, "auth_ref": [] }, "iva_MaximumGrossProceedsReceivableUponExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "MaximumGrossProceedsReceivableUponExerciseOfWarrants", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "The maximum gross proceeds from receivable upon exercise of warrants.", "label": "Maximum Gross Proceeds Receivable upon Exercise of Warrants", "terseLabel": "Maximum gross proceeds" } } }, "auth_ref": [] }, "iva_MaximumPotentialGrossProceedsFromExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "MaximumPotentialGrossProceedsFromExerciseOfWarrants", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum potential amount of gross proceeds that the company will receive from exercise of warrants.", "label": "Maximum Potential Gross Proceeds From Exercise Of Warrants", "terseLabel": "Maximum potential gross proceeds from exercise of warrants" } } }, "auth_ref": [] }, "iva_MaximumProceedsFromAtMarketProgram": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "MaximumProceedsFromAtMarketProgram", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum proceeds from at the market program", "label": "Maximum proceeds from at the market program" } } }, "auth_ref": [] }, "iva_MaximumRoyaltiesPayableToRoyaltyCertificateHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "MaximumRoyaltiesPayableToRoyaltyCertificateHolders", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum royalties payable to royalty certificate holders", "label": "Maximum royalties payable to royalty certificate holders" } } }, "auth_ref": [] }, "iva_MaximumShareholdingInEntityToBeLegallyAllowedToParticipateInPlan": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "MaximumShareholdingInEntityToBeLegallyAllowedToParticipateInPlan", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum shareholding in entity to be legally allowed to participate in plan", "label": "Maximum shareholding in entity to be legally allowed to participate in plan" } } }, "auth_ref": [] }, "iva_MaximumSubcontractingExpensesToBeClaimed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "MaximumSubcontractingExpensesToBeClaimed", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of maximum subcontracting expenses to be claimed.", "label": "Maximum Subcontracting Expenses to be Claimed", "terseLabel": "Maximum expenses to be claimed" } } }, "auth_ref": [] }, "iva_MinimumPeriodToHoldLessThanThresholdValueOfSharesToBecomeEligibleForParticipationInPlan": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "MinimumPeriodToHoldLessThanThresholdValueOfSharesToBecomeEligibleForParticipationInPlan", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Minimum period to hold less than threshold value of shares to become eligible for participation in plan", "label": "Minimum period to hold less than threshold value of shares to become eligible for participation in plan" } } }, "auth_ref": [] }, "iva_MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "MinimumUpfrontPaymentsForOutLicensingPartnershipOrRoyaltyTransaction", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of minimum upfront payments for out-licensing, partnership or royalty transaction.", "label": "Minimum Upfront Payments For Out-Licensing, Partnership Or Royalty Transaction", "verboseLabel": "Minimum upfront payments for out-licensing, partnership or royalty transaction" } } }, "auth_ref": [] }, "ifrs-full_MiscellaneousNoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MiscellaneousNoncurrentAssetsAbstract", "lang": { "en-us": { "role": { "label": "Other non current assets" } } }, "auth_ref": [] }, "ifrs-full_MiscellaneousOtherOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MiscellaneousOtherOperatingExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_OtherOperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Miscellaneous other operating expense", "negatedTotalLabel": "Total other operating expenses" } }, "en": { "role": { "documentation": "The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]" } } }, "auth_ref": [ "r284" ] }, "ifrs-full_MiscellaneousOtherOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "MiscellaneousOtherOperatingIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_OtherOperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Miscellaneous other operating income", "terseLabel": "Total other operating income" } }, "en": { "role": { "documentation": "The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]" } } }, "auth_ref": [ "r284" ] }, "iva_Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the NATiV3 Phase III trial of lanifibranor in non-cirrhotic NASH", "label": "NATiV3 Phase III trial of lanifibranor in non-cirrhotic NASH [Member]", "terseLabel": "NATiV3 Phase III trial of lanifibranor in non-cirrhotic NASH" } } }, "auth_ref": [] }, "iva_NetProceedsFromIssuanceOfEquityAndRoyaltyCertificates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NetProceedsFromIssuanceOfEquityAndRoyaltyCertificates", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of net proceeds from the issuance of share capital and royalty certificates.", "label": "Net Proceeds from Issuance of Equity and Royalty Certificates", "terseLabel": "Net proceeds from issuance of equity and royalty certificates" } } }, "auth_ref": [] }, "iva_NetProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NetProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of net proceeds from issuing shares", "label": "Net Proceeds From Issuing Shares", "terseLabel": "Net proceeds from issuing shares", "verboseLabel": "Capital increase net of transaction costs" } } }, "auth_ref": [] }, "ifrs-full_NetworkInfrastructureMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NetworkInfrastructureMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Technical facilities" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing network infrastructure. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r293" ] }, "iva_NewBonusShareAwardPlan20191Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NewBonusShareAwardPlan20191Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2019-1).", "label": "AGA 2019-1 [Member]", "terseLabel": "AGA 2019-1" } } }, "auth_ref": [] }, "iva_NewBonusShareAwardPlan20231Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NewBonusShareAwardPlan20231Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2023-1).", "label": "New Bonus Share Award Plan 2023-1 [Member]", "terseLabel": "AGA Plan 2023-1" } } }, "auth_ref": [] }, "iva_NewBonusShareAwardPlan20232Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NewBonusShareAwardPlan20232Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2023-2).", "label": "AGA 2023-2 [Member]", "terseLabel": "AGA 2023-2" } } }, "auth_ref": [] }, "iva_NewBonusShareAwardPlanAga20211Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NewBonusShareAwardPlanAga20211Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2021-1)", "label": "AGA 2021-1" } } }, "auth_ref": [] }, "iva_NewBonusShareAwardPlanAga2021BisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NewBonusShareAwardPlanAga2021BisMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2021-bis).", "label": "AGA 2021-bis" } } }, "auth_ref": [] }, "iva_NewBonusShareAwardPlanAga2021Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NewBonusShareAwardPlanAga2021Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2021)", "label": "AGA 2021 [Member]", "terseLabel": "AGA 2021" } } }, "auth_ref": [] }, "iva_NewBsa20211ShareWarrantPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NewBsa20211ShareWarrantPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for new BSA 2021-1 share warrant plan.", "label": "BSA - Plan 2021-1" } } }, "auth_ref": [] }, "iva_NewBsa2021ShareWarrantPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NewBsa2021ShareWarrantPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for new BSA 2021 share warrant plan.", "label": "BSA 2021", "verboseLabel": "BSA 2021" } } }, "auth_ref": [] }, "iva_NewShareWarrantPlansBsa2019BisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NewShareWarrantPlansBsa2019BisMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for a new share warrant plan (\"BSA 2019 bis).", "label": "BSA 2019 bis" } } }, "auth_ref": [] }, "iva_NewShareWarrantPlansBsa2019TerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NewShareWarrantPlansBsa2019TerMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for a new share warrant plan (\"BSA 2019 ter).", "label": "BSA 2019 ter" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "iva_NonCurrentAdvancesToSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NonCurrentAdvancesToSuppliers", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsAdvancesPaymentsNonCurrentDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount represents the non current advances of suppliers.", "label": "Non Current Advances To Suppliers", "terseLabel": "Advance payments - non-current", "verboseLabel": "Non-current advances to suppliers" } } }, "auth_ref": [] }, "iva_NonCurrentAssetsExcludingDeferredAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NonCurrentAssetsExcludingDeferredAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "documentation": "Non-current assets excluding deferred assets", "label": "Non-current assets excluding deferred assets", "totalLabel": "Total non-current assets" } } }, "auth_ref": [] }, "iva_NonCurrentLongTermDepositsFromCustomers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NonCurrentLongTermDepositsFromCustomers", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents information about non current long term deposits from customers.", "label": "Non Current Long Term Deposits From Customers", "terseLabel": "Longterm deposit accounts" } } }, "auth_ref": [] }, "iva_NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "Non-current portion of non-current borrowings and non-current lease liabilities", "label": "Non-current portion of non-current borrowings and non-current lease liabilities", "terseLabel": "Long-term debt" } } }, "auth_ref": [] }, "iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 3.0 }, "http://www.inventivapharma.com/role/DisclosureFinancialDebtFinancialDebtDetails": { "parentTag": "ifrs-full_Borrowings", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "The non-current portion of non-current royalty certificates issued.", "label": "Non-current Portion of Non-current Royalty Certificates Issued", "terseLabel": "Royalty certificates liabilities" } } }, "auth_ref": [] }, "iva_NonCurrentSecurityDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NonCurrentSecurityDeposits", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The non-current amount of security deposits.", "label": "Non-current Security Deposits", "terseLabel": "Security deposits" } } }, "auth_ref": [] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r44" ] }, "ifrs-full_NonadjustingEventsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NonadjustingEventsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [member]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r44" ] }, "ifrs-full_NoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncontrollingInterests", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Non-controlling interests" } }, "en": { "role": { "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r20", "r123", "r124" ] }, "ifrs-full_NoncurrentAccruedIncomeIncludingNoncurrentContractAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentAccruedIncomeIncludingNoncurrentContractAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Non-current accrued income including non-current contract assets", "terseLabel": "Accrued income" } }, "en": { "role": { "documentation": "The amount of non-current accrued income including non-current contract assets. [Refer: Accrued income including contract assets]" } } }, "auth_ref": [ "r287", "r290" ] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current assets", "totalLabel": "Total non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r25", "r129", "r248" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current assets [abstract]", "terseLabel": "Noncurrent assets" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentContractLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current contract liabilities", "terseLabel": "Long-term contract liabilities" } }, "en": { "role": { "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r147" ] }, "ifrs-full_NoncurrentDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentDerivativeFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/DisclosureFinancialDebtFinancialDebtDetails": { "parentTag": "ifrs-full_Borrowings", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtFinancialDebtDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current derivative financial liabilities", "terseLabel": "Long-term debt - derivatives", "verboseLabel": "Derivatives" } }, "en": { "role": { "documentation": "The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r287" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities", "totalLabel": "Total non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r26", "r131", "r248" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities [abstract]", "terseLabel": "Noncurrent liabilities" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentProvisionsForEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NoncurrentProvisionsForEmployeeBenefits", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current provisions for employee benefits", "terseLabel": "Provisions for retirement benefit obligations" } }, "en": { "role": { "documentation": "The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]" } } }, "auth_ref": [ "r29" ] }, "ifrs-full_NotLaterThanOneMonthMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NotLaterThanOneMonthMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "label": "Due in 30 days", "terseLabel": "Due in 30 days" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one month." } } }, "auth_ref": [ "r259", "r261", "r267" ] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMaturityOfLongTermDebtAndOfShortTermBorrowingsAndDebtDetails" ], "lang": { "en-us": { "role": { "label": "Less than 1 year" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r23", "r154", "r155", "r164", "r260", "r267" ] }, "ifrs-full_NotLaterThanThreeMonthsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NotLaterThanThreeMonthsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "3 months or less" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than three months." } } }, "auth_ref": [ "r284" ] }, "ifrs-full_NotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NotionalAmount", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskDetails" ], "lang": { "en-us": { "role": { "label": "Notional Amount", "terseLabel": "Notional amount", "verboseLabel": "Total amount of loan" } }, "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } } }, "auth_ref": [ "r284" ] }, "iva_NotionalAmountPerTranche": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NotionalAmountPerTranche", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Notional amount per tranche", "label": "Notional Amount Per Tranche", "terseLabel": "Notional amount per tranche" } } }, "auth_ref": [] }, "iva_NumberOfActiveClinicalSitesInNativ3Trial": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfActiveClinicalSitesInNativ3Trial", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of active clinical sites in NATiV3 trial", "label": "Number of active clinical sites in NATiV3 trial" } } }, "auth_ref": [] }, "iva_NumberOfAtmEmissions": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfAtmEmissions", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of ATM emissions.", "label": "Number Of ATM Emissions", "terseLabel": "Number of ATM emissions" } } }, "auth_ref": [] }, "iva_NumberOfBeneficiaries": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfBeneficiaries", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of beneficiaries", "label": "Number of beneficiaries" } } }, "auth_ref": [] }, "iva_NumberOfBiopsiesUnderClinicalTrials": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfBiopsiesUnderClinicalTrials", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents the number of clinical trial.", "label": "Number Of Biopsies Under Clinical Trials", "terseLabel": "Number of Biopsies Under the Phase III trial" } } }, "auth_ref": [] }, "iva_NumberOfBonusShareAwardPlansInShareBasedPaymentArrangement": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfBonusShareAwardPlansInShareBasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of bonus share award plans approved by the reporting entity during the period.", "label": "Number of Bonus Share Award Plans In Share-based Payment Arrangement", "terseLabel": "Number of bonus share award plans" } } }, "auth_ref": [] }, "iva_NumberOfCountriesInWhichClinicalTrialHasBeenApproved": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfCountriesInWhichClinicalTrialHasBeenApproved", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of countries in which the entity's clinical trial has been approved", "label": "Number Of Countries In Which The Clinical Trial Has Been Approved", "terseLabel": "Number of countries in which the Phase III trial has been approved" } } }, "auth_ref": [] }, "iva_NumberOfDerivativeContractsCompleted": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfDerivativeContractsCompleted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of derivative contracts completed during the period.", "label": "Number Of Derivative Contracts Completed", "verboseLabel": "Number of foreign currency forward contracts" } } }, "auth_ref": [] }, "ifrs-full_NumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfEmployees", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Number of employees", "verboseLabel": "Number of employees" } }, "en": { "role": { "documentation": "The number of personnel employed by the entity at a date." } } }, "auth_ref": [ "r284" ] }, "iva_NumberOfEmployeesGrantedWithBonusSharesInShareBasedPaymentArrangement": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfEmployeesGrantedWithBonusSharesInShareBasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of employees for whom bonus shares were granted.", "label": "Number of Employees Granted With Bonus Shares In Share-based Payment Arrangement", "terseLabel": "Number of employees for whom bonus shares were granted" } } }, "auth_ref": [] }, "iva_NumberOfEntitiesBeingConsolidated": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfEntitiesBeingConsolidated", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of entities being consolidated", "label": "Number of entities being consolidated" } } }, "auth_ref": [] }, "iva_NumberOfEqualTranches": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfEqualTranches", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the information of number of equal tranches .", "label": "Number of Equal Tranches", "terseLabel": "Number of equal tranches" } } }, "auth_ref": [] }, "iva_NumberOfForwardContractsExpired": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfForwardContractsExpired", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of foreign forward contracts expired.", "label": "Number of Forward Contracts Expired", "terseLabel": "Number of contracts expired" } } }, "auth_ref": [] }, "ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfInstrumentsGrantedInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of instruments granted in share-based payment arrangement", "terseLabel": "Number of bonus shares granted" } }, "en": { "role": { "documentation": "The number of instruments granted in share-based payment arrangement." } } }, "auth_ref": [ "r256", "r257" ] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments granted in share-based payment arrangement", "terseLabel": "Issued", "verboseLabel": "Number of equity instruments granted" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r171", "r315" ] }, "iva_NumberOfLoanAgreements": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfLoanAgreements", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of loan agreements.", "label": "Number of Loan Agreements", "terseLabel": "Number of loan agreements" } } }, "auth_ref": [] }, "iva_NumberOfLoansObtainedGuaranteedByFrenchState": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfLoansObtainedGuaranteedByFrenchState", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of loans obtained which are guaranteed by the french state.", "label": "Number Of Loans Obtained Guaranteed By The French State", "verboseLabel": "Number of loans obtained guaranteed by the french state" } } }, "auth_ref": [] }, "iva_NumberOfNewSharesIssuedUponVestingOfAwardsInShareBasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfNewSharesIssuedUponVestingOfAwardsInShareBasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of new shares issued upon vesting of awards under share-based payment arrangement", "label": "Number Of New Shares Issued Upon Vesting Of Awards In Share-based Payment Arrangement", "terseLabel": "Number of new shares issued upon vesting" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments exercisable in share-based payment arrangement", "terseLabel": "Number of exercisable shares" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r315" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments exercised or vested in share-based payment arrangement", "negatedLabel": "Exercised/Vesting" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } } }, "auth_ref": [ "r315" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExpiredInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments expired in share-based payment arrangement", "verboseLabel": "Instruments lapsed" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) expired in a share-based payment arrangement." } } }, "auth_ref": [ "r315" ] }, "iva_NumberOfOtherEquityInstrumentsForfeitedDueToDepartureOfEmployeesInShareBasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfOtherEquityInstrumentsForfeitedDueToDepartureOfEmployeesInShareBasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement, due to departure of employees.", "label": "Number Of Other Equity Instruments Forfeited Due To Departure Of Employees, In Share-Based Payment Arrangement", "terseLabel": "Number of shares forfeited due to departure of employees" } } }, "auth_ref": [] }, "iva_NumberOfOtherEquityInstrumentsForfeitedDueToRecruitmentConditionsNotReachedInShareBasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfOtherEquityInstrumentsForfeitedDueToRecruitmentConditionsNotReachedInShareBasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement, due to recruitment conditions that haven't been reached.", "label": "Number Of Other Equity Instruments Forfeited Due To Recruitment Conditions Not Reached, In Share-Based Payment Arrangement", "terseLabel": "Number of shares forfeited due to recruitments conditions not reached" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments forfeited in share-based payment arrangement", "negatedLabel": "Forfeited/ Lapsed", "terseLabel": "Number of bonus shares forfeited" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r315" ] }, "iva_NumberOfOtherEquityInstrumentsForfeitedOrLapsedInShareBasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfOtherEquityInstrumentsForfeitedOrLapsedInShareBasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited or lapsed in a share-based payment arrangement.", "label": "Number of other equity instruments forfeited or lapsed in share-based payment arrangement", "negatedLabel": "Forfeited/lapsed" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments outstanding in share-based payment arrangement", "periodEndLabel": "Outstanding, Ending balance", "periodStartLabel": "Outstanding, Beginning balance" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r315" ] }, "iva_NumberOfPatientsInStudy": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfPatientsInStudy", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of patients in study", "label": "Number of patients in study" } } }, "auth_ref": [] }, "iva_NumberOfPerformanceObligationsInContract": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfPerformanceObligationsInContract", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of performance obligations in contract", "label": "Number of performance obligations in contract" } } }, "auth_ref": [] }, "iva_NumberOfPlansOutstanding": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfPlansOutstanding", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of plans outstanding", "label": "Number of plans outstanding" } } }, "auth_ref": [] }, "iva_NumberOfPledgesOverCash": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfPledgesOverCash", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of pledges that the company has pledged over cash.", "label": "Number Of Pledges Over Cash", "terseLabel": "Number of pledges over cash" } } }, "auth_ref": [] }, "iva_NumberOfPledgesOverCashReleased": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfPledgesOverCashReleased", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number Of Pledges Over Cash Released", "label": "Number Of Pledges Over Cash Released", "terseLabel": "Number of pledges over cash released" } } }, "auth_ref": [] }, "iva_NumberOfPotentialNewSharesFromShareBasedPaymentArrangement": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfPotentialNewSharesFromShareBasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents the information relating to number of potential shares", "label": "Number Of Potential New Shares From Share Based Payment Arrangement", "terseLabel": "Potential new shares" } } }, "auth_ref": [] }, "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of share options exercised in share-based payment arrangement", "terseLabel": "Option exercised to buy ordinary shares" } }, "en": { "role": { "documentation": "The number of share options exercised in a share-based payment arrangement." } } }, "auth_ref": [ "r166" ] }, "iva_NumberOfSharesAcquiredInAssociate": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfSharesAcquiredInAssociate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares acquired in associate", "label": "Number of shares acquired in associate", "terseLabel": "Number of shares acquired in associate" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Number of shares outstanding", "periodEndLabel": "Balance at the end (in shares)", "periodStartLabel": "Balance at the beginning (in shares)", "terseLabel": "Number of shares outstanding", "verboseLabel": "Number of fully authorized, subscribed and paid up shares" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r32" ] }, "iva_NumberOfSharesPerOtherEquityInstrumentGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfSharesPerOtherEquityInstrumentGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that each equity instruments other than share options granted in a share-based payment arrangement, entitles the holder.", "label": "Number Of Shares Per Other Equity Instrument Granted", "terseLabel": "Number of shares per AGA" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesRepresentedByOneDepositaryReceipt": { "xbrltype": "pureItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "NumberOfSharesRepresentedByOneDepositaryReceipt", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares represented by one depositary receipt", "terseLabel": "Number of ordinary shares represented by each ADS" } }, "en": { "role": { "documentation": "The number of shares represented by one depositary receipt." } } }, "auth_ref": [ "r284" ] }, "iva_NumberOfSitesOperatingUnderCentralIrbOverseeing": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfSitesOperatingUnderCentralIrbOverseeing", "presentation": [ "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of sites operating under central IRB overseeing", "label": "Number of sites operating under central IRB overseeing" } } }, "auth_ref": [] }, "iva_NumberOfSubjectsRandomized": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfSubjectsRandomized", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of subjects randomized.", "label": "Number of Subjects Randomized", "terseLabel": "Number of subjects randomized" } } }, "auth_ref": [] }, "iva_NumberOfWarrantsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfWarrantsIssued", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants issued", "label": "Number of warrants issued", "terseLabel": "Number of warrants issued" } } }, "auth_ref": [] }, "iva_NumberOfWeeksUnderActiveTreatmentExtensionStudy": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "NumberOfWeeksUnderActiveTreatmentExtensionStudy", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of weeks under the active treatment extension study of the entity.", "label": "Number Of Weeks Under The Active Treatment Extension Study", "verboseLabel": "Number of weeks under the active treatment extension study" } } }, "auth_ref": [] }, "ifrs-full_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OfficeEquipmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Office equipment" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r232" ] }, "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "OperatingExpenseExcludingOtherOperatingIncomeExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to amount of all operating expenses.", "label": "Operating Expense Excluding Other Operating Income Expense", "negatedTotalLabel": "Total operating expenses" } } }, "auth_ref": [] }, "iva_OperatingExpensesOnResearchAndDevelopmentMarketingAndGeneralAdministrativeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "OperatingExpensesOnResearchAndDevelopmentMarketingAndGeneralAdministrativeTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of Research and Development, Marketing and General administrative expenses.", "label": "Operating Expenses on Research and Development, Marketing and General Administrative [Table Text Block]", "terseLabel": "schedule of Operating expenses" } } }, "auth_ref": [] }, "iva_OptionMaturityPeriodMeasurementInputInFairValueOfOptionsToAcquireSharesInAssociate": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "OptionMaturityPeriodMeasurementInputInFairValueOfOptionsToAcquireSharesInAssociate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Option maturity period, measurement input in fair value of options to acquire shares in associate", "label": "Option maturity period, measurement input in fair value of options to acquire shares in associate" } } }, "auth_ref": [] }, "iva_OptionToAcquireSharesInCompanyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "OptionToAcquireSharesInCompanyPercentage", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Option to acquire shares in company, percentage", "label": "Option to acquire shares in company, percentage", "terseLabel": "Percent of acquisition", "verboseLabel": "Option to acquire shares in company, percentage" } } }, "auth_ref": [] }, "ifrs-full_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OrdinarySharesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Ordinary shares" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used." } } }, "auth_ref": [ "r86", "r291" ] }, "iva_OtherAccruedTaxesAndEmployeeRelatedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "OtherAccruedTaxesAndEmployeeRelatedExpenses", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of accrued taxes and employee related expenses.", "label": "Other Accrued taxes And Employee Related Expenses", "terseLabel": "Other accrued taxes and employeerelated expenses" } } }, "auth_ref": [] }, "ifrs-full_OtherAdjustmentsForNoncashItems": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherAdjustmentsForNoncashItems", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other adjustments for non-cash items", "terseLabel": "Other" } }, "en": { "role": { "documentation": "Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r310" ] }, "iva_OtherAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "OtherAgreementsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCommitmentsRelatedToOperationalActivitiesCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other agreements.", "label": "Other Agreements [Member]", "terseLabel": "Others" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income", "terseLabel": "Other comprehensive income (loss)", "verboseLabel": "Other comprehensive income" } }, "en": { "role": { "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]" } } }, "auth_ref": [ "r3", "r36", "r42", "r134" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations", "terseLabel": "Currency translation differences", "verboseLabel": "Exchange difference on translation of foreign operations" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r27", "r42" ] }, "iva_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations including effects of translation of investments accounted for using equity method", "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations including effects of translation of investments accounted for using equity method", "terseLabel": "Currency translation differences" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfActuarialGainsAndLossesRecognizedInComprehensiveIncomeDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans", "terseLabel": "Remeasurement of defined benefit plans", "totalLabel": "Total" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]" } } }, "auth_ref": [ "r27", "r42", "r296" ] }, "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax", "totalLabel": "Items that will be reclassified subsequently to profit or loss" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r227", "r228" ] }, "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax", "totalLabel": "Items that will not be reclassified subsequently to profit or loss", "verboseLabel": "Items that will not be reclassified subsequently to profit or loss" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r227", "r228" ] }, "iva_OtherCurrentAndNonCurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "OtherCurrentAndNonCurrentLiabilitiesAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available", "label": "Other current and non-current liabilities" } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherCurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails": { "parentTag": "iva_CurrentAssetsExcludingDeferredAssets", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "iva_OtherCurrentAssetsAndReceivables", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other current assets", "terseLabel": "Other current assets", "totalLabel": "Other current assets" } }, "en": { "role": { "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]" } } }, "auth_ref": [ "r287" ] }, "iva_OtherCurrentAssetsAndReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "OtherCurrentAssetsAndReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of other current assets and receivables as of balance sheet date.", "label": "Other Current Assets And Receivables", "totalLabel": "Other current assets and receivables" } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 4.0 }, "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other current liabilities", "terseLabel": "Other current liabilities", "totalLabel": "Other current liabilities" } }, "en": { "role": { "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]" } } }, "auth_ref": [ "r287" ] }, "ifrs-full_OtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other current payables", "terseLabel": "Other miscellaneous payables" } }, "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r287" ] }, "ifrs-full_OtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherCurrentReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Other current receivables", "terseLabel": "Other receivables" } }, "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } } }, "auth_ref": [ "r225" ] }, "iva_OtherCurrentTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "OtherCurrentTaxReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_CurrentTaxAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of other tax receivables, classified as current.", "label": "Other Current Tax Receivables", "terseLabel": "Other" } } }, "auth_ref": [] }, "ifrs-full_OtherFinanceCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherFinanceCost", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other finance cost", "negatedLabel": "Other financial expenses" } }, "en": { "role": { "documentation": "The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]" } } }, "auth_ref": [ "r284" ] }, "iva_OtherIncomeFromOrdinaryActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "OtherIncomeFromOrdinaryActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "ifrs-full_RevenueAndOperatingIncome", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "documentation": "The amount of other income from ordinary activities.", "label": "Other income from ordinary activities", "terseLabel": "Other income", "totalLabel": "Total other income" } } }, "auth_ref": [] }, "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherInflowsOutflowsOfCashClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other inflows (outflows) of cash, classified as investing activities", "verboseLabel": "Decrease / (Increase) in other non-current financial assets" } }, "en": { "role": { "documentation": "Inflows (outflows) of cash, classified as investing activities, that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r112" ] }, "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other inflows (outflows) of cash, classified as operating activities", "verboseLabel": "Other" } }, "en": { "role": { "documentation": "Inflows (outflows) of cash, classified as operating activities, that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r110" ] }, "iva_OtherLongTermProvisionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "OtherLongTermProvisionsAbstract", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Long term provisions" } } }, "auth_ref": [] }, "ifrs-full_OtherLongtermProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherLongtermProvisions", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other non-current provisions", "periodEndLabel": "Closing balance", "periodStartLabel": "Beginning balance", "terseLabel": "Long-term provisions", "verboseLabel": "Reversal of provisions" } }, "en": { "role": { "documentation": "The amount of non-current provisions other than provisions for employee benefits. [Refer: Non-current provisions]" } } }, "auth_ref": [ "r29" ] }, "iva_OtherMiscellaneousPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "OtherMiscellaneousPayablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other miscellaneous payables.", "label": "Other miscellaneous payables", "terseLabel": "Other miscellaneous payables" } } }, "auth_ref": [] }, "iva_OtherNonCurrentAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "OtherNonCurrentAssetsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsAdvancesPaymentsNonCurrentDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Other Non Current Assets [Line Items]", "terseLabel": "Company Information", "verboseLabel": "Other Non Current Assets" } } }, "auth_ref": [] }, "iva_OtherNonCurrentAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "OtherNonCurrentAssetsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsAdvancesPaymentsNonCurrentDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to other non-current assets.", "label": "Other Non Current Assets [Table]" } } }, "auth_ref": [] }, "ifrs-full_OtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other non-current asset", "terseLabel": "Other non-current assets", "totalLabel": "Other noncurrent assets" } }, "en": { "role": { "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]" } } }, "auth_ref": [ "r287" ] }, "ifrs-full_OtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherNoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other non-current liabilities", "terseLabel": "Other non-current liabilities" } }, "en": { "role": { "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]" } } }, "auth_ref": [ "r287" ] }, "iva_OtherOperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "OtherOperatingExpenses", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to other operating expenses.", "label": "Other operating expenses", "negatedLabel": "Other operating expenses" } } }, "auth_ref": [] }, "ifrs-full_OtherOperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherOperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 4.0 }, "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other operating income (expense)", "terseLabel": "Other operating income (expenses)", "totalLabel": "Other operating income (expenses)" } }, "en": { "role": { "documentation": "The amount of operating income (expense) that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r292" ] }, "iva_OtherOperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "OtherOperatingIncomeExpenseAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Other operating income and expenses" } } }, "auth_ref": [] }, "iva_OtherOperatingIncomeExpenseLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "OtherOperatingIncomeExpenseLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Other Operating Income (Expense) [Line Items]", "terseLabel": "Other operating income and expenses" } } }, "auth_ref": [] }, "iva_OtherOperatingIncomeExpenseTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "OtherOperatingIncomeExpenseTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information pertaining to other operating income (expense).", "label": "Other Operating Income (Expense) [Table]" } } }, "auth_ref": [] }, "ifrs-full_OtherPropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherPropertyPlantAndEquipmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Other property, plant and equipment" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing property, plant and equipment that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r293" ] }, "ifrs-full_OtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherProvisions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Other provisions", "periodEndLabel": "Other provisions at end of period", "periodStartLabel": "Other provisions at beginning of period" } }, "en": { "role": { "documentation": "The amount of provisions other than provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r29", "r92" ] }, "ifrs-full_OtherProvisionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherProvisionsAbstract", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Total Provisions" } } }, "auth_ref": [] }, "ifrs-full_OtherProvisionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherProvisionsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxDisputeSettlementDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Other provisions [member]" } }, "en": { "role": { "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]" } } }, "auth_ref": [ "r95" ] }, "iva_OtherReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "OtherReceivablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other receivables.", "label": "Other receivables", "terseLabel": "Other receivables" } } }, "auth_ref": [] }, "iva_OtherShortTermProvisionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "OtherShortTermProvisionsAbstract", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Short term provisions" } } }, "auth_ref": [] }, "ifrs-full_OtherShorttermProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "OtherShorttermProvisions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Other current provisions", "periodEndLabel": "Closing balance", "periodStartLabel": "Beginning balance" } }, "en": { "role": { "documentation": "The amount of current provisions other than provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r29" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Par value per share", "terseLabel": "Par value of share", "verboseLabel": "Nominal value" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r31" ] }, "ifrs-full_PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PastServiceCostAndLossesGainsArisingFromSettlementsDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails" ], "lang": { "en-us": { "role": { "label": "Past service cost and losses (gains) arising from settlements, defined benefit plans", "negatedLabel": "Benefits for the period" } }, "en": { "role": { "documentation": "The amount of expense (income) resulting from past service cost and losses (gains) arising from settlements. [Refer: Post-employment benefit expense in profit or loss, defined benefit plans; Past service cost, defined benefit plans] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from past service cost and losses (gains) arising from settlements]" } } }, "auth_ref": [ "r296" ] }, "iva_Patents": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "Patents", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to patents.", "label": "Patents", "negatedLabel": "Patents" } } }, "auth_ref": [] }, "iva_PayablesForPayrollTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PayablesForPayrollTaxes", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount payable by the company for payroll taxes including penalties and late payment interest.", "label": "Payables For Payroll Taxes", "terseLabel": "Payroll taxes payable", "verboseLabel": "Accrued expense" } } }, "auth_ref": [] }, "iva_PayablesForSeveranceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PayablesForSeveranceCosts", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Payables for severance costs", "label": "Payables for severance costs" } } }, "auth_ref": [] }, "iva_PaymentForServicesRendered": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PaymentForServicesRendered", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Payment for services rendered", "label": "Payment for services rendered" } } }, "auth_ref": [] }, "ifrs-full_PaymentsForDebtIssueCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PaymentsForDebtIssueCosts", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Payments for debt issue costs" } }, "en": { "role": { "documentation": "The cash outflow for debt issue costs." } } }, "auth_ref": [ "r308" ] }, "ifrs-full_PaymentsForShareIssueCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PaymentsForShareIssueCosts", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Payments for share issue costs" } }, "en": { "role": { "documentation": "The cash outflow for share issue costs." } } }, "auth_ref": [ "r308" ] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of lease liabilities, classified as financing activities", "negatedLabel": "Repayment of lease liabilities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r244" ] }, "iva_PaymentsReceivedFromResearchTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PaymentsReceivedFromResearchTaxCredit", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationPaymentsReceivedFromResearchTaxCreditDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount received from Research Tax Credit (CIR).", "label": "Payments Received From Research Tax Credit", "terseLabel": "Amount of entire CIR received" } } }, "auth_ref": [] }, "iva_PaymentsReceivedFromResearchTaxCreditRelatingToSubcontractingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PaymentsReceivedFromResearchTaxCreditRelatingToSubcontractingExpenses", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationPaymentsReceivedFromResearchTaxCreditDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount received from Research Tax Credit (CIR) relating to subcontracting expenses.", "label": "Payments Received From Research Tax Credit Relating To Subcontracting Expenses", "terseLabel": "Amount of additional reimbursements of CIR" } } }, "auth_ref": [] }, "iva_PayrollTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PayrollTaxes", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "A class of employee benefits expense that represents payroll taxes.", "label": "Payroll taxes", "negatedLabel": "Payroll taxes" } } }, "auth_ref": [] }, "iva_PercentageOfAnnualRoyaltiesOnFutureSalesForRoyaltyCertificateHolders": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PercentageOfAnnualRoyaltiesOnFutureSalesForRoyaltyCertificateHolders", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage Of Annual Royalties On Future Sales for Royalty Certificate Holders", "label": "Percentage Of Annual Royalties On Future Sales for Royalty Certificate Holders", "terseLabel": "Percentage of right annual royalties on future sales for royalty certificate holders" } } }, "auth_ref": [] }, "iva_PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PercentageOfCompanySShareCapitalOutstandingIssuedAsWarrants", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of Company's share capital outstanding, issued as warrants by the entity.", "label": "Percentage Of Company's Share Capital Outstanding, Issued As Warrants", "terseLabel": "Percentage of company's share capital outstanding, issued as warrants" } } }, "auth_ref": [] }, "iva_PercentageOfDilutionSubjectToRegulatoryLimitForAggregateSalesProceeds": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PercentageOfDilutionSubjectToRegulatoryLimitForAggregateSalesProceeds", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of dilution subject to regulatory limit for aggregate sales proceeds under issuance of shares.", "label": "Percentage Of Dilution Subject To Regulatory Limit For Aggregate Sales Proceeds", "terseLabel": "Percentage of dilution subject to regulatory limit" } } }, "auth_ref": [] }, "iva_PercentageOfDiscountToVolumeWeightedAverageTradingPrice": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PercentageOfDiscountToVolumeWeightedAverageTradingPrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of discount to volume weighted average trading price of shares applied to the price of the stock offering.", "label": "Percentage Of Discount To Volume Weighted Average Trading Price", "terseLabel": "Percentage of discount to volume weighted average trading price of Company's ADS", "verboseLabel": "Percentage of discount to volume weighted average trading price" } } }, "auth_ref": [] }, "iva_PercentageOfIncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PercentageOfIncreaseDecreaseInCashAndCashEquivalents", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage of increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies.", "label": "Percentage Of Increase Decrease In Cash And Cash Equivalents", "terseLabel": "Percentage of decrease in cash and cash equivalents" } } }, "auth_ref": [] }, "iva_PercentageOfLiverTriglycerideReductionAchievedInHigherProportionOfPatients": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PercentageOfLiverTriglycerideReductionAchievedInHigherProportionOfPatients", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of liver triglyceride reduction achieved in a higher proportion of patients", "label": "Percentage of liver triglyceride reduction achieved in a higher proportion of patients" } } }, "auth_ref": [] }, "iva_PercentageOfLoanGuaranteedByFrenchState": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PercentageOfLoanGuaranteedByFrenchState", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of loan guaranteed by French state.", "label": "Percentage of Loan Guaranteed by French State", "terseLabel": "Percentage of loan guaranteed by French state" } } }, "auth_ref": [] }, "iva_PercentageOfPatientsRandomizedInMainCohort": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PercentageOfPatientsRandomizedInMainCohort", "presentation": [ "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of patients randomized in the main cohort", "label": "Percentage of patients randomized in the main cohort" } } }, "auth_ref": [] }, "iva_PercentageOfPatientsWithSignificantFibrosis": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PercentageOfPatientsWithSignificantFibrosis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of patients with significant fibrosis", "label": "Percentage of patients with significant fibrosis" } } }, "auth_ref": [] }, "iva_PercentageOfPopulationSufferingFromNash": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PercentageOfPopulationSufferingFromNash", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of population suffering from NASH", "label": "Percentage of population suffering from NASH" } } }, "auth_ref": [] }, "iva_PercentageOfReasonablyPossibleIncreaseDecreaseInRiskAssumption": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PercentageOfReasonablyPossibleIncreaseDecreaseInRiskAssumption", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "The reasonably possible percentage of the increase (decrease) in the designated risk component used to determine the value of the financial instrument. Excludes defined benefit plan obligations.", "label": "Percentage Of Reasonably Possible Increase (Decrease) In Risk Assumption", "terseLabel": "Percentage of reasonably possible increase (decrease) in risk assumption" } } }, "auth_ref": [] }, "iva_PercentageOfReasonablyPossibleIncreaseOrDecreaseInActuarialAssumption": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PercentageOfReasonablyPossibleIncreaseOrDecreaseInActuarialAssumption", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of reasonably possible increase or decrease in actuarial assumption", "label": "Percentage of reasonably possible increase or decrease in actuarial assumption" } } }, "auth_ref": [] }, "iva_PercentageOfReasonablyPossibleIncreaseOrDecreaseInVolatility": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PercentageOfReasonablyPossibleIncreaseOrDecreaseInVolatility", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of reasonably possible increase or decrease in volatility", "label": "Percentage of reasonably possible increase or decrease in volatility" } } }, "auth_ref": [] }, "iva_PercentageOfSeverancePaymentCappedOnSalary": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PercentageOfSeverancePaymentCappedOnSalary", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of severance payment capped on individuals salary for the preceding twelve months period.", "label": "Percentage of Severance Payment Capped on Salary", "terseLabel": "Percentage of severance payment capped on salary" } } }, "auth_ref": [] }, "iva_PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PercentageOfShareCapitalHeldByCounterpartyIfAllOutstandingWarrantsAreExercised", "presentation": [ "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of share capital held by counterparty if all outstanding warrants are exercised", "label": "Percentage of share capital held by counterparty if all outstanding warrants are exercised" } } }, "auth_ref": [] }, "iva_PermanentDifferencesForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PermanentDifferencesForReconciliationBetweenAccountingProfitAndTaxExpenseIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount due to permanent differences for reconciliation between accounting profit and tax expense income.", "label": "Permanent Differences for Reconciliation Between Accounting Profit and Tax Expense Income", "terseLabel": "Permanent differences" } } }, "auth_ref": [] }, "iva_PersonnelCostsAndHeadcount": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PersonnelCostsAndHeadcount", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesTables" ], "lang": { "en-us": { "role": { "documentation": "Personnel costs and headcount", "label": "Personnel costs and headcount", "terseLabel": "Schedule of personnel costs and headcount" } } }, "auth_ref": [] }, "iva_PgeBpiFrance2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PgeBpiFrance2020Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The information pertaining to PGE BPI France 2020.", "label": "PGE BPI France 2020 [Member]", "terseLabel": "PGE BPI France 2020" } } }, "auth_ref": [] }, "iva_PgeBpiFrance2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PgeBpiFrance2022Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The information pertaining to PGE BPI France 2022.", "label": "PGE BPI France 2022 [Member]", "terseLabel": "PGE BPI France 2022" } } }, "auth_ref": [] }, "iva_PgeCa2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PgeCa2020Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The information pertaining to PGE CA 2020.", "label": "PGE CA 2020 [Member]", "terseLabel": "PGE CA 2020" } } }, "auth_ref": [] }, "iva_PgeSg2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PgeSg2020Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The information pertaining to PGE SG 2020.", "label": "PGE SG 2020 [Member]", "terseLabel": "PGE SG 2020" } } }, "auth_ref": [] }, "iva_PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the Phase II clinical trial evaluating lanifibranor in patients with T2D and nonalcoholic fatty liver disease", "label": "Phase II clinical trial evaluating lanifibranor in patients with T2D and nonalcoholic fatty liver disease [Member]", "terseLabel": "Phase II clinical trial evaluating lanifibranor in patients with T2D and nonalcoholic fatty liver disease" } } }, "auth_ref": [] }, "iva_PierreBroquaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PierreBroquaMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Pierre Broqua", "label": "Pierre Broqua [Member]", "terseLabel": "Pierre Broqua" } } }, "auth_ref": [] }, "iva_PledgeAsPercentageOfSumNotCoveredByIndemnityPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PledgeAsPercentageOfSumNotCoveredByIndemnityPercent", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the pledge as percentage of sum not covered by the indemnity.", "label": "Pledge As Percentage Of Sum Not Covered By The Indemnity, Percent", "terseLabel": "Amount of pledge as a percentage of sum not covered by the indemnity to be received" } } }, "auth_ref": [] }, "iva_PledgeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PledgeAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information pertaining to pledge.", "label": "Pledge [Axis]" } } }, "auth_ref": [] }, "iva_PledgeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PledgeDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to pledge.", "label": "Pledge [Domain]" } } }, "auth_ref": [] }, "iva_PledgeOverCashAbbottAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PledgeOverCashAbbottAgreementMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for pledge over cash, Abbott agreement", "label": "Pledge over cash, Abbott agreement [Member]", "terseLabel": "Pledge over cash, Abbott agreement" } } }, "auth_ref": [] }, "iva_PledgeOverCashTaxAuthoritiesFiscalYear2016Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PledgeOverCashTaxAuthoritiesFiscalYear2016Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Pledge over cash, tax authorities, fiscal year 2016", "label": "Pledge over cash, tax authorities, fiscal year 2016 [Member]", "terseLabel": "Pledge over cash, tax authorities, fiscal year 2016" } } }, "auth_ref": [] }, "iva_PledgeOverCashTaxAuthoritiesFiscalYear2017Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PledgeOverCashTaxAuthoritiesFiscalYear2017Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Pledge over cash, tax authorities, fiscal year 2017", "label": "Pledge over cash, tax authorities, fiscal year 2017 [Member]", "terseLabel": "Pledge over cash, tax authorities, fiscal year 2017" } } }, "auth_ref": [] }, "iva_PledgeOverCashTaxAuthoritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PledgeOverCashTaxAuthoritiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Pledge over cash, tax authorities", "label": "Pledge over cash, tax authorities [Member]", "terseLabel": "Pledge over cash, tax authorities" } } }, "auth_ref": [] }, "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PostemploymentBenefitExpenseDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsForRetirementBenefitObligationsBreakdownOfExpenseRecognizedForYearDetails" ], "lang": { "en-us": { "role": { "label": "Post-employment benefit expense, defined benefit plans", "negatedTotalLabel": "Total" } }, "en": { "role": { "documentation": "The amount of post-employment benefit expense included in profit or loss relating to defined benefit plans. [Refer: Profit (loss); Defined benefit plans [member]] [Contrast: Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss]" } } }, "auth_ref": [ "r296", "r300" ] }, "ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PostemploymentBenefitExpenseInProfitOrLoss", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Post-employment benefit expense in profit or loss", "negatedLabel": "Provisions for retirement benefit obligations" } }, "en": { "role": { "documentation": "The amount of post-employment benefit expense included in profit or loss" } } }, "auth_ref": [ "r300" ] }, "iva_PprCa2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PprCa2022Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The information pertaining to PPR CA 2022.", "label": "PPR CA 2022 [Member]", "terseLabel": "PPR CA 2022" } } }, "auth_ref": [] }, "iva_PprSg2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PprSg2022Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The information pertaining to PPR SG 2022.", "label": "PPR SG 2022 [Member]", "terseLabel": "PPR SG 2022" } } }, "auth_ref": [] }, "iva_PresentationOfResultsFromStudyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PresentationOfResultsFromStudyMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the presentation of results from a study.", "label": "Presentation of results from study [Member]", "terseLabel": "Presentation of results from study" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from borrowings, classified as financing activities", "terseLabel": "Subscription of borrowings", "verboseLabel": "Loan obtained" } }, "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } } }, "auth_ref": [ "r242" ] }, "ifrs-full_ProceedsFromExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromExerciseOfWarrants", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of warrants" } }, "en": { "role": { "documentation": "The cash inflow from the exercise of share purchase warrants." } } }, "auth_ref": [ "r308" ] }, "iva_ProceedsFromFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ProceedsFromFinancing", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash proceeds from financing.", "label": "Proceeds From Financing", "terseLabel": "Gross cash proceeds" } } }, "auth_ref": [] }, "iva_ProceedsFromFrenchResearchTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ProceedsFromFrenchResearchTaxCredit", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationPaymentsReceivedFromResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from French Research Tax Credit (CIR).", "label": "Proceeds From French Research Tax Credit", "terseLabel": "French Research Tax Credit (CIR), payments received" } } }, "auth_ref": [] }, "iva_ProceedsFromIssueOfEquityNetOfTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ProceedsFromIssueOfEquityNetOfTransactionCosts", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of proceeds from issuance of equity net of transaction costs.", "label": "Proceeds from Issue of Equity Net of Transaction Costs", "terseLabel": "Capital increase in cash" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromIssueOfOrdinaryShares", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from issue of ordinary shares", "verboseLabel": "Aggregate offering price" } }, "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } } }, "auth_ref": [ "r308" ] }, "iva_ProceedsFromIssueOfRoyaltyCertificatesNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ProceedsFromIssueOfRoyaltyCertificatesNoncurrentBorrowings", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuing of royalty certificates.", "label": "Proceeds from Issue of Royalty Certificates, Noncurrent Borrowings", "terseLabel": "Issue of royalty certificates" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuing shares", "terseLabel": "Capital increase", "verboseLabel": "Proceeds from issuance of shares" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r241" ] }, "iva_ProceedsFromLicensingArrangements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ProceedsFromLicensingArrangements", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationLicenseAndCollaborationAgreementWithCttqDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount paid on licensing arrangements.", "label": "Proceeds From Licensing Arrangements", "terseLabel": "Amount received on licensing arrangements" } } }, "auth_ref": [] }, "iva_ProceedsFromLicensingArrangementsAfterDeductionOfWithholdingTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ProceedsFromLicensingArrangementsAfterDeductionOfWithholdingTaxes", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount paid on licensing arrangements after deduction of withholding taxes", "label": "Proceeds From Licensing Arrangements after Deduction of Withholding Taxes", "terseLabel": "Amount received on licensing arrangements after deduction of withholding taxes" } } }, "auth_ref": [] }, "iva_ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from the disposal of property, plant and equipment and intangible assets, classified as investing activities.", "label": "Proceeds From Sales Of Property Plant And Equipment And Intangible Assets Classified As Investing Activities", "terseLabel": "Disposals of property, plant and equipment and intangible assets" } } }, "auth_ref": [] }, "ifrs-full_ProductsAndServicesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProductsAndServicesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Products and services [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r214", "r251" ] }, "ifrs-full_ProductsAndServicesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProductsAndServicesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Products and services [member]" } }, "en": { "role": { "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used." } } }, "auth_ref": [ "r214", "r251" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 3.0 }, "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceConsolidatedFinancialStatementsDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss)", "terseLabel": "Net loss for the period", "totalLabel": "Net loss for the period", "verboseLabel": "Loss for the period" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r2", "r35", "r111", "r120", "r122", "r207", "r210", "r248", "r254" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "Operating profit (loss)", "verboseLabel": "Net operating loss" } }, "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r235", "r292" ] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment", "terseLabel": "Property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r10", "r58" ] }, "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment including right-of-use assets", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "terseLabel": "Property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of property, plant and equipment including right-of-use assets whose underlying assets would be presented as property, plant and equipment if they were owned. [Refer: Property, plant and equipment; Right-of-use assets]" } } }, "auth_ref": [ "r286", "r294" ] }, "ifrs-full_PropertyPlantAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "PropertyPlantAndEquipmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment [member]" } }, "en": { "role": { "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r59", "r236", "r253" ] }, "ifrs-full_ProportionOfOwnershipInterestInAssociate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProportionOfOwnershipInterestInAssociate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails" ], "lang": { "en-us": { "role": { "label": "Proportion of ownership interest in associate", "terseLabel": "Group's share in %", "verboseLabel": "Proportion of ownership interest" } }, "en": { "role": { "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]" } } }, "auth_ref": [ "r80", "r82", "r127" ] }, "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProportionOfOwnershipInterestInSubsidiary", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationInvestmentInSubsidiaryDetails" ], "lang": { "en-us": { "role": { "label": "Proportion of ownership interest in subsidiary", "terseLabel": "Percent of ownership interest" } }, "en": { "role": { "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]" } } }, "auth_ref": [ "r80", "r82", "r125" ] }, "iva_ProvisionForFrenchResearchTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ProvisionForFrenchResearchTaxCredit", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of provision for French Research Tax Credit (CIR).", "label": "Provision For French Research Tax Credit", "terseLabel": "CIR provision" } } }, "auth_ref": [] }, "iva_ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYears2013To2015Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYears2013To2015Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails", "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Provision For French Research Tax Credit Related To Tax Audit For Years 2013 to 2015.", "label": "Provision For CIR Related To Tax Audit For Years 2013 To 2015 [Member]", "terseLabel": "Provision for CIR related to tax audit for years 2013 to 2015" } } }, "auth_ref": [] }, "iva_ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYearsEnded20132014And2015Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYearsEnded20132014And2015Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxDisputeSettlementDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for provision for French Research Tax Credit (CIR) related to tax audit for the years ended December 31, 2013, 2014 and 2015.", "label": "Provision For French Research Tax Credit elated To Tax Audit For Years Ended 2013 2014 And 2015 [Member]", "terseLabel": "CIR 2013 - 2015" } } }, "auth_ref": [] }, "iva_ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYearsEnded2017Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ProvisionForFrenchResearchTaxCreditRelatedToTaxAuditForYearsEnded2017Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxDisputeSettlementDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Provision For French Research Tax Credit Related To Tax Audit For Years Ended 2017", "label": "Provision For French Research Tax Credit Related To Tax Audit For Years Ended 2017 [Member]", "terseLabel": "CIR 2017" } } }, "auth_ref": [] }, "iva_ProvisionForPayrollTaxAudit20162017Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ProvisionForPayrollTaxAudit20162017Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxDisputeSettlementDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for provision for payroll tax audits for the years 2016 and 2017.", "label": "Payroll Tax Audit, 2016 and 2017", "terseLabel": "Payroll Tax Audit, 2016 and 2017" } } }, "auth_ref": [] }, "iva_ProvisionForRiskOnPayrollTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ProvisionForRiskOnPayrollTaxes", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of provision for payroll taxes.", "label": "Provision For Risk On Payroll Taxes", "terseLabel": "Provision for risk on payroll taxes" } } }, "auth_ref": [] }, "iva_ProvisionForTaxAdjustmentRiskInRespectOfPayrollTaxesForYearsEnded20162017And2018Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ProvisionForTaxAdjustmentRiskInRespectOfPayrollTaxesForYearsEnded20162017And2018Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for provision for tax adjustment risk in respect of payroll taxes with regard to the years ended December 31, 2016, 2017 and 2018.", "label": "Provision for tax adjustment risk in respect of payroll taxes for the years ended December 31, 2016, 2017 and 2018" } } }, "auth_ref": [] }, "iva_ProvisionForTaxAuditForYearsEnded20132014And2015Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ProvisionForTaxAuditForYearsEnded20132014And2015Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for provision related to tax audit for the fiscal years 2013, 2014 and 2015.", "label": "Provision Related To Tax Audit For The Years Ended 2013, 2014 And 2015 [Member]", "terseLabel": "Provision related to tax audit for the years ended 2013, 2014 and 2015" } } }, "auth_ref": [] }, "iva_ProvisionForTaxAuditForYearsEnded2016And2017Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ProvisionForTaxAuditForYearsEnded2016And2017Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Provision For Tax Audit For Years Ended 2016 and 2017.", "label": "Provision For Tax Audit For The Years Ended December 31, 2016 And December 31, 2017 [Member]", "terseLabel": "Provision related to tax audit for the years ended december 2016 and 2017" } } }, "auth_ref": [] }, "ifrs-full_ProvisionForTaxesOtherThanIncomeTaxMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ProvisionForTaxesOtherThanIncomeTaxMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Tax disputes", "terseLabel": "Tax Litigation" } }, "en": { "role": { "documentation": "This member stands for a provision for taxes other than income tax. Income taxes include all domestic and foreign taxes which are based on taxable profits. Income taxes also include taxes, such as withholding taxes, which are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity. [Refer: Other provisions [member]]" } } }, "auth_ref": [ "r303" ] }, "iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Purchase of interests in investments accounted for using equity method, price per share", "label": "Purchase of interests in investments accounted for using equity method, price per share", "terseLabel": "Purchase of interests in investments accounted for using equity method, price per share" } } }, "auth_ref": [] }, "iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Purchase Of Property Plant And Equipment And Intangible Assets Classified As Investing Activities", "label": "Purchase Of Property Plant And Equipment And Intangible Assets Classified As Investing Activities", "negatedLabel": "Purchases of property, plant and equipment and intangible assets" } } }, "auth_ref": [] }, "iva_PurchasesInForeignCurrencyAsPercentageOfOperatingExpenses": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "PurchasesInForeignCurrencyAsPercentageOfOperatingExpenses", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesForeignCurrencyTransactionsAndSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The percentage amount of operating expenses that were paid in a currency other than the reporting currency.", "label": "Purchases In Foreign Currency As A Percentage Of Operating Expenses", "terseLabel": "Foreign currency expenses as a percentage of operating expenses" } } }, "auth_ref": [] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r146", "r158", "r168", "r249", "r250", "r316" ] }, "ifrs-full_RangesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RangesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Ranges [member]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r146", "r158", "r168", "r249", "r250", "r316" ] }, "ifrs-full_ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReconciliationOfChangesInIntangibleAssetsOtherThanGoodwillAbstract", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Reconciliation of changes in intangible assets other than goodwill", "terseLabel": "Intangible assets" } } }, "auth_ref": [] }, "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Reconciliation of changes in property, plant and equipment [abstract]" } } }, "auth_ref": [] }, "iva_ReferencePricePerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ReferencePricePerUnit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Reference price per unit", "label": "Reference price per unit", "terseLabel": "Reference price" } } }, "auth_ref": [] }, "ifrs-full_RepairsAndMaintenanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RepairsAndMaintenanceExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Repairs and maintenance expense", "negatedLabel": "Maintenance" } }, "en": { "role": { "documentation": "The amount of expenses incurred for the day-to-day servicing of assets, which may include the cost of labour, consumables or small parts." } } }, "auth_ref": [ "r292" ] }, "iva_RepaymentPeriodOfLoan": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "RepaymentPeriodOfLoan", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "The period for repayment of loan.", "label": "Repayment Period of Loan", "terseLabel": "Repayment period for loan" } } }, "auth_ref": [] }, "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of borrowings, classified as financing activities", "negatedLabel": "Repayment of debt", "terseLabel": "Repayments of borrowings" } }, "en": { "role": { "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]" } } }, "auth_ref": [ "r243" ] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Research and development expense", "negatedLabel": "Research and development costs", "terseLabel": "Research and development expenses" } }, "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } } }, "auth_ref": [ "r102" ] }, "iva_ResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ResearchAndDevelopmentMarketingBusinessDevelopmentAndGeneralAndAdministrativeExpensesAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Notes to the income statement" } } }, "auth_ref": [] }, "iva_ResearchCollaborationWithAbbvieMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ResearchCollaborationWithAbbvieMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for research collaboration with AbbVie.", "label": "AbbVie [Member]", "terseLabel": "AbbVie" } } }, "auth_ref": [] }, "iva_ResearchTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ResearchTaxCredits", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the income from research tax credits.", "label": "Research Tax Credits", "terseLabel": "Research tax credits" } } }, "auth_ref": [] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Reserve of exchange differences on translation", "terseLabel": "Translation reserve" } }, "en": { "role": { "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r70" ] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Reserve of exchange differences on translation [member]", "terseLabel": "Translation reserves" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r70", "r222" ] }, "ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetainedEarningsExcludingProfitLossForReportingPeriod", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "label": "Retained earnings, excluding profit (loss) for reporting period", "terseLabel": "earnings brought forward" } }, "en": { "role": { "documentation": "A component of equity representing the entity\u2019s cumulative undistributed earnings or deficit excluding the profit or loss for the reporting period. [Refer: Retained earnings]" } } }, "auth_ref": [ "r289" ] }, "iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "A component of equity representing retained earnings excluding profit (loss) for the reporting period, and treasury shares", "label": "Retained earnings excluding profit (loss) for the reporting period and treasury shares", "terseLabel": "Reserves" } } }, "auth_ref": [] }, "iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "This member represent a component of equity consisting of retained earnings excluding the current reporting period, and treasury shares.", "label": "Retained earnings excluding profit (loss) from current reporting period and treasury shares [Member]", "terseLabel": "Reserves" } } }, "auth_ref": [] }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetainedEarningsProfitLossForReportingPeriod", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Retained earnings, profit (loss) for reporting period", "terseLabel": "Net loss for the period" } }, "en": { "role": { "documentation": "A component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings; Profit (loss)]" } } }, "auth_ref": [ "r289" ] }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RetainedEarningsProfitLossForReportingPeriodMember", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained earnings, profit (loss) for reporting period [member]", "terseLabel": "Net profit (loss)" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings [member]; Profit (loss)]" } } }, "auth_ref": [ "r283" ] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "Revenue", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Revenue", "terseLabel": "Revenues", "totalLabel": "Total revenues" } }, "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } } }, "auth_ref": [ "r38", "r133", "r174", "r204", "r209", "r214", "r215", "r217", "r220", "r221", "r248" ] }, "ifrs-full_RevenueAndOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevenueAndOperatingIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Revenue and other operating income", "totalLabel": "Total revenues and other income" } }, "en": { "role": { "documentation": "The aggregate amount of the entity's revenue and other operating income. [Refer: Revenue]" } } }, "auth_ref": [ "r292" ] }, "iva_RevenueAndOperatingIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "RevenueAndOperatingIncomeAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Revenue And Operating Income [Abstract]", "terseLabel": "Revenues and other income" } } }, "auth_ref": [] }, "iva_RevenueAndOtherIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "RevenueAndOtherIncomeAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Revenues and other income" } } }, "auth_ref": [] }, "iva_RevenueAndOtherIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "RevenueAndOtherIncomeTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue and other income.", "label": "Revenue and Other Income [Table Text Block]", "terseLabel": "Schedule of revenues and other income" } } }, "auth_ref": [] }, "ifrs-full_RevenueFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RevenueFromContractsWithCustomers", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "ifrs-full_RevenueAndOperatingIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Revenue from contracts with customers", "terseLabel": "Revenue", "verboseLabel": "Revenues" } }, "en": { "role": { "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration." } } }, "auth_ref": [ "r148", "r149" ] }, "iva_RevenueFromResearchPartnershipsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "RevenueFromResearchPartnershipsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for revenue from research partnerships.", "label": "Revenue From Research Partnerships [Member]", "terseLabel": "Revenue From Research Partnerships" } } }, "auth_ref": [] }, "iva_ReversalOfImpairmentOnCarryBackReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ReversalOfImpairmentOnCarryBackReceivable", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Reversal of impairment of tax loss carry back receivable during the period.", "label": "Reversal Of Impairment On Carry Back Receivable", "terseLabel": "Reversal of impairment on the carry back receivable" } } }, "auth_ref": [] }, "iva_ReversalOfOtherProvisionsIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ReversalOfOtherProvisionsIncome", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Reversal of other provisions, income", "label": "Reversal of other provisions, income", "terseLabel": "Reversal of provision" } } }, "auth_ref": [] }, "iva_ReversalOfShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ReversalOfShareBasedCompensationExpense", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of reversal of share-based compensation expense.", "label": "Reversal of Share Based Compensation Expense", "terseLabel": "Reversal of share-based compensation expense" } } }, "auth_ref": [] }, "ifrs-full_RightofuseAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "RightofuseAssetsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosurePropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Right of use" } }, "en": { "role": { "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r151" ] }, "iva_RiskFreeInterestRateOtherEquityInstrumentsGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "RiskFreeInterestRateOtherEquityInstrumentsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate of other equity instruments granted.", "label": "Risk-Free Interest Rate, Other Equity Instruments Granted", "terseLabel": "Risk-free rate" } } }, "auth_ref": [] }, "iva_RiskFreeRateMeasurementInputInFairValueOfOptionsToAcquireSharesInAssociate": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "RiskFreeRateMeasurementInputInFairValueOfOptionsToAcquireSharesInAssociate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Risk-free rate, measurement input in fair value of options to acquire shares in associate", "label": "Risk-free rate, measurement input in fair value of options to acquire shares in associate" } } }, "auth_ref": [] }, "iva_RoyaltiesOnCommercialSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "RoyaltiesOnCommercialSalesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for royalties on commercial sales.", "label": "Royalties on commercial sales", "terseLabel": "Royalties on commercial sales" } } }, "auth_ref": [] }, "iva_RoyaltyCertificateIssuanceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "RoyaltyCertificateIssuanceAmount", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of Royalty certificate issuance.", "label": "Royalty Certificate Issuance Amount", "terseLabel": "Royalty certificate issuance amount" } } }, "auth_ref": [] }, "iva_RoyaltyCertificateLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "RoyaltyCertificateLiabilitiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Royalty Certificate Liabilities.", "label": "Royalty Certificate Liabilities [Member]", "terseLabel": "Royalty Certificate" } } }, "auth_ref": [] }, "iva_RoyaltyCertificatesEffectiveInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "RoyaltyCertificatesEffectiveInterestRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate on royalty certificates.", "label": "Royalty Certificates, Effective Interest Rate", "terseLabel": "Royalty certificates, effective interest rate" } } }, "auth_ref": [] }, "iva_RoyaltyCertificatesLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "RoyaltyCertificatesLiabilitiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for royalty certificates liabilities.", "label": "Royalty Certificates Liabilities [Member]", "terseLabel": "Royalty certificates liabilities" } } }, "auth_ref": [] }, "iva_RoyaltyCertificatesLiabilitiesPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "RoyaltyCertificatesLiabilitiesPolicyPolicyTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for Royalty Certificates liabilities.", "label": "Royalty Certificates Liabilities Policy [Policy Text Block]", "terseLabel": "Royalty Certificates liabilities" } } }, "auth_ref": [] }, "iva_RoyaltyCertificatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "RoyaltyCertificatesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtMovementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The information pertaining to royalty certificates.", "label": "Royalty Certificates [Member]" } } }, "auth_ref": [] }, "ifrs-full_SalesAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SalesAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Sales and marketing expense", "negatedLabel": "Marketing - Business development expenses" } }, "en": { "role": { "documentation": "The amount of expense relating to the marketing and selling of goods or services." } } }, "auth_ref": [ "r292" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [] }, "iva_ScheduleOfInventoryDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ScheduleOfInventoryDisclosureLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInventoriesDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Schedule of Inventory Disclosure [Line Items]", "terseLabel": "Inventories" } } }, "auth_ref": [] }, "iva_ScheduleOfInventoryDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ScheduleOfInventoryDisclosureTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInventoriesDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to inventories.", "label": "Schedule of Inventory Disclosure [Table]" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r269" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r271" ] }, "ifrs-full_SensitivityAnalysisForEachTypeOfMarketRisk": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SensitivityAnalysisForEachTypeOfMarketRisk", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementTables" ], "lang": { "en-us": { "role": { "label": "Sensitivity analysis for types of market risk [text block]", "terseLabel": "Schedule of sensitivity analysis of the company's assets" } }, "en": { "role": { "documentation": "The disclosure of the sensitivity analysis for types of market risk to which the entity is exposed, showing how profit or loss and equity would have been affected by changes in the relevant risk variable that were reasonably possible at that date. [Refer: Market risk [member]]" } } }, "auth_ref": [ "r190" ] }, "ifrs-full_SeparateMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SeparateMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceConsolidatedFinancialStatementsDetails" ], "lang": { "en-us": { "role": { "label": "Separate [member]", "terseLabel": "Separate" } }, "en": { "role": { "documentation": "This member stands for separate financial statements. Separate financial statements are those presented by an entity in which the entity could elect, subject to the requirements in IAS 27, to account for its investments in subsidiaries, joint ventures and associates either at cost, in accordance with IFRS 9, or using the equity method as described in IAS 28." } } }, "auth_ref": [ "r84" ] }, "iva_ServiceAgreementWithSummitClinicalServicesLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ServiceAgreementWithSummitClinicalServicesLlcMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Service agreement with Summit Clinical Services LLC.", "label": "Service Agreement With Summit Clinical Services LLC [member]", "terseLabel": "Service agreement with Summit Clinical Services LLC" } } }, "auth_ref": [] }, "iva_ServiceContractWithAvantSanteMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ServiceContractWithAvantSanteMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for service contract with Avant Sante.", "label": "Service contract with Avant Sante [Member]", "terseLabel": "Service contract with Avant Sante" } } }, "auth_ref": [] }, "iva_ServiceProvidersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ServiceProvidersMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to service providers.", "label": "Service Providers", "terseLabel": "Service providers" } } }, "auth_ref": [] }, "iva_ShareBasedPaymentActivityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ShareBasedPaymentActivityMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for share-based payment activity", "label": "Share-based payment activity [Member]", "terseLabel": "Share-based payment activity" } } }, "auth_ref": [] }, "ifrs-full_ShareIssueRelatedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShareIssueRelatedCost", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share issue related cost", "negatedTerseLabel": "Transaction costs" } }, "en": { "role": { "documentation": "The amount of cost related to the issuance of shares." } } }, "auth_ref": [ "r282" ] }, "ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Share of other comprehensive income of associates and joint ventures accounted for using equity method that will be reclassified to profit or loss, net of tax", "terseLabel": "Currency translation differences - equity method" } }, "en": { "role": { "documentation": "Share of the other comprehensive income of associates and joint ventures accounted for using the equity method that will be reclassified to profit or loss, net of tax." } } }, "auth_ref": [ "r41" ] }, "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 4.0 }, "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Share of profit (loss) of associates accounted for using equity method", "totalLabel": "Share of net profit - Equity method", "verboseLabel": "Share of net loss - Equity method" } }, "en": { "role": { "documentation": "The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Profit (loss)]" } } }, "auth_ref": [ "r292" ] }, "iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails": { "parentTag": "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails" ], "lang": { "en-us": { "role": { "documentation": "Share of profit (loss) of associates accounted for using equity method before eliminations", "label": "Share of profit (loss) of associates accounted for using equity method before eliminations", "terseLabel": "Share of net loss" } } }, "auth_ref": [] }, "ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodAbstract", "lang": { "en-us": { "role": { "label": "Share of net profit - Equity method" } } }, "auth_ref": [] }, "iva_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethod" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure on share of profit loss of associates and joint ventures accounted for using equity method investments.", "label": "Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method Investments {Text Block]", "terseLabel": "Share of net profit - Equity method" } } }, "auth_ref": [] }, "ifrs-full_SharePremium": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SharePremium", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Share premium", "terseLabel": "Premiums related to share capital" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r226" ] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Premiums related to share capital" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r6" ] }, "iva_ShareWarrantPlansBsa2017Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ShareWarrantPlansBsa2017Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for share warrant plans for bsa 2017.", "label": "Share Warrant Plans Bsa 2017 [Member]", "terseLabel": "BSA 2017" } } }, "auth_ref": [] }, "ifrs-full_SharebasedPaymentArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SharebasedPaymentArrangementsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Sharebased compensation expense" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r169" ] }, "iva_SharesIssuableUponExerciseOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "SharesIssuableUponExerciseOfWarrants", "presentation": [ "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Shares issuable upon exercise of warrants.", "label": "Shares Issuable Upon Exercise of Warrants", "terseLabel": "Shares issuable upon exercise of warrants" } } }, "auth_ref": [] }, "iva_ShortTermDepositAccountsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ShortTermDepositAccountsCurrent", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsOtherCurrentAssetsAndReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of short term deposits accounts, classified as current.", "label": "Short-Term Deposit Accounts, Current", "terseLabel": "Short-term deposit accounts" } } }, "auth_ref": [] }, "iva_ShortTermDepositAccountsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "ShortTermDepositAccountsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for short-term deposit accounts.", "label": "Shortterm deposit accounts", "terseLabel": "Short-term deposit accounts" } } }, "auth_ref": [] }, "ifrs-full_ShorttermBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShorttermBorrowingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Short-term debt", "terseLabel": "Short-term debt" } }, "en": { "role": { "documentation": "This member stands for short-term borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r245", "r247" ] }, "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShorttermDepositsClassifiedAsCashEquivalents", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "label": "Short-term deposits, classified as cash equivalents", "verboseLabel": "Other cash equivalents" } }, "en": { "role": { "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r312" ] }, "ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "ShorttermDepositsNotClassifiedAsCashEquivalents", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "label": "Short-term deposits, not classified as cash equivalents", "terseLabel": "Short-term deposits" } }, "en": { "role": { "documentation": "The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r287" ] }, "ifrs-full_SignificantInvestmentsInAssociatesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SignificantInvestmentsInAssociatesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareOfNetProfitEquityMethodDetails" ], "lang": { "en-us": { "role": { "label": "Associates [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r81", "r83", "r141" ] }, "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SignificantInvestmentsInSubsidiariesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationInvestmentInSubsidiaryDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiaries [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r81", "r83", "r140" ] }, "ifrs-full_SignificantUnobservableInputLiabilities": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "SignificantUnobservableInputLiabilities", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Significant Unobservable Input Liabilities", "terseLabel": "Significant unobservable input, liabilities" } }, "en": { "role": { "documentation": "The value of significant unobservable input used in the measurement of the fair value of liabilities." } } }, "auth_ref": [ "r144" ] }, "iva_SocieteGeneraleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "SocieteGeneraleMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Societe Generale.", "label": "Societe Generale" } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [line items]", "terseLabel": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r6" ] }, "iva_StatementOfComplianceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "StatementOfComplianceAbstract", "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Basis of preparation and statement of compliance" } } }, "auth_ref": [] }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)" } } }, "auth_ref": [] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "CONSOLIDATED STATEMENTS OF FINANCIAL POSITION" } } }, "auth_ref": [] }, "ifrs-full_StatementOfIFRSCompliance": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "StatementOfIFRSCompliance", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfCompliance" ], "lang": { "en-us": { "role": { "label": "Statement of IFRS compliance [text block]", "terseLabel": "Basis of preparation and statement of compliance" } }, "en": { "role": { "documentation": "An explicit and unreserved statement of compliance with all the requirements of IFRSs." } } }, "auth_ref": [ "r8" ] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [] }, "iva_StockIssuedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "StockIssuedDuringPeriodShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period.", "label": "Stock Issued During Period, Shares", "terseLabel": "Number of shares issued during the period", "verboseLabel": "Number of shares issued during the period" } } }, "auth_ref": [] }, "iva_Studies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "Studies", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to studies.", "label": "Studies", "negatedLabel": "Studies" } } }, "auth_ref": [] }, "iva_SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "SubscriptionPremiumPricePerShareOfOtherEquityInstrumentsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Subscription premium price per share of other equity instruments granted in share-based payment arrangement.", "label": "Subscription Premium Price Per Share Of Other Equity Instruments Granted", "terseLabel": "Subscription premium price per share (\u20ac)" } } }, "auth_ref": [] }, "iva_SubscriptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "SubscriptionPricePerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Subscription price per share in new issue of shares", "label": "Subscription Price Per Share" } } }, "auth_ref": [] }, "iva_SubsidiesIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "SubsidiesIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails": { "parentTag": "iva_OtherIncomeFromOrdinaryActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of income from subsidies.", "label": "Subsidies income", "terseLabel": "Subsidies" } } }, "auth_ref": [] }, "iva_SupportCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "SupportCosts", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to support costs.", "label": "Support costs", "negatedLabel": "Support costs (including taxes)" } } }, "auth_ref": [] }, "iva_TaxAuditForPayrollTaxesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TaxAuditForPayrollTaxesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for tax audit for payroll taxes.", "label": "Tax Audit For Payroll Taxes [Member]", "terseLabel": "Tax audit for payroll taxes" } } }, "auth_ref": [] }, "iva_TaxAuditProposedTaxAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TaxAuditProposedTaxAdjustment", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of proposed tax adjustment (including penalties and late payment interest) received from French tax authorities.", "label": "Tax Audit, Proposed Tax Adjustment", "terseLabel": "Proposed tax adjustment", "verboseLabel": "Proposed payroll tax adjustment" } } }, "auth_ref": [] }, "iva_TaxDeductionAmountForAdditionalClaim": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TaxDeductionAmountForAdditionalClaim", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnResearchTaxCreditDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of tax deduction amount for additional claim", "label": "Tax Deduction Amount for Additional Claim", "terseLabel": "Tax deduction amount for Additional claim" } } }, "auth_ref": [] }, "iva_TaxDisputesWithFrenchTaxAuthorityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TaxDisputesWithFrenchTaxAuthorityMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails", "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for tax disputes with French tax .", "label": "Tax Disputes With French Tax Authority [Member]", "verboseLabel": "Tax disputes with French tax authorities" } } }, "auth_ref": [] }, "iva_TaxEffectImpairmentLossOfDeferredTaxAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TaxEffectImpairmentLossOfDeferredTaxAsset", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to impairment loss of deferred tax asset.", "label": "Tax Effect, Impairment loss Of Deferred Tax Asset", "negatedLabel": "Impairment loss of deferred tax asset" } } }, "auth_ref": [] }, "ifrs-full_TaxEffectOfForeignTaxRates": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxEffectOfForeignTaxRates", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Tax effect of foreign tax rates", "negatedLabel": "Tax rate differences" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]" } } }, "auth_ref": [ "r47" ] }, "iva_TaxEffectOfTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TaxEffectOfTaxCredits", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to tax effect of tax credits.", "label": "Tax effect of tax credits", "terseLabel": "Tax credits" } } }, "auth_ref": [] }, "iva_TaxEffectOfTemporaryDifferencesForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TaxEffectOfTemporaryDifferencesForReconciliationBetweenAccountingProfitAndTaxExpenseIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to temporary differences.", "label": "Tax Effect Of Temporary Differences For Reconciliation Between Accounting Profit And Tax Expense Income", "terseLabel": "Temporary differences" } } }, "auth_ref": [] }, "iva_TaxExpenseFromDerecognitionOfDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TaxExpenseFromDerecognitionOfDeferredTaxAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "Tax expense from derecognition of deferred tax assets", "label": "Tax expense from derecognition of deferred tax assets" } } }, "auth_ref": [] }, "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TaxExpenseIncomeAtApplicableTaxRate", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails": { "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Tax expense (income) at applicable tax rate", "negatedLabel": "Tax benefit at theoretical rate" } }, "en": { "role": { "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]" } } }, "auth_ref": [ "r47" ] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetsDetails", "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r52" ] }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetsDetails", "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [member]" } }, "en": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r52" ] }, "iva_TermDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TermDepositMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherNonCurrentAssetsLongTermDepositAccountsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for term deposit.", "label": "Term Deposit [Member]", "terseLabel": "Term deposit" } } }, "auth_ref": [] }, "iva_TermDepositsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TermDepositsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for term deposits.", "label": "Term deposits [Member]", "terseLabel": "Term deposits" } } }, "auth_ref": [] }, "iva_TermOfPaymentsForServicesRenderedUnderContract": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TermOfPaymentsForServicesRenderedUnderContract", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Term of payments for services rendered under contract", "label": "Term of payments for services rendered under contract" } } }, "auth_ref": [] }, "iva_TermOfRoyaltyCertificate": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TermOfRoyaltyCertificate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Term of royalty certificate in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Term Of Royalty Certificate", "terseLabel": "Term of royalty certificate" } } }, "auth_ref": [] }, "iva_TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TermOverWhichVolumeWeightedAveragePricePerShareToDetermineNumberOfWarrantsToBeIssued", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the term over which volume weighted average price per share to determine number of warrants to be issued.", "label": "Term Over Which Volume Weighted Average Price Per Share To Determine Number Of Warrants To Be Issued", "terseLabel": "Term over which volume weighted average price per share to determine number of warrants to be issued" } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails", "http://www.inventivapharma.com/role/DisclosureRelatedPartyTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Maximum", "terseLabel": "Maximum" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r146", "r158", "r168", "r249", "r250", "r316" ] }, "iva_TotalPaymentOfDutiesToFrenchTaxAuthorities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TotalPaymentOfDutiesToFrenchTaxAuthorities", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxAuditOnPayrollTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the total amount paid to French tax authorities.", "label": "Total Payment of Duties to French Tax Authorities", "terseLabel": "Total amount paid to French tax authorities" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "label": "Trade and other current payables", "terseLabel": "Trade payable" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r16" ] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails": { "parentTag": "iva_TradePayablesAndOtherCurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails", "http://www.inventivapharma.com/role/DisclosureTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current trade payables", "terseLabel": "Trade payables" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r224", "r290" ] }, "ifrs-full_TradeAndOtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherCurrentReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Trade and other current receivables", "terseLabel": "Trade receivables and others" } }, "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } } }, "auth_ref": [ "r14", "r28" ] }, "ifrs-full_TradeAndOtherCurrentReceivablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeAndOtherCurrentReceivablesAbstract", "lang": { "en-us": { "role": { "label": "Trade receivables, tax receivables and other current assets" } } }, "auth_ref": [] }, "iva_TradePayableAndOtherCurrentLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TradePayableAndOtherCurrentLiabilitiesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Trade Payable And Other Current Liabilities [Line Items]" } } }, "auth_ref": [] }, "iva_TradePayableAndOtherCurrentLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TradePayableAndOtherCurrentLiabilitiesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherCurrentAndNonCurrentLiabilitiesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Trade Payable And Other Current Liabilities [Table]" } } }, "auth_ref": [] }, "iva_TradePayablesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TradePayablesAndOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradePayablesShortTermContractLiabilitiesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of trade payables and other current liabilities.", "label": "Trade Payables And Other Current Liabilities.", "totalLabel": "Trade payables and other current liabilities" } } }, "auth_ref": [] }, "iva_TradePayablesAndOtherCurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TradePayablesAndOtherCurrentLiabilitiesAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Trade payables, short-term contract liabilities and other current liabilities" } } }, "auth_ref": [] }, "iva_TradePayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TradePayablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for trade payables.", "label": "Trade payables", "terseLabel": "Trade payables" } } }, "auth_ref": [] }, "iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Trade Receivables and Other Current Assets and Receivables [Line Items]", "terseLabel": "Trade receivables, tax receivables and other current assets" } } }, "auth_ref": [] }, "iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureTradeReceivablesTaxReceivablesAndOtherCurrentAssetsTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to trade receivables and other current assets and receivables.", "label": "Trade Receivables and Other Current Assets and Receivables [Table]" } } }, "auth_ref": [] }, "ifrs-full_TradeReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TradeReceivablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Trade receivables", "terseLabel": "Trade receivables" } }, "en": { "role": { "documentation": "This member stands for trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r182", "r186", "r258", "r284" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "iva_TransactionCostsOnIssueOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TransactionCostsOnIssueOfWarrants", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Transaction costs on issue of warrants", "label": "Transaction costs on issue of warrants" } } }, "auth_ref": [] }, "iva_TransactionsCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TransactionsCosts", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of transactions costs incurred during the period.", "label": "Transactions Costs", "terseLabel": "Transaction costs" } } }, "auth_ref": [] }, "ifrs-full_TreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TreasuryShares", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodInvestmentInHepalysAccountedForUsingEquityMethodOfAccountingDetails" ], "lang": { "en-us": { "role": { "label": "Treasury shares", "negatedLabel": "Treasury Shares" } }, "en": { "role": { "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } } }, "auth_ref": [ "r85", "r226" ] }, "iva_TreatmentPeriodUnderStudy": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TreatmentPeriodUnderStudy", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Treatment period under study", "label": "Treatment period under study" } } }, "auth_ref": [] }, "iva_TypesOfRevenuesAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TypesOfRevenuesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to types of revenues.", "label": "Types Of Revenues [Axis]" } } }, "auth_ref": [] }, "iva_TypesOfRevenuesDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "TypesOfRevenuesDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to types of revenues.", "label": "Types Of Revenues [Domain]" } } }, "auth_ref": [] }, "ifrs-full_TypesOfRisksAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfRisksAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Types of risks [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r159", "r160", "r161", "r163", "r176", "r180", "r181" ] }, "ifrs-full_TypesOfRisksMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfRisksMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "Risks [member]" } }, "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } } }, "auth_ref": [ "r159", "r160", "r161", "r163", "r176", "r180", "r181" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r169" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGeographicalSplitDetails" ], "lang": { "en-us": { "role": { "label": "USA" } } }, "auth_ref": [] }, "currency_USD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "USD", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialRiskManagementExposureToForeignExchangeRiskSensitivityAnalysisDetails" ], "lang": { "en-us": { "role": { "label": "United States of America, Dollars", "terseLabel": "USD" } } }, "auth_ref": [] }, "ifrs-full_UnderlyingEquityInstrumentAndDepositaryReceiptsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnderlyingEquityInstrumentAndDepositaryReceiptsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Underlying equity instrument and depositary receipts [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r284" ] }, "ifrs-full_UnderlyingEquityInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnderlyingEquityInstrumentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationEquityFinancingDetails" ], "lang": { "en-us": { "role": { "label": "Underlying equity instrument [member]" } }, "en": { "role": { "documentation": "This member represents the standard value for the \u2018Underlying equity instrument and depositary receipts\u2019 axis if no other member is used." } } }, "auth_ref": [ "r284" ] }, "ifrs-full_UnobservableInputsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnobservableInputsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Unobservable inputs [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r144", "r314" ] }, "ifrs-full_UnobservableInputsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnobservableInputsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Unobservable inputs [member]" } }, "en": { "role": { "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used." } } }, "auth_ref": [ "r144", "r314" ] }, "iva_UnusedProvisionReversedOtherLongTermProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "UnusedProvisionReversedOtherLongTermProvisions", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount reversed for unused other provisions, classified as long-term.", "label": "Unused Provision Reversed, Other Long-Term Provisions", "negatedLabel": "Reversals" } } }, "auth_ref": [] }, "ifrs-full_UnusedProvisionReversedOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnusedProvisionReversedOtherProvisions", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Unused provision reversed, other provisions", "negatedLabel": "Unused provision reversed, other provisions" } }, "en": { "role": { "documentation": "The amount reversed for unused other provisions. [Refer: Other provisions]" } } }, "auth_ref": [ "r94" ] }, "iva_UnusedProvisionReversedOtherShortTermProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "UnusedProvisionReversedOtherShortTermProvisions", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureProvisionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount reversed for unused other provisions, classified as short-term.", "label": "Unused Provision Reversed, Other Short-Term Provisions", "negatedLabel": "Reversals" } } }, "auth_ref": [] }, "ifrs-full_UnusedTaxCreditsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnusedTaxCreditsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Unused tax credits [member]", "terseLabel": "Tax credits" } }, "en": { "role": { "documentation": "This member stands for tax credits that have been received and are carried forward for use against future taxable profit." } } }, "auth_ref": [ "r52" ] }, "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Unused tax losses for which no deferred tax asset recognised", "terseLabel": "Unrecognized Deferred tax assets" } }, "en": { "role": { "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]" } } }, "auth_ref": [ "r49" ] }, "ifrs-full_UnusedTaxLossesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UnusedTaxLossesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureDeferredTaxAssetsAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Unused tax losses [member]", "terseLabel": "Tax losses" } }, "en": { "role": { "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit." } } }, "auth_ref": [ "r52" ] }, "iva_UpfrontPaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "UpfrontPaymentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureRevenuesAndOtherIncomeAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for upfront payment.", "label": "Upfront payment", "terseLabel": "Upfront payment" } } }, "auth_ref": [] }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": { "xbrltype": "durationItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Useful life measured as period of time, property, plant and equipment", "terseLabel": "Useful lives of property, plant and equipment" } }, "en": { "role": { "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r54" ] }, "iva_VolatilityMeasurementInputInFairValueOfOptionsToAcquireSharesInAssociate": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "VolatilityMeasurementInputInFairValueOfOptionsToAcquireSharesInAssociate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureInvestmentsAccountedForUsingEquityMethodAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Volatility, measurement input in fair value of options to acquire shares in associate", "label": "Volatility, measurement input in fair value of options to acquire shares in associate" } } }, "auth_ref": [] }, "ifrs-full_WagesAndSalaries": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WagesAndSalaries", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Wages and salaries", "negatedLabel": "Wages, salaries and similar costs" } }, "en": { "role": { "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]" } } }, "auth_ref": [ "r302" ] }, "iva_WaiverClaim": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "WaiverClaim", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Waiver of CIR 2017 claim.", "label": "Waiver Claim", "terseLabel": "Waiver claim" } } }, "auth_ref": [] }, "iva_WarrantAgreementWithEuropeanInvestmentBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "WarrantAgreementWithEuropeanInvestmentBankMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCapitalIncreasesAndOtherSignificantEventsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Warrant agreement with the European Investment Bank.", "label": "Warrant Agreement With The European Investment Bank [Member]", "terseLabel": "Warrant agreement with the European Investment Bank" } } }, "auth_ref": [] }, "iva_WarrantAverageLife": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "WarrantAverageLife", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Average life used to calculate fair value of warrant.", "label": "Warrant Average Life", "terseLabel": "Average life (years)", "verboseLabel": "Maturity (years)" } } }, "auth_ref": [] }, "iva_WarrantsCapOfPutOption": { "xbrltype": "decimalItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "WarrantsCapOfPutOption", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Cap of the put option used to calculate fair value of warrants.", "label": "Warrants, Cap of Put Option", "terseLabel": "Cap of the put option (m\u20ac)" } } }, "auth_ref": [] }, "iva_WarrantsDisclosureAfterEndOfReportingPeriodMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "WarrantsDisclosureAfterEndOfReportingPeriodMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationWarrantAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for a warrants disclosure after the end of the reporting period", "label": "Warrants disclosure after end of reporting period [Member]", "terseLabel": "Warrants disclosure after end of reporting period" } } }, "auth_ref": [] }, "iva_WarrantsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "WarrantsExercisePrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants, exercise price", "label": "Warrants, exercise price" } } }, "auth_ref": [] }, "iva_WarrantsFairValueAtGrantDate": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "WarrantsFairValueAtGrantDate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "The fair value at grant date per warrant.", "label": "Warrants, Fair Value at Grant Date", "terseLabel": "Fair value at grant date (\u20ac)", "verboseLabel": "Fair Value (k\u20ac)" } } }, "auth_ref": [] }, "iva_WarrantsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "WarrantsRiskFreeInterestRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Risk free interest rate used to calculate fair value of warrants.", "label": "Warrants, Risk Free Interest Rate", "terseLabel": "Risk-free rate" } } }, "auth_ref": [] }, "iva_WarrantsStockPrice": { "xbrltype": "decimalItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "WarrantsStockPrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock price used to calculate fair value of warrants.", "label": "Warrants, Stock Price", "terseLabel": "Stock price (\u20ac)" } } }, "auth_ref": [] }, "iva_WarrantsSubscriptionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "WarrantsSubscriptionPrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "The subscription price per warrant.", "label": "Warrants, Subscription Price", "terseLabel": "Subscription price", "verboseLabel": "Subscription price per share" } } }, "auth_ref": [] }, "iva_WarrantsTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "WarrantsTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails" ], "lang": { "en-us": { "role": { "documentation": "Term of warrants.", "label": "Warrants Term", "terseLabel": "Term of warrants" } } }, "auth_ref": [] }, "iva_WarrantsThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "WarrantsThresholdTradingDays", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of warrants must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Warrants, Threshold Trading Days", "terseLabel": "Threshold trading days of warrants" } } }, "auth_ref": [] }, "iva_WarrantsUnitFairValue": { "xbrltype": "decimalItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "WarrantsUnitFairValue", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "The fair value per warranty unit outstanding", "label": "Warrants, Unit Fair Value", "verboseLabel": "Unit fair value" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.inventivapharma.com/role/DisclosureShareholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments granted in share-based payment arrangement", "verboseLabel": "Exercise price" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r315" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://www.inventivapharma.com/role/DisclosureFinancialDebtDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityBsaAndAgaPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement", "terseLabel": "Exercise price (in euros)", "verboseLabel": "BSPCE exercise price (\u20ac)" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r315" ] }, "ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCttqAndShareBasedPaymentsDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityCharacteristicsOfBspceShareWarrantsPlansDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average fair value at measurement date, other equity instruments granted", "verboseLabel": "Fair value per AGA at grant date" } }, "en": { "role": { "documentation": "The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r171" ] }, "ifrs-full_WeightedAverageSharePrice2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageSharePrice2019", "presentation": [ "http://www.inventivapharma.com/role/DisclosureEventsAfterReportingDateDetails", "http://www.inventivapharma.com/role/DisclosureShareholdersEquityShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average share price", "terseLabel": "Share price", "verboseLabel": "Stock price at grant date (in euros)" } }, "en": { "role": { "documentation": "The weighted average share price. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r167" ] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementConsolidatedStatementsOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating basic earnings per share", "terseLabel": "Weighted average number of shares outstanding used to calculate basic loss per share" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r88" ] }, "iva_WithHoldingTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "WithHoldingTaxRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "It represents the percentage of withholding tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets.", "label": "With Holding Tax Rate", "terseLabel": "Withholding tax (as a percent)" } } }, "auth_ref": [] }, "iva_WithholdingTaxExpenseIncomeRecognizedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "WithholdingTaxExpenseIncomeRecognizedInProfitOrLoss", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOperatingExpensesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of withholding tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets.", "label": "Withholding Tax Expense Income Recognized In Profit Or Loss", "terseLabel": "Withholding taxes" } } }, "auth_ref": [] }, "iva_WriteOffOfFrenchResearchTaxCreditReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20231231", "localname": "WriteOffOfFrenchResearchTaxCreditReceivables", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationTaxDisputeSettlementDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of French Research Tax Credit (CIR) receivables written off during the period.", "label": "Write Off Of French Research Tax Credit Receivables", "terseLabel": "Write-off of CIR receivables" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard", "URIDate": "2023-03-23" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2023-03-23" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2023-03-23" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2023-03-23" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard", "URIDate": "2023-03-23" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard", "URIDate": "2023-03-23" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard", "URIDate": "2023-03-23" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard", "URIDate": "2023-03-23" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2023-03-23" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2023-03-23" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_e&doctype=Standard", "URIDate": "2023-03-23" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_g&doctype=Standard", "URIDate": "2023-03-23" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_h&doctype=Standard", "URIDate": "2023-03-23" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2023-03-23" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_k&doctype=Standard", "URIDate": "2023-03-23" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "l", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_l&doctype=Standard", "URIDate": "2023-03-23" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "n", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_n&doctype=Standard", "URIDate": "2023-03-23" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_o&doctype=Standard", "URIDate": "2023-03-23" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "q", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_q&doctype=Standard", "URIDate": "2023-03-23" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard", "URIDate": "2023-03-23" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_56&doctype=Standard", "URIDate": "2023-03-23" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_a&doctype=Standard", "URIDate": "2023-03-23" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61&doctype=Standard", "URIDate": "2023-03-23" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard", "URIDate": "2023-03-23" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard", "URIDate": "2023-03-23" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_d&doctype=Standard", "URIDate": "2023-03-23" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2023-03-23" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard", "URIDate": "2023-03-23" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2023-03-23" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_b&doctype=Standard", "URIDate": "2023-03-23" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2023-03-23" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2023-03-23" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2023-03-23" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2023-03-23" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82A&doctype=Standard", "URIDate": "2023-03-23" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2023-03-23" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard", "URIDate": "2023-03-23" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2023-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_21&doctype=Standard", "URIDate": "2023-03-23" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2023-03-23" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard", "URIDate": "2023-03-23" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2023-03-23" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_e&doctype=Standard", "URIDate": "2023-03-23" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2023-03-23" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2023-03-23" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2023-03-23" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2023-03-23" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2023-03-23" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2023-03-23" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_ix&doctype=Standard", "URIDate": "2023-03-23" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2023-03-23" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73&doctype=Standard", "URIDate": "2023-03-23" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2023-03-23" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI", "URIDate": "2023-03-23" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "140", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_140_a&doctype=Standard", "URIDate": "2023-03-23" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "141", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141_c&doctype=Standard", "URIDate": "2023-03-23" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_142&doctype=Standard", "URIDate": "2023-03-23" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "145", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_145&doctype=Standard", "URIDate": "2023-03-23" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI", "URIDate": "2023-03-23" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2023-03-23" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "2", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS02_g36-39_TI", "URIDate": "2023-03-23" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2023-03-23" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2023-03-23" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS21_g51-57_TI", "URIDate": "2023-03-23" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2023-03-23" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2023-03-23" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard", "URIDate": "2023-03-23" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "18", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18&doctype=Standard", "URIDate": "2023-03-23" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "19", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19_f&doctype=Standard", "URIDate": "2023-03-23" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard", "URIDate": "2023-03-23" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2023-01-01", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2023-03-23" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2023-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2023-03-23" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2023-03-23" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2023-03-23" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2023-01-01", "Paragraph": "4", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_4&doctype=Standard", "URIDate": "2023-03-23" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "32", "IssueDate": "2023-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard", "URIDate": "2023-03-23" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard", "URIDate": "2023-03-23" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard", "URIDate": "2023-03-23" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2023-03-23" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2023-03-23" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "134", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_a&doctype=Standard", "URIDate": "2023-03-23" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "135", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_135_a&doctype=Standard", "URIDate": "2023-03-23" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "84", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_a&doctype=Standard", "URIDate": "2023-03-23" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "84", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_b&doctype=Standard", "URIDate": "2023-03-23" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "84", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_d&doctype=Standard", "URIDate": "2023-03-23" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "84", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84&doctype=Standard", "URIDate": "2023-03-23" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2023-03-23" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_i&doctype=Standard", "URIDate": "2023-03-23" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e_vi&doctype=Standard", "URIDate": "2023-03-23" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2023-03-23" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard", "URIDate": "2023-03-23" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard", "URIDate": "2023-03-23" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS38_g118-128_TI", "URIDate": "2023-03-23" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_76&doctype=Standard", "URIDate": "2023-03-23" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2023-03-23" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2023-03-23" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2023-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard", "URIDate": "2023-03-23" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2023-03-23" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard", "URIDate": "2023-03-23" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "14", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_14&doctype=Standard", "URIDate": "2023-03-23" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2023-03-23" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_21&doctype=Standard", "URIDate": "2023-03-23" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard", "URIDate": "2023-03-23" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard", "URIDate": "2023-03-23" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard", "URIDate": "2023-03-23" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "46", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_46&doctype=Standard", "URIDate": "2023-03-23" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2023-03-23" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2023-03-23" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2023-03-23" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "10", "IssueDate": "2023-01-01", "Paragraph": "22", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22&doctype=Standard", "URIDate": "2023-03-23" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "12", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_f&doctype=Standard", "URIDate": "2023-03-23" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "19B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_19B_c&doctype=Standard", "URIDate": "2023-03-23" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "2", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_2_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "21", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_21_a_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B14", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B14_b&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B16&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B4", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B4", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2023-03-23" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2023-03-23" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2023-03-23" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2023-03-23" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2023-03-23" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_105&doctype=Standard", "URIDate": "2023-03-23" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "113", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2023-03-23" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_114&doctype=Standard", "URIDate": "2023-03-23" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard", "URIDate": "2023-03-23" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2023-03-23" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_h&doctype=Standard", "URIDate": "2023-03-23" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard", "URIDate": "2023-03-23" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_97&doctype=Standard", "URIDate": "2023-03-23" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109&doctype=Standard", "URIDate": "2023-03-23" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2023-03-23" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard", "URIDate": "2023-03-23" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_124&doctype=Standard", "URIDate": "2023-03-23" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_125&doctype=Standard", "URIDate": "2023-03-23" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard", "URIDate": "2023-03-23" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "128", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2023-03-23" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2023-03-23" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2023-03-23" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "C32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2023-03-23" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2023-03-23" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2023-03-23" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2023-03-23" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2023-03-23" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2023-03-23" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2023-03-23" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2023-01-01", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2023-03-23" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "14", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_14_a&doctype=Standard", "URIDate": "2023-03-23" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2023-03-23" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2023-03-23" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard", "URIDate": "2023-03-23" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard", "URIDate": "2023-03-23" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard", "URIDate": "2023-03-23" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard", "URIDate": "2023-03-23" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2023-03-23" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2023-03-23" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2023-03-23" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35M", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M_b_iii&doctype=Standard", "URIDate": "2023-03-23" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2023-03-23" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_36&doctype=Standard", "URIDate": "2023-03-23" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2023-03-23" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "40", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_40_a&doctype=Standard", "URIDate": "2023-03-23" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2023-03-23" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2023-03-23" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_6&doctype=Standard", "URIDate": "2023-03-23" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_a&doctype=Standard", "URIDate": "2023-03-23" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_e&doctype=Standard", "URIDate": "2023-03-23" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_f&doctype=Standard", "URIDate": "2023-03-23" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2023-03-23" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "8", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8&doctype=Standard", "URIDate": "2023-03-23" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B2", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B2_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Section": "Defined terms", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI", "URIDate": "2023-03-23" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2023-03-23" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2023-03-23" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2023-03-23" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2023-03-23" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard", "URIDate": "2023-03-23" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2023-03-23" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2023-03-23" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2023-03-23" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2023-03-23" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2023-03-23" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2023-03-23" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard", "URIDate": "2023-03-23" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2023-03-23" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard", "URIDate": "2023-03-23" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2023-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard", "URIDate": "2023-03-23" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2023-01-01", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2023-03-23" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2023-01-01", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2023-03-23" }, "r220": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard", "URIDate": "2023-03-23" }, "r221": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard", "URIDate": "2023-03-23" }, "r222": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard", "URIDate": "2023-03-23" }, "r223": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_68&doctype=Standard", "URIDate": "2023-03-23" }, "r224": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_70&doctype=Standard", "URIDate": "2023-03-23" }, "r225": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23" }, "r226": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23" }, "r227": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "82A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82A&doctype=Standard", "URIDate": "2023-03-23" }, "r228": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r229": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "80", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80_a&doctype=Standard", "URIDate": "2023-03-23" }, "r230": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "37", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_a&doctype=Standard", "URIDate": "2023-03-23" }, "r231": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "37", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_g&doctype=Standard", "URIDate": "2023-03-23" }, "r232": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "37", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_h&doctype=Standard", "URIDate": "2023-03-23" }, "r233": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2023-03-23" }, "r234": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2023-03-23" }, "r235": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2023-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2023-03-23" }, "r236": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "36", "IssueDate": "2023-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard", "URIDate": "2023-03-23" }, "r237": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "87", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_87&doctype=Standard", "URIDate": "2023-03-23" }, "r238": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Section": "Example 10 A court case", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS37_IE_C_ex10_TI", "URIDate": "2023-03-23" }, "r239": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "119", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_119_c&doctype=Standard", "URIDate": "2023-03-23" }, "r240": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "14", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_14_f&doctype=Standard", "URIDate": "2023-03-23" }, "r241": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2023-03-23" }, "r242": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2023-03-23" }, "r243": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2023-03-23" }, "r244": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2023-03-23" }, "r245": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "44C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2023-03-23" }, "r246": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2023-03-23" }, "r247": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI", "URIDate": "2023-03-23" }, "r248": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2023-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r249": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r250": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2023-03-23" }, "r251": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "B89", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r252": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2023-01-01", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r253": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard", "URIDate": "2023-03-23" }, "r254": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2023-03-23" }, "r255": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2023-01-01", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2023-03-23" }, "r256": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_a&doctype=Standard", "URIDate": "2023-03-23" }, "r257": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "IG23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_IG23&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r258": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2023-03-23" }, "r259": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B11", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r260": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r261": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B35", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r262": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B35", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_e&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r263": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B35", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_f&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r264": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r265": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2023-03-23" }, "r266": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "IG20D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG20D&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r267": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2023-03-23" }, "r268": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r269": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r270": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r273": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r274": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r275": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r277": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r278": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r279": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r280": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2023-03-23" }, "r281": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard", "URIDate": "2023-03-23" }, "r282": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2023-03-23" }, "r283": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard", "URIDate": "2023-03-23" }, "r284": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2023-03-23" }, "r285": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard", "URIDate": "2023-03-23" }, "r286": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2023-03-23" }, "r287": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard", "URIDate": "2023-03-23" }, "r288": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23" }, "r289": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23" }, "r290": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard", "URIDate": "2023-03-23" }, "r291": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2023-03-23" }, "r292": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2023-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard", "URIDate": "2023-03-23" }, "r293": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard", "URIDate": "2023-03-23" }, "r294": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_a&doctype=Standard", "URIDate": "2023-03-23" }, "r295": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2023-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2023-03-23" }, "r296": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "135", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2023-03-23" }, "r297": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "141", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_141&doctype=Standard", "URIDate": "2023-03-23" }, "r298": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "144", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_144&doctype=Standard", "URIDate": "2023-03-23" }, "r299": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "145", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_145&doctype=Standard", "URIDate": "2023-03-23" }, "r300": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "5", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_5&doctype=Standard", "URIDate": "2023-03-23" }, "r301": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "57", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_57_a&doctype=Standard", "URIDate": "2023-03-23" }, "r302": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2023-01-01", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_9&doctype=Standard", "URIDate": "2023-03-23" }, "r303": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "37", "IssueDate": "2023-01-01", "Paragraph": "84", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84&doctype=Standard", "URIDate": "2023-03-23" }, "r304": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2023-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2023-03-23" }, "r305": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "40", "IssueDate": "2023-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2023-03-23" }, "r306": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "41", "IssueDate": "2023-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2023-03-23" }, "r307": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard", "URIDate": "2023-03-23" }, "r308": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard", "URIDate": "2023-03-23" }, "r309": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2023-03-23" }, "r310": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2023-03-23" }, "r311": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard", "URIDate": "2023-03-23" }, "r312": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r313": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2023-03-23" }, "r314": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2023-01-01", "Paragraph": "93", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_h&doctype=Standard", "URIDate": "2023-03-23" }, "r315": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2023-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23" }, "r316": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2023-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23" } } }